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1.1 ISCHEMIA/REPERFUSION INJURY
Ischemia/reperfusion (I/R) is an inevitable and injurious event in clinical 
conditions such as infarction, sepsis and solid organ transplantation. Ischemia 
occurs after insufficient local blood supply leading to oxygen deprivation (i.e. 
hypoxia), accumulation of cellular waste, nutrient deprivation and an excess of 
carbon dioxide (i.e. hypercapnia). Depletion of cellular energy (ATP) is the most 
prominent cause of cellular injury during ischemia. Reperfusion of ischemic 
tissue e.g.. following transplantation provides oxygen as well as substrates 
that are necessary for tissue regeneration, restoration of energy levels and 
concurrent removal of toxic metabolites. Nevertheless, restoration of blood 
flow to ischemic tissue paradoxically exacerbates tissue damage by initiating 
a cascade of inflammatory events including release of reactive oxygen species 
(ROS), pro-inflammatory cytokines and chemokines, recruitment of leukocytes 
and activation of the complement system (1-4). Such deterioration of tissue 
function and integrity after reperfusion is defined as ischemia/reperfusion injury 
(IRI). The close interaction between many cell types and mediators involved in 
the pathophysiology of IRI complicates the treatment of this condition. To date, 
no effective therapy or treatment for IRI in the clinic exists.
1.1.1 Renal ischemia/reperfusion injury
Renal I/R is an inflammatory process that leads to acute kidney injury (AKI). 
AKI is a clinical syndrome characterized by a rapid (hours to days) decrease 
in renal function and accumulation of products of nitrogen metabolism in the 
plasma, such as creatinine and urea. Other common clinical manifestations 
include decreased urine output (oliguria), accumulation of metabolic acids and 
increased potassium and phosphate concentrations. AKI may not only occur 
in the context of kidney transplantation in which I/R is inevitable, but is also a 
consequence of impaired kidney perfusion e.g. during major surgery or sepsis. 
Incidence of AKI varies from more than 5000 cases per million people per year for 
non-dialysis-requiring AKI, to 295 cases per million people per year for dialysis-
requiring disease (5). AKI has a frequency of 1,9% in hospitalized patients (6) 
and is especially common in critically ill patients, in whom the prevalence of AKI 
is greater than 40% at admission to the intensive-care unit if sepsis is present. 
Occurrence is more than 36% on the day after admission to an intensive-care unit 
(7), and prevalence is greater than 60% during intensive-care-unit admission (2). 
In the renal transplant setting, ischemia during the transplant procedure, under 
toxic therapautical conditions (calcineurin inhibitors) or immunological injury, 
affects viability and promotes alloimmunity. Therefore, AKI not only has a major 
impact on short-term but also on long-term graft survival following kidney
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transplantation and is strongly associated with delayed graft function (DGF), 
clinical morbidity and mortality (8-12). In order to resolve the shortage of 
kidney donors, there is an increased use of marginal donors, including older and 
cardiac death donors (CDD). In contrast to organ donation from living or brain 
death donors, the delay between circulatory arrest and organ preservation in 
CDD causes additional ischemic injury in these organs. As a consequence, the 
incidence of DGF and primary nonfunction in CDD kidney transplantation is 
relatively high. Currently, approximately a quarter of all kidney transplantations 
in the Netherlands are performed using kidneys from CDD donors, and therefore 
an effective therapy for renal IRI is imperative.
1.1.2 Kidney anatomy
The human kidney (Fig 1A) contains approximately one million functional units 
(the nephrons; Fig 1B) that consist of a filter (the glomerulus) and a processing 
portion i.e. the proximal tubule, the distal tubule and collecting duct. The renal 
cortex is the outer portion of the kidney between the renal capsule and the 
renal medulla and is the part of the kidney where ultrafiltration takes place. The 
cortex includes the renal filters (glomeruli), Bowmans capsule and renal tubules. 
The renal medulla is the innermost part of the kidney and contains the loops of 
Henle, which are responsible for maintaining and fine-tuning the salt and water 
balance of the blood. The renal medulla is made up of approximately seven 
Figure 1. Normal kidney and nephron with medullary microvascular anatomy. 
Anatomy of the kidney (A) and a nephron (B) with regions identified. Outer medulla 
vasculature is shown with capillaries in red and venous system in blue. The vasa recta 
with countercurrent exchange of oxygen resulting in a gradient of decreasing oxygen 
tension. Adapted by permission from Bonventre et al, J Clin Invest. 2011; copyright 
American Society for clinical investigation.
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pyramids of which the apex or papilla points internally into the medulla. The 
renal papilla is the location, where the urine from the collecting ducts ends up 
in the calyses before it passes further into the urinary tract via the renal pelvis 
and ureter to the bladder. 
The glomeruli produce approximately 180 liters of primary filtrate (pre-urine) 
every day of which only 1 to 2 liters are finally excreted as urine. Filtered 
metabolites in the primary filtrate are reabsorbed in the tubular structure, which 
is covered by a single layer of epithelial cells. These tubular cells are specialized in 
tubular reabsorption and are surrounded by peritubular capillaries (13). Tubular 
reabsorption is the process by which filtered metabolites e.g. salts, proteins and 
glucose are taken up from the primary filtrate and transported back into the 
blood via the tubular cells. Eighty percent of the renal oxygen consumption is 
utilized to drive the Na+-Ka+-ATPases on the basal side of the tubular cells, which 
are responsible for sodium reabsorption from the urine. The proximal tubular 
epithelial cells (PTEC) play an important role herein. The luminal surface of the 
epithelial cells of this segment of the nephron is covered with densely packed 
microvilli forming the brush border. These microvilli greatly increase the luminal 
surface area of the cells, facilitating their reabsorptive function (13). Because 
resaborption is a process with very high energy expenditure, PTEC are equipped 
with a vast amount of mitochondria and are highly dependent on oxidative 
phosphorylation. 
In the cortex, the partial pressure of oxygen (PO2) is 50 mmHg, but only 10–20 
mm Hg in the outer medulla, which harbors the S3 segment of the proximal 
tubule. This low oxygen-pressure is not only a consequence of the high 
metabolic requirements of the PTEC here, but is also due to the countercurrent 
arrangement of vessels that drain the outer and inner medulla (Fig 1B). As blood 
flows down toward the tip of the medulla, most of the oxygen diffuses out of 
the descending vasa recta into the interstitium, the space between the tubules. 
It can then either diffuse to the surrounding tubules, where it is consumed for 
active transport processes, or be reabsorbed into the ascending vasa recta and 
carried back to the cortex. Oxygenation of the outer medulla is therefore limited 
by the diffusional shunting of oxygen between descending and ascending vasa 
recta (14). Shortage of oxygen during and after renal ischemia therefore most 
profoundly affects PTEC in the S3 segment of the outer medulla, which have a 
high energy expenditure, but due to the countercurrent vessel arrangement a 
relatively low surrounding PO2. 
1.1.3 Acute tubular necrosis
Ischemic AKI following renal I/R is characterized by injury to the PTEC in the S3 
segment of the nephron in the outer medulla and cortico-medullary junction 
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(Fig 2). During an ischemic event, there is shedding of the proximal tubular brush 
border within several minutes (15) and loss of polarity with mislocalization of 
adhesion molecules, complement regulators and other membrane proteins like 
the Na+-Ka+-ATPase and integrins (16;17). Disruption of the cytoskeleton leads 
to a loss of tight and adherens junctions, which normally actively participate in 
function as paracellular transport, cell polarity, and cell morphology. Opening 
of tight junctions leads to an increased paracellular permeability and backleak 
of the glomerular filtrate from the lumen to the interstitium (18). Disruption of 
microvilli and their detachment from the apical cell surface leads to formation 
of membrane-bound blebs early following ischemia, which are released into 
the tubular lumen. In advanced ischemic injury, viable and necrotic tubular 
epithelial cells are desquamated, leaving the denuded basement membrane as 
the only barrier between the filtrate and the peritubular interstitium, resulting in 
even more backleak of glomerular filtrate (4;19;20). The sloughed tubular cells, 
Figure 2. Ischemic acute tubular necrosis. Tubular injury is a direct consequence 
of metabolic pathways induced by ischemia but is potentiated by inflammation and 
microvascular compromise. Acute tubular necrosis is characterized by shedding of 
epithelial cells and denudation of the basement membrane in the proximal tubule, 
with backleak of filtrate and obstruction by sloughed tubular cells. Reproduced with 
permission from Abuelo et al, N Engl J Med. 2007, Copyright Massachusetts Medical 
Society.
General introduction   •   15
   1
brush-border vesicle remnants and cellular debris along with tamm-horsefall 
protein form characteristic tubular casts, which have the potential to obstruct 
the tubular lumen, thereby increasing intratubular pressure and preventing 
glomerular filtration in the affected nephron. Denuded basement membranes 
and casts obstructing tubules are therefore a hallmark of ischemic AKI (Fig 
3). In addition, proximal tubular cell injury and dysfunction during ischemia/
reperfusion results in afferent arteriolar vasoconstriction mediated by the 
tubuloglomerular feedback, luminal obstruction and backleak of filtrate leading 
to a persistant regional hypoxia and additional tubular injury, even when the 
kidney is reperfused (21;22). 
1.1.4 Tubular injury markers
At present, the diagnosis of AKI is mainly based on measurement of serum 
creatinine and ureum levels. However, these traditional methods are not very 
sensitive and specific for the diagnosis of AKI, given that a 50% loss in renal 
function is required before creatinine levels rise (23), the method is dependent 
on nonrenal factors independent of kidney function (age, sex, muscle mass, 
infection) and several medications alter the tubular secretion of creatinine 
leading to changes in serum creatinine independent of glomerular filtration (24). 
AKI is associated with increased morbidity and mortality in critically ill patients 
and a quick detection is difficult with serum creatinine and ureum. A number 
of serum and urinary proteins have been identified that may detect AKI prior 
to a rise in ureum and serum creatinine. Promising new biomarkers of AKI are 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney-injury molecule 
(KIM)-1 (25). 
NGAL is a 25 kDa protein firstly identified in specific granules of the neutrophil, 
where it was bound to gelatinase. NGAL is an important component of innate 
immunity to bacterial infection and is expressed by hepatocytes, immune cells 
Figure 3. Ischemic acute tubular 
necrosis in the outer medullary 
region following I/R in rats. ATN is 
characterized by loss of the brush 
border and tight and adherens 
junctions between tubular epithelial 
cells (2h after I/R) followed by 
detachment from the basement 
membrane (5h after I/R). Basement 
membranes are completely 
denuded after 24h reperfusion 
and characteristic tubular casts of 
sloughed tubular cells are present in 
the lumen of the tubules.
2 hours
5 hours 24 hours
sham
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and renal tubular cells in various disease states (25;26). NGAL is highly resistant 
to proteolysis, which enhance the potential suitability as a clinical biomarker. In 
the kidney, NGAL is produced by tubular epithelial cells of the proximal and distal 
segment. In addition, circulating NGAL is freely filtered by the glomerulus and 
is undergoing rapid clearance by the proximal tubule via receptor binding and 
endocytosis. In healthy kidneys, NGAL is only detectable at low levels, however, in 
the setting of acute tubular injury, it undergoes rapid and profound upregulation 
with large increases in both urine and plasma. This rapid response enables NGAL 
to potentially identify injured kidneys much earlier than was previously possible 
using traditional markers of renal function such as creatinine. The functional 
role of NGAL has not been completely unraveled. It seems to be involved in iron 
transportation to and from the proximal tubular epithelial cells. Animal studies 
have demonstrated a renoprotective effect of exogenously administered NGAL 
in the setting of acute ischemic injury (27).
Kidney injury molecule-1 (KIM-1) is a putative epithelial cell adhesion molecule 
containing an immunoglobulin domain (28). KIM-1 mRNA and protein are 
expressed at a very low level in normal kidney, however in the setting of acute 
tubular injury (Fig 4), its expression increases dramatically in proximal tubular 
epithelial cells (29;30). KIM-1 has also been identified as the first nonmyeloid 
phosphatidylserine receptor that confers a phagocytic phenotype on injured 
proximal tubular epithelial cells both in vivo and in vitro (31). Similiar to NGAL, 
urinary KIM-1 has been found to be an early indicator of AKI that compares 
favorably to a number of conventional biomarkers and tubular enzymes (29;32).
1.1.5 Endothelial injury 
Besides the tubular compartment of the kidney, the microvascular compartment 








Figure 4. Kidney injury 
molecule (KIM)-1 after 
I/R. Whole rat kidney 
staining of KIM-1 in an 
untreated (sham) or 
clamped (45 min) kidney 
24 hours after reperfusion. 
KIM-1 is most present in 
the outer medulla, which 
harbors the proximal 
tubular epithelial cells 
in the S3 segment of the 
nephron. 
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during the reperfusion phase when leukocytes are able to interact with ischemic 
and injured endothelium (19). As stated earlier, blood flow to the outer medulla 
of the kidney is largely reduced following perfusion (33-36). This marked 
hypoperfusion of the outer medulla is persistent even though cortical blood flow 
improves during reperfusion after an ischemic insult. Small arterioles in kidneys 
following reperfusion vasoconstrict more than do vessels in normal kidneys 
(37;38). Enhanced vasoconstriction together with small vessel occlusion due to 
endothelial-leukocyte interactions and activation of the coagulation system result 
in local compromise of the microcirculation and regional ischemia, especially 
in the outer medulla further inducing tubular ischemic injury (39). Local blood 
flow to the outer medulla, already reduced due to arteriolar vasoconstriction, is 
further compromised by local edema. In addition, endothelial cells contributes 
to the pathology of IRI by enhanced endothelium-leukocyte interactions due to 
increased expression of cell adhesion molecules such as ICAM-1 on damaged 
endothelial cells combined with increased expression of counterreceptors on 
leukocytes (40). This results in activation of leukocytes, obstruction of capillaries, 
further activation and transmigration of leukocytes, production of cytokines, 
and an extensive proinflammatory state (39). Damage to the endothelium, loss 
of the glycocalyx, disruption of the endothelial cytoskeleton, breakdown of the 
perivascular matrix and alteration of endothelial cell-cell contacts all culminate 
in increased microvascular permeability during AKI and loss of fluid into the 
interstitium (19;41;42). 
Renal I/R impairs the integrity of endothelial cells and leads to loss of peritubular 
capillaries (41;43-48). This reduced number of vessels is associated with chronic 
hypoxia (49), which can be expected to lead to increased tubular injury and 
tubulointerstitial fibrosis. Pericytes, also called perivascular fibroblasts, play a 
critical role in the stabilization and proliferation of peritubular capillaries via 
interaction with endothelial cells (50-52). Recent studies have shown that in 
renal I/R, pericytes detach from the endothelium and migrate to the interstitium 
to become activated and differentiate into myofibroblasts contributing to renal 
fibrosis (53;54). The critical stabilization of endothelial cells by pericytes is 
mediated by several angioregulatory factors, including the anti-inflammatory 
factor Ang-1 produced by pericytes and the pro-inflammatory factor Ang-2 
produced by activated endothelial cells (52;55;56). Angiopoietins are a group of 
vascular regulatory molecules that bind to the receptor tyrosine kinase Tie-2, 
which is predominantly expressed by vascular endothelial cells. Ang-1 is a strong 
vascular protective agonist of the Tie-2 receptor responsible for preventing 
vascular leakage, maintaining endothelial cell survival and inhibiting vascular 
inflammation. Ang-2 acts as an antagonist of Ang-1 and in a dose dependent 
manner promotes destabilization, vessel leakage and inflammation. A dysbalance 
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towards Ang-2 will therefore lead to loosening contacts between endothelial 
cells and perivascular cells, with subsequent vessel destabilization and abnormal 
microvascular remodeling (55-57). 
1.1.6 Stress and cell death mechanisms 
During and following renal ischemia, several cellular stress mechanisms are 
activated to cope with nutrient and energy depletion, ROS formation and 
accumulation of toxic metabolites. During ischemia, ATP shortage caused by 
hypoxia and glucose deprivation decreases the calcium concentration in the 
endoplasmic reticulum (ER) of tubular cells, thereby impairing the activity of 
chaperone molecules and maturation of native proteins. The accumulation of 
excessive amounts of mis- and unfolded proteins in the ER following ischemia 
causes ER-stress, which results in activation of the so called ER-stress response 
or unfolded protein response (UPR) (58-60). The ER-stress response is aimed 
to adjust cell functions in response to ER-stress and to re-establish normal ER 
function both at the translational and transcriptional level. 
Upon accumulation of unfolded proteins, 78-kDa glucose-regulated protein 
(GRP78 or BIP), which  is one of the most abundant ER luminal chaperones (61;62), 
binds to unfolded proteins and thereby dissociates from the three membrane-
bound ER-stress sensors (Fig 5). These stress sensors include pancreatic ER 
kinase (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and 
activating transcription factor 6 (ATF6). The dissociation of GRP78 from these 
stress sensors allows their subsequent autophosphorylation and activation. 
Phosphorylated PERK decreases protein synthesis by phosphorylation of eIF2α. 
Phosphorylated IRE1 increases cellular degradation of unfolded proteins by 
splicing of transcription factor XBP-1, inducing expression of genes involved 
in ER-associated protein degradation (ERAD). Proteolytic cleaved ATF6, also a 
transcription factor, enhances the protein folding machinery by inducing the 
transcription of ER-chaperones. Thus, all three pathways are critical for handling 
ER stress and for return to normal homeostasis. The adaptive responses to the 
accumulation of un- or misfolded proteins in the ER provide initial protection 
from cell death. However, prolonged or excessive ER-stress can trigger cell 
death, classically through the process of apoptosis. ER-stress-induced apoptosis 
is mediated by mitochondria-dependent and -independent pathways (60;63). 
In renal IRI several morphologically distinct cell death programs have been 
recognized including type I cell death (apoptosis), type II cell death (autophagy) and 
type III cell death (necrosis) (64-67). These death programs are often intertwined 
and depending on the energy status, signaling events and therapeutics applied 
can occur simultaneously or as a continuum. Even features of both apoptosis 
and necrosis may coexist in the same cell. Moreover, the process of autophagy 
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Figure 5. Stress sensors in the ER-
stress response. Accumulation 
of mis- or unfolded proteins in 
the ER-lumen results in ER-stress 
and activation of the ER-stress or 
unfolded protein response (UPR). 
Release and binding of GRP78/
BiP to mis- or unfolded proteins 
activate the ER-stress sensors 
PERK, ATF6 and IRE1 at the onset 
of ER stress. To re-establish 
homeostasis and normal ER 
function, the ER-stress response 
initiates a global decrease in 
protein synthesis, while increasing 
the production of ER-chaperone 
proteins and ER-associated degradation (ERAD). Reprinted by permission from Macmillan 
Publishers Ltd: Cyr et al, EMBO reports (2009) 10, 1206 - 1210), copyright 2009.
is used to engulf apoptotic or necrotic cells (68). In addition, if engulfment is 
absent, dead cells in the late stages of apoptosis may present necrotic features 
due to the loss of cellular energy and plasma membrane integrity. This process 
is called apoptotic necrosis or secondary necrosis (69). Collectively, these death 
programs following renal I/R are often, although mistaken, defined as acute 
tubular necrosis (ATN). Apoptosis (type I) is a regulated, genetically determined 
mechanism designed to dismantle cells systematically (e.g. cells that are no 
longer functionally viable) (70). Importantly, apoptosis is therefore an energy-
dependent process and often cannot take place during severe ischemia. The 
process involves an orchestrated caspase signalling cascade that ultimately leads 
to cell rounding and shrinkage, chromatin condensation, DNA fragmentation, 
blebbing of the plasma membrane and nuclear fragmentation. Subsequently, 
the formed apoptotic bodies can be cleared effectively by phagocytes. Therefore 
immunogenic endogenous molecules are not released into the extracellular 
environment (69;71;72) and inflammation is prevented.
Autophagy is responsible for the degradation of cytoplasmic material, e.g. 
proteins and organelles, which are sequestered by intracellular double-
membrane structures called autophagosomes. These autophagosomes then 
subsequently fuses with lysosomes resulting in proteolytic degradation yielding 
new macromolecules for the synthesis of vital cellular components. Autophagy 
occurs at a basal level in most cells and contributes to the turnover of long-
lived proteins and organelles to maintain intracellular homeostasis. In response 
to cellular stress (e.g. ischemia), autophagy is up-regulated and can provide an 
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adaptive strategy for cell survival, but may also lead to autophagic cell death 
(type II) (69;71;72). Because of this dual role, it remains uncertain whether 
autophagy is a mechanism of cell death or survival in the pathophysiology of 
renal IRI (67;73;74). 
During ischemia, necrosis (type III) takes place when insufficient ATP is available. 
The process involves cellular and organelle swelling, reactive oxygen species 
production and rupture of the plasma membrane. The processes might result in 
the release of intracellular molecules and danger-associated molecular patterns 
(DAMPs) that can elicit a sterile inflammatory response (69;71;72). Importantly, 
both late apoptotic as well as necrotic cells activate the complement system 
(75-78). 
1.1.7 Inflammation
Depletion of cellular energy is the most prominent cause of tubular injury 
during ischemia. Nevertheless, reperfusion of ischemic tissue paradoxically 
exacerbates tissue damage by initiating a cascade of inflammatory events. 
For this reason, deterioration of tissue function following reperfusion is often 
defined as reperfusion-injury, however both the injury during the ischemic 
and reperfusion phase is included herein. DAMPs released during ischemic 
tissue injury, altered or enhanced expression of membrane-bound proteins 
and activation of endothelial and tubular cells during reperfusion collectively 
promote an inflammatory environment in which both innate and adaptive 
immunity are involved and contribute to the pathology of IRI (39). Innate 
immunity is responsible for the early response to injury in a non-antigen-
specific fashion and comprises humoral components including the complement 
system as well as innate immune cells including neutrophils, macrophages and 
dendritic cells (DCs). In the renal transplant setting, adaptive immunity activated 
by specific alloantigens is initiated within hours, lasts over the course of several 
days after injury and includes DC maturation and alloantigen presentation, and 
T- and B-lymphocyte proliferation and activation. 
Tubular cells themselves also actively participate in the inflammatory response 
in renal IRI (79;80). In addition to generating proinflammatory and chemotactic 
cytokines such as TNF-α, MCP-1,IL-8,IL-6,IL-1β and RANTES which activate 
inflammatory cells, tubular cells also express Toll-like receptors (TLRs), 
complement proteins and receptors (79;80), and costimulatory molecules, which 
regulate T-lymphocyte activity. Endogenous ligands released from damaged and 
stressed tissue signal through TLRs on tubular cells (81;82). These ligands include 
heat-shock proteins (binding to TLR2 and -4), the non-histone chromatin-binding 
protein high-mobility group box 1 (HMGB1) (TLR2 and -4), and ECM components 
such as hyaluronan (TLR2 and -4), fibronectin (TLR4), heparan sulfate (TLR4), 
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and biglycan (TLR2 and -4) (83-88). Activation of TLR-2 and -4 on tubular cells 
initiates a proinflammatory response marked by the release of cytokines and 
chemokines, which attract inflammatory cells. In addition, tubular cells express 
MHCII and costimulatory molecules and can activate T-cells (80;89-91). 
Neutrophils interacting with the activated endothelium, infiltrate into 
the interstitium and there excrete reactive oxygen species, proteases, 
myeloperoxidase and cytokines. These events lead to increased vascular 
permeability and reduced tubular epithelial and endothelial cell integrity (92), 
aggravating kidney injury (93). 
One of the major cell types that accumulates around tubules after I/R is the 
macrophage (94). Proinflammatory (M1) macrophages are recruited into the 
kidney in the first 48 hours after I/R, whereas mannose receptor–positive, non-
inflammatory (M2) macrophages predominate at later time points. Depletion 
of macrophages before I/R has been shown to diminish kidney injury, whereas 
depletion at several days after injury slows tubular cell proliferation and repair, 
indicating a switch from a proinflammatory to a trophic macrophage phenotype 
that supports the transition from tubule injury to tubule repair (95).
In addition to macrophages and DCs, also T-lymphocytes infiltrate into the 
kidney in both the early and later phases of AKI and can facilitate injury, but also 
promote repair after renal IRI (96). As a consequence of renal ischemia, there 
is an altered localization and expression of complement regulators on tubular 
cells (97), which makes these cells prone for vigorous complement activation. 
In addition, apoptotic as well as necrotic cells generated during I/R are potent 
activators of the complement system (75-78). Therefore, it is thought that 
also the complement system is an important contributor to renal injury and 
inflammatory response following IRI.
1.2 THE COMPLEMENT SYSTEM
The complement system, an essential component of the innate immune system, 
is a major player in host defense against invading pathogens and at the same time 
is closely involved in the effective clearance of apoptotic and necrotic cells. The 
complement cascade was first described in the late 1800s (98) and so named to 
reflect its capacity to enhance antibacterial activity of humoral immunity. It is a 
complex cascade of approximately thirty plasma and membrane-bound proteins 
that are stratified according to their respective surface recognition patterns into 
three major pathways. i.e. the classical pathway (CP), the lectin pathway (LP) 
and the alternative pathway (AP). Each pathway has its own characteristics of 
target recognition, activation and regulation, but all converge at the level of C3, 
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the central component of the complement system (Fig 6). Once sufficient C3 is 
activated and deposited, generation of the membrane attack complex (MAC) is 
initiated, resulting in cytolysis of the target cell (99). 
1.2.1 Classical pathway
The CP is activated via binding of C1q to the Fc-tails of immunoglobulins (i.e. IgG 
and IgM bound to their antigen), acute phase proteins, DNA, and apoptotic cells 
or necrotic cell debris. When bound to its substrate, a conformational change of 
C1q results in the activation of its natural serine proteases C1r and C1s, which are 
associated with the collagen-like tail of C1q. Activated C1s then cleaves C4 into 
C4b which becomes covalent linked to the target. Subsequently C2 is cleaved 
which binds to C4b forming the classical (membrane-attached) C3 convertase, 
the C4b2a complex. This classical C3 convertase activates and cleaves other C3 
molecules to C3b and C3a. During cleavage of C3, the internal reactive thioester 
bond is exposed (100) and covalently links C3b to its target, thereby functioning 
as an opsonin directing effective clearance by phagocytes via the C3b receptor 
CR1 (99).
1.2.2 Lectin pathway
The LP is activated in response to binding of the pattern recognition molecule 
Mannan-binding lectin (MBL) as well as L-ficolin and H-ficolin to various 
carbohydrate ligands. MBL is the major recognition molecule of the LP of 
complement activation. Activation of this pathway via MBL and ficolins resembles 
the CP, but (instead of C1s) the MBL-associated serine proteases (MASP)-1 
or -2 are responsible for the activation of C4 and C2 (99). Single-nucleotide 
polymorphisms in both structural and regulatory parts of the MBL gene have 
been found to lead to large inter-individual variations in the concentration of 
functional MBL (0-4000 ng/ml) in plasma (101). 
1.2.3 Alternative pathway
The AP is continuously activated at a low level (so-called tickover), does not 
require C4, and is tightly regulated by complement regulatory proteins, which are 
lacking on e.g. pathogens. The continuous hydrolysis of C3 leads to formation of 
C3(H2O). Factor B subsequently binds hydrolyzed C3 in the presence of factor D 
leading to formation of the alternative C3 convertase C3(H2O)Bb after cleavage 
and activation of factor B by factor D. This process results in continuous low-
level production and deposition of C3b on unprotected surfaces. Deposited C3b 
binds factor B and subsequent cleavage by factor D results in the formation of 
a highly active C3 convertase, C3bBb. A very important step in this pathway 
is the stabilization of C3bBb by properdin which increases the lifetime of this 
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convertase sevenfold. The deposited C3b generated by the classical and lectin C3 
convertases (C4b2a) can in turn be transformed in an alternative C3 convertase 
by binding of properdin and factor B, and cleavage of factor D, generating 
additional stable C3 convertases (C3bBbP). In this way the AP is a very potent 
amplifier of both the CP and LP and is thought to account for approximately 80% 
of deposited C3b (102-104). 
1.2.4 Terminal pathway
After formation of the classical C3 convertase C4b2a or the alternative C3 
convertase C3bBb, the final pathway (common to all three pathways) may be 
initiated. Incorporation of an additional C3b molecule in the C3 convertase 
leads to the formation of the C5 convertase. After activation and cleavage of 
C5, binding of C6, C7, C8 and multiple C9 molecules takes place resulting in the 
formation of the MAC, i.e. the C5b-9 complex, a lipid-soluble pore structure 
which can cause osmotic lysis of cells. 
1.2.5 Complement regulators
Because of its tendency for rapid activation and its ability to amplify its own 
activation, tight regulation of complement is required. To fully prevent self-
depletion and excessive deposition on host cell two types of complement 
Figure 6. The complement 
system. The central 
complement component C3 
is activated by three major 
pathways. The classical 
pathway is triggered by 
immune surveillance 
molecules (such as IgG, IgM 
and C-reactive protein) that 
are bound to the activating 
surface, whereas the lectin 
pathway is initiated by 
carbohydrate residues on the 
activating surface and the alternative pathway is triggered by direct binding of C3b to 
the activating surface. All three pathways progress to form enzyme complexes (classical 
or alternative convertases) that cleave either C3 (into C3a and C3b) or C5 (into C5a and 
C5b). C5b triggers the terminal pathway, which involves the formation of a multimeric 
membrane attack complex (C5b-9) that creates a pore in the target cell membrane. 
Specific cell receptors detect the soluble complement effectors (namely, C3a and C5a) 
and the membrane-bound effectors (namely, C3b and its metabolites inactive C3b 
(iC3b) and C3d). Adapted by permission from Macmillan Publishers Ltd: Atkinson et al, 
Nature Reviews Immunology 7, 9-18 (2007) copyright 2007. 
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regulatory proteins (CRPs) are present, i.e. fluid-phase and solid-phase (105). 
Fluid-phase CRPs circulate in the plasma and include C1 esterase inhibitor 
(C1INH), C4-binding protein (C4bp), factor H and S protein (vitronectin). C1INH 
is a serine protease inhibitor belonging to the serpin superfamily, acts as a 
major inhibitor of complement system activation and prevents uncontrolled 
activation. C1INH can inhibit both the classical and lectin pathway, and upon 
complement activation, C1INH binds to activated MASP or C1r and C1s to 
generate MASP(C1INH) (106) and C1rC1s (C1INH)2 complexes (107-109), which 
subsequently dissociate from the MBL or C1q molecule, respectively. These 
complexes are then rapidly cleared from circulation. 
C4bp is a multichain inhibitor of the classical and lectin C3 convertase C4b2a and 
acts as a decay-accelerating factor for C4b2a and as a cofactor for cleavage of 
C4b to iC4b by the plasma serine-protease factor I. 
Factor H is the fluid-phase inhibitor of the alternative C3 convertase C3bBb. In 
absence of factor H the AP will deplete itself almost completely. Upon binding to 
C3b, factor H competes with factor B for binding to C3b. Factor H also displaces 
Bb from the C3bBb convertase (decay-accelerating activity). In addition, factor 
H acts as a cofactor for factor I in the cleavage of C3b to inactive iC3b. Factor H 
can bind C3b much more easily in the presence of sialic acid which is present on 
all host cells but is absent on e.g. pathogens (99).
Every cell in the human body is protected by one or more cell-membrane-
anchored complement regulatory protein including CD35 (complement receptor 
1; CR1), CD46 (Membrane cofactor protein; MCP), CD55 (Decay accelerating 
factor; DAF) and CD59 (protectin) which generally prevent or disable the 
formation of C3b (CD46, CD55) or MAC (CD59). During apoptosis (110), but 
also following renal ischemia/reperfusion (97), changes in surface molecules 
occur, leading to loss of CD46 and CD59 allowing complement activation and 
consequent opsonization by C3b and C4b followed by phagocytosis. Further 
activation of the complement cascade will lead to generation of C5b-9 and 
release of C5a inducing an inflammatory environment. 
1.2.6 Biological activities of complement
In summary, the main biological activities (99) of the complement system are: 
(1) the opsonization of pathogens, apoptotic or necrotic cells mediated by the 
cleavage products of C3 (C3b and iC3b) and C4 (C4b); (2) the recruitment and 
activation of inflammatory cells by the anaphylatoxins C3a and C5a, which are 
proteolytically released from C3 and C5 and signal to cells and tissues via two 
members of the G-protein-coupled receptor family, the C3a receptor (C3aR) and 
C5a receptor (C5aR) respectively; (3) the direct elimination of pathogens through 
phagocytosis via complement receptors (e.g.. CR1, Calreticulin/CD91, C1qR) or 
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by cell lysis as a result of formation of the membrane attack complex (MAC, 
C5b-9); and (4) the tuning of adaptive immunity by downstream stimulation of 
B- and T-cells (111). 
1.2.7 Complement production
The circulating complement components are mainly produced in the liver and are 
likely to be present in vast excess of locally generated components. Exceptions 
to these are properdin and C1q which are mainly produced by neutrophils (112) 
and DCs (113), respectively. A number of complement components are also 
produced in the kidney. Ironically, the kidney cells most profoundly targeted by 
complement during renal I/R, i.e. the PTEC produce vast amounts of complement 
proteins including C4, C2, C3, factor B and factor H (79). Also, macrophages and 
dendritic cells present in the interstitium can produce C1q. Pro-inflammatory 
cytokines upregulate expression of complement components by resident 
renal cells. In this respect, it was reported that expression of C3 by PTEC was 
strongly increased during renal allograft rejection in the mouse and in the rat, 
in association with both ischemic injury and rejection (114;115). In addition 
to complement production by resident renal cells, also leukocytes infiltrating 
during inflammation can produce a majority of complement factors (116;117). 
1.3 MANNAN-BINDING LECTIN
MBL, initiator of the LP of complement, belongs to a family of proteins called 
collectins, which consists of a collagenous domain and a carbohydrate recognition 
domain (CRD) or lectin domain (118-120). The collectins are encoded by a cluster 
of genes found on the long arm of chromosome 10 in humans and chromosome 
14 in mouse. In rodents, the cluster contains SP-A, SP-D, and MBL-A, but there is 
a second MBL-C gene, thought to have arisen by a gene duplication event, and 
found on chromosome 19 (121). 
1.3.1 MBL structure and ligands
MBL consists of multimers of an identical polypeptide chain of 25 kDa (Fig 7). 
Each chain comprises four distinct regions: (1) a cysteine-rich N-terminal region; 
(2) a collagenous domain; (3) a short α-helical coiled-coil domain, the so-called 
neck region; and (4) a CRD at C-terminal (Fig 7). Three polypeptide chains 
form a triple helix through the collagenous region, stabilized by hydrophobic 
interaction and interchain disulphide bonds within the N-terminal cysteine-rich 
region (122). This trimeric form is the basic structural subunit of the circulating 
form of MBL. In circulation, this trimeric subunit can form oligomers ranging 
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from dimers to hexamers. The higher order oligomers of MBL (e.g. tetramers 
to hexamers) are the effective forms in terms of the protein functions, e.g. 
the glycan interaction and complement activation on microbial surfaces 
(123;124). MBL shows selective and calcium-dependent binding to terminal 
sugars D-mannose, L-fucose and N-acetyl-D-glucosamine (GlcNAc), but not to 
D-galactose and sialic acid (125;126). All these sugars are commonly found on 
the surface of many microorganisms. The α-helical coiled-coil domain provides 
flexibility to the orientation of the CRD of MBL that recognize the specific 
orientation of hydroxyl groups present in certain sugars such as D-mannose and 
L-fucose. However, the affinity of a single CRD for one monosaccharide is weak 
(127), and high-avidity binding therefore requires concurrent binding of multiple 
CRDs. Patterns of repeating sugar structures on microbial surfaces provide an 
optimal target for MBL binding. Structural studies have demonstrated that the 
three sugar binding sites of one MBL subunit (i.e. the triple helix) are separated 
at a constant distance (45 Å in human; 54 Å in rat) (122;128), offering a flat 
platform to recognize multiple sugars simultaneously. The clustering of the triple 
helix (e.g. higher order oligomers) therefore confers the ability to achieve high-
avidity binding. In addition to sugar structures, it has been shown that MBL can 
also bind to phospholipids (129) and nucleic acids (130;131).
1.3.2 MBL-associated serine proteases
The effector ability of MBL is facilitated by activation of the LP through a specific 
interaction between MBL and MBL-associated serine proteases (MASPs). The 
Figure 7. MBL structure. MBL is 
composed of identical 25 kDa 
polypeptides, including an N-terminal 
cysteine-rich region cross linking the 
polypeptides, a collagen-like stalk 
region, an α-helic neck region and 
a C-type carbohydrate recognition 
domain (CRD). Three polypeptide 
chains form a triple helix through the 
collagenous region. This trimeric form 
is the basic structural subunit of all 
circulating forms of MBL. MBL consists 
of oligomers of the subunit, ranging 
from dimers to hexamers. The affinity of 
a single CRD for a single carbohydrate is 
very weak but there is increased avidity of binding when multiple CRDs of MBL interact 
with carbohydrates, as hexameric MBL has 18 CRDs. The lower panel illustrates one 
of the predominant forms of MBL found in serum, which consists of four subunits of 
triple helices of MBL polypeptides. Adapted by permission from Macmillan Publishers 
Ltd: Garred et al, Genes Immun. 2006 Mar;7(2):85-94, copyright 2006. 
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minimum functional unit required to activate the LP is a MASP dimer bound 
to two MBL trimeric units (132). There are three known MASPs that have been 
termed MASP-1, -2 and -3 (133;134). MASP-1 and MASP-2 are encoded by distinct 
genes whereas MASP-3 represents an alternative splice form of the MASP1 gene 
that lacks a serine protease domain. MASP-2 is the functionally most relevant 
enzyme in initiation of the lectin complement pathway. Ligand binding induces 
a conformational change in MASP-2 that activates the terminal serine protease 
domain, which is then able to cleavage C4 and C2, which together forms the 
classical C3 convertase C4b2a. The roles of MASP-1 and MASP-3 in lectin 
complement pathway actvation requires further clarification, but recently it was 
demonstrated that MASP-1 and MASP-3 were able to convert the proenzyme of 
factor D to an active form, thereby regulating the AP. In addition, MASP-1 was 
able to activate MASP-2 and MASP-3 as C1r activates C1s (135). 
1.3.3 MBL polymorphisms
The main site of production for MBL is the liver. Although it predominantly 
circulates as a serum protein, MBL has also been detected at various sites, e.g. 
in middle ear fluid, in synovial fluid of inflamed joint and in nasopharyngeal and 
vaginal secretion (136;137). In humans, MBL is transcribed from the mbl2 gene, 
whereas the mbl1 gene is a pseudogene. The mbl2 gene in humans appears to be 
highly polymorphic (Fig 7). Three mbl2 gene polymorphisms have been identified 
that are associated with strongly decreased MBL serum concentrations. These 
single nucleotide polymorphisms (SNPs) (138) are located in codon 54 (B 
genotype), codon 57 (C genotype), and codon 52 (D genotype) of the first exon, 
encoding the collagenous tail region of the MBL molecule, and are proposed 
to hamper the polymerization of the MBL molecule (139-141). Furthermore, 
SNPs in the promoter of the mbl2 gene modify the basal serum level of MBL 
(142). A number of studies demonstrated that low serum levels of MBL and 
MBL gene polymorphisms are associated with decreased pathogen resistance, 
mainly in childhood but also in adults (141;143-146). An increased susceptibility 
to infections is predominantly observed in situations in which other defense 
mechanisms fail, such as in patients with additional immunological defects (147-
149), and in patients with other chronic diseases (144;150). 
Among the complement deficiencies described in humans, deficiency of MBL 
has the highest frequency. Depending on ethnicity, the total allele frequency of 
the B, C and D allele may be above 40 % (151). Since these polymorphisms are 
not subject to a high negative selection pressure, it has been suggested that 
the polymorphisms, although conferring LP dysfunction, are also associated 
with host protection in certain situations (152). In this regard, epidemiological 
evidence has been provided for a protective role of MBL gene polymorphisms 
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against the induction of tissue damage in rheumatoid arthritis (153) and 
against the development of inflammatory bowel disease (154). Furthermore, 
glomerular deposition of MBL in renal diseases such as post-streptococcal 
glomerulonephritis (155), IgA nephropathy (137;156-158) and lupus nephritis 
(159) also supports a potential role for MBL in amplification of tissue injury. In 
this respect, an unfavorable role for MBL in renal IRI might be possible as well. 
 
1.4 COMPLEMENT IN RENAL I/R
Although not the scope of this thesis, which mainly focusses on the role of 
complement in renal IRI, it is important to stress that complement activation 
might not only be involved in the initial phase of kidney transplantation, but may 
also play a main role in graft rejection following transplantation. Transplantation 
results in alloantigen-independent and alloantigen-dependent tissue damage. 
Among the potential alloantigen-independent causes of damage is the condition 
of the graft before transplantation including type of donor (living, brain-death 
or cardiac death donor), warm and cold ischemia times, the surgical procedure, 
and the medical treatment of the recipient, including possible drug toxicity. All 
these conditions can give rise to tissue injury that can lead to activation of the 
complement system (160). Accordingly, deposition of complement factors has 
been observed in graft biopsies obtained early after rejection, both in kidney 
and heart allografts (161;162). A critical role for local complement production in 
kidney transplantation has been recently established. Kidneys from C3-deficient 
mice showed long-term survival when transplanted in MHC-incompatible C3-
sufficient recipients without immune suppression, whereas C3-sufficient kidneys 
from the same strain were subject of rapid acute allograft rejection (115). In this 
respect, it has been shown that locally produced complement fragments C3a 
and C5a provide both costimulatory and survival signals to naive CD4+ T cells 
(163). In addition, antigen-presenting cell-produced C5a and C3a regulates CD4 
T-cell help to CD8 T cells, which is required for allograft rejection (164). Together, 
these experiments provide strong evidence that C3 is a crucial factor in renal 
allograft rejection.
1.4.1 Complement activation following ischemia/reperfusion
Whether complement activation following ischemia/reperfusion during kidney 
transplantation is beneficial or detrimental has been intensively studied in 
several animal models over the past years. Renal I/R generates a massive and 
dangerous burden of dead cell material, and if not cleared efficiently might lead 
to inflammation and activation of an early innate response, which may be a 
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prerequisite for the full development of adaptive alloimmunity and subsequent 
allograft rejection. 
All initiating factors of the complement cascade, including C1q, MBL, ficolins 
and properdin have been shown to interact with late apoptotic and necrotic 
cells in vitro (75-78) facilitating effective clearance via direct interaction with 
phagocytic cells or by further opsonzation via activation of the complement 
cascade. In this respect, opsonization by complement factors followed by 
efficient clearance could therefore dampen inflammation. However, the role of 
complement in clearance of dying tubular cells following renal I/R is unclear. 
Infiltration of professional phagocytic cells, e.g. macrophages in renal IRI is 
well-known (94;95), however this infiltrate remains mostly interstially and is 
very rarely observed passing the basolateral membrane entering the lumen of 
the tubule. Dying tubular cells detach from the basement membrane ending 
up in the lumen where they obstruct tubular flow. These casts may remain 
there for several days following AKI. In this respect, a different mechanism for 
apoptotic and necrotic cell clearance has been proposed recently. Expression of 
Kidney-injury molecule (KIM)-1 on PTEC, might transform these cells into semi-
professional phagocytes (31). KIM-1 is a type-1 membrane receptor that is the 
most highly upregulated protein in the proximal tubule of the injured kidney 
and functions as a phosphatidylserine receptor, that recognizes and internalizes 
apoptotic cells. KIM-1 also functions as a scavenger receptor, mediating the 
uptake of modified low-density lipoprotein and necrotic cellular debris. The role 
of complement herein is unknown, however, it is clear that activation of the 
complement system is one of the hallmarks of renal IRI. 
Importantly, several studies mainly performed in mice have shown that 
complement activation following IRI is harmful and that deletion or inhibition 
of complement proteins protects against renal IRI, indicating that complement 
activation following reperfusion might induce further tissue injury and 
inflammation (165-171). Terminal complement cascade activation including 
release of C5a and formation of C5b-9 has been shown to be one the factors that 
contribute to tubular injury. Reperfusion of the kidney following ischemia induces 
endothelial activation and release of nitrous oxide leading to vasodilatation and 
leakage of complement components into the interstitial space. Additionally, 
tubular cells are able to produce complement components locally (79). In 
combination with a decreased expression of complement regulators at the 
basolateral side following I/R, viable as well as apoptotic or necrotic tubular 
cells are easily targeted for (terminal) complement activation. It is therefore not 
surprising that (terminal) complement activation is observed following renal I/R. 
Several studies performed in mice deficient for C3, C5, C6 (171) have shown 
(partial) protection against renal IRI. In addition, a very elegant kinetic IRI study 
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performed in mice (166) showed that the first C3 deposition was observed 
several hours after reperfusion and was localized on cellular debris and injured 
tubular epithelial cells. Intrarenal depositions of C6 were seen at 12 hours after 
reperfusion and increased over time. C5b-9 deposition was first observed after 
18 hours of reperfusion and was distributed similar to C6 deposition, although 
more intense in tubular casts. Moreover, this study also indicates that inhibition 
of C5 protects against renal IRI with reduced renal dysfunction and neutrophil 
influx into the kidney. Interestingly, inhibition of C5 totally prevented C5b-
9 formation, but also reduced C3 deposition, clearly indicating that terminal 
complement activation results in additional local inflammation and collateral 
damage leading to more tissue destruction and renal dysfunction in rodents. 
In rats, kinetics of complement activation is more delayed with first signs of 
complement activation and deposition of C3 at 24 hours of reperfusion (Fig 
8). In human thus far, in-depth studies for the role and kinetics of complement 
activation in renal IRI are still lacking.
1.4.2 Pathogenic role of complement activation
Although local complement activation might be injurious in renal IRI, the 
question remains whether activation of the complement cascade by tubular 
cells is the very initial trigger for cellular injury following reperfusion or that 
sham 2 hours 5 hours
24 hours 48 hours 72 hours
Figure 8. Production and deposition of complement component C3 after renal I/R. 
Normal rat kidney (sham) showing characteristic half-moon shaped staining of C3, 
reflecting local renal production. Upon renal ischemia (45 min clamping), first signs 
of complement activation and deposition of C3 on tubular cells are observed after 24 
hours of reperfusion peaking at 48 hours. At 72 hours of reperfusion, deposition of C3 
is still present on desquamated tubular epithelial cells and tubular casts in the lumen 
of the tubules.
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complement merely aggravates inflammation and local tissue injury by 
activation of the terminal complement cascade on injured and dead cells. 
Currently, only one study has been published that supports the hypothesis that 
terminal complement activation, i.e the lytic C5b-9 complex is the initial trigger 
for tubular cell injury following reperfusion (171). In this study, a central role for 
the terminal complement cascade in renal IRI was suggested from C6-deficient 
mice which were partially protected. Only a minor role was ascribed to the 
release of C5a and subsequent recruitment of neutrophils into the kidney, given 
that treatment with an antibody to C5 did not show any additional protection 
in C6-deficient mice. In contrast, a study performed in rats (172) demonstrated 
that blocking of the C5aR pathway by a specific C5a receptor antagonist had 
a protective effect against renal dysfunction following I/R. In another study 
(166), blocking of C5 cleavage in mice using a monoclonal antibody and thereby 
preventing C5b-9 formation only abrogated late I/R-induced apoptosis and 
inflammation, whereas early apoptosis was not prevented, indicating that C5a 
does not have a direct harmful effect on tubular cells. Since both C5a and C5b-9 
have been reported to be involved in the induction of inflammatory cytokines 
and chemokines, such as TNF-alpha, KC, and MIP-2 (173-178), this might explain 
the observed protective effects. Given that tubular cell death early following 
reperfusion is not prevented by blocking C5, this suggests that other cell death-
inducing mechanisms independent of (terminal) complement activation might 
be involved.
1.4.3 Differential pathway activation between species
Although the role of complement in the early pathogenesis of renal IRI has not 
been completely elucidated, it is clear that complement activation induces 
additional local inflammation and collateral damage leading to more tissue 
destruction and renal dysfunction. Therefore, therapeutic interference with 
complement activation might be an interesting option to treat and ameliorate 
renal IRI. However, to therapeutically target complement in renal IRI, it is 
important to delineate which pathways of complement activation are involved 
since blocking of all complement pathways early after transplantation could lead 
to a higher risk of e.g. urinary tract infections, a major complication following 
kidney transplantation. 
Complement activation in the mouse kidney is mainly attributed to the alternative 
pathway (AP) of complement activation (179;180). Renal IRI in mice does not 
induce antibody deposition and subsequent CP activation (181). Furthermore, 
mice lacking a functional AP are protected against renal IRI (179). In contrast, 
RAG-1-/- mice incapable of producing antibodies are not protected, suggesting 
that renal IRI in mice is not mediated via the CP (181). These data have been 
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confirmed in C3-/-, C5-/- and C6-/- mice which are protected, whereas C4-/- 
mice are not (181;182). This seems to be in contrast to murine models of IRI in 
heart, skeletal muscle, intestine and limb, which are all dependent on natural 
IgM and CP or LP activation. 
Intriguingly, although C4-deficient mice were not protected, studies using MBL-
knockout mice have shown a protective effect of MBL deficiency in the setting of 
renal IRI (168), and also renal deposition of MBL has been demonstrated. In line 
with this, it has been demonstrated in several mouse models of IRI, that MBL in 
association with MASP-2 can bypass C4 and directly cleave C3 (183) followed by 
further amplification via the AP. This might explain why MBL-deficient mice are 
protected against renal IRI, although other effectors functions of MBL might be 
involved. Glycosylated tubular meprins, which bind MBL (167), might be involved 
in the activation of complement in the mouse kidney. 
In contrast to these studies in mice, it was recently shown in a porcine IRI model 
that both the CP and LP might be involved. Reduced IRI is observed when pigs 
are treated with human C1 Inhibitor (C1INH), an inhibitor of both the CP and LP. 
An important difference between these species is the presence of peritubular 
C4d staining in pigs following reperfusion (165), which is completely absent in 
mice. This suggests that classical and lectin pathway activation by C1q and MBL 
leading to C4 deposition in the kidney following reperfusion in pigs is occurring, 
but is virtually absent in rodents. Importantly, C1INH has several other effector 
functions besides regulating complement, including regulation of coagulation 
and vascular permeability and inhibition of apoptosis (184-187). These effector 
functions might therefore also explain the observed protective effect, which lead 
to reduced renal IRI and subsequent less C4 and C3 deposition on tubular cells. 
The role and pathways of complement activation in porcine, but also human IRI 
is therefore not completely been elucidated yet. 
Interestingly, two studies by Berger et al (101;188) were showing that high 
serum levels of MBL in human are associated with inferior renal allograft survival 
following clinical kidney transplantation, suggesting an unfavorable role for 
MBL in kidney transplantation. However, we can only speculate whether this 
was due to involvement of MBL in the initial phase during transplantation or 
in later rejection episodes. Altogether, these findings point towards important 
species-specific differences in complement activation following I/R, however 
in-depth studies on the mechanism and involvement of different pathways of 
complement activation in humans are still lacking. The possible differences in 
the mechanisms of complement activation by mouse and human tubular cells 
might have important implications for the interpretation of experimental data 
obtained in mice. To successfully develop therapeutic interventions targeted 
towards different pathways of complement activation, it is essential to establish 
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the validity of murine data relative to what takes place in the human situation. 
Therefore, there is a great demand for studies analyzing the activation of 
complement pathways in human kidney transplantation. 
 
1.5 THESIS AIM AND OUTLINE
The aim of the research described in this thesis was to study the role of complement 
in renal ischemia/reperfusion injury (IRI) and to delineate the contribution of 
the different complement pathways involved. So far, in human renal IRI, the 
activation pathways of complement by ischemic proximal tubular epithelial cells 
(PTEC) are still incompletely elucidated. In chapter 2 we therefore established an 
in vitro model to simulate IRI on human and mouse PTEC by culturing these cells 
under normoxic or hypoxic conditions and then investigated the subsequent 
effects on complement activation following reoxygenation (reperfusion). We 
specifically focused on the question which pathway(s) of complement activation 
are initiated by human and mouse PTEC after hypoxic stress. In chapter 3 we 
addressed the lack of evidence for involvement of complement in human IRI. We 
assessed the formation and release of C5b-9 during early reperfusion in clinical 
kidney transplantation in living donor, brain-dead donor, and cardiac dead donor 
kidney transplantation. Complement activation following I/R may take place in 
both tubular and vascular compartments. Therefore, we systematically measured 
terminal complement activation during early reperfusion in human kidney 
transplantation in both the tubular compartment by immunohistochemistry 
and the intravascular compartment by selective arteriovenous measurements 
over the transplanted kidney. In chapter 4 we studied whether C5b-9 could 
also be detected in urines of transplant recipients early after transplantation. In 
addition, we investigated the possibility whether in proteinuric urine, which is 
common following transplantation, C5b-9 might be generated independent of a 
renal contribution. 
Based on previous clinical studies that high serum levels of MBL were associated 
with inferior renal allograft survival following clinical transplantation, we 
examined in chapter 5 the role of MBL in the pathophysiology of renal IRI and 
explored the therapeutic targeting of MBL in a rat model of renal IRI. We identified 
an entirely novel role for MBL in mediating reperfusion-induced kidney injury 
following ischemia which is completely independent of complement activation. 
In chapter 6 we studied the mechanism by which MBL might mediate tubular 
injury following renal I/R. Vascular leakage results in exposure of tubular cells to 
MBL, which was shown to be the primary culprit of tubular injury. Recombinant 
human C1 inhibitor (rhC1INH) is a serine protease inhibitor that inhibits 
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complement activation, reduces vascular permeability and interacts with MBL. 
In chapter 7 we therefore explored the therapeutic application of rhC1INH in 
renal IRI and studied whether rhC1INH is able to attenuated MBL-mediated 
kidney injury. In chapter 8 we investigated the impact of short- and long-term IRI 
on vascular integrity, pericytes and angiopoietin expression. Finally, in chapter 
9 the findings presented in this thesis are critically discussed and the possible 
implications for kidney transplantation are presented. 
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ABSTRACT
Ischemia/reperfusion injury (IRI) has a major impact on graft survival after 
transplantation. Renal proximal tubular epithelial cells (PTEC) located at the 
cortico-medullary zone are relatively susceptible to IRI and have been identified 
as one of the main targets of complement activation. Studies in mice have 
shown an important role for the alternative pathway of complement activation 
in renal IRI. However, it is unclear whether experimental data obtained in mice 
can be extrapolated to humans. Therefore, we developed an in vitro model to 
induce hypoxia/reoxygenation in human and mouse PTEC and studied the role 
of the different pathways of complement activation. Exposure of human PTEC 
to hypoxia followed by reoxygenation in human serum resulted in extensive 
complement activation. Inhibition studies using different complement inhibitors 
revealed no involvement of the alternative or lectin pathway of complement 
activation by hypoxic human PTEC. In contrast, complement activation by 
hypoxic murine PTEC was shown to be exclusively dependent on the alternative 
pathway. Hypoxic human PTEC induced classical pathway activation, supported 
by studies in C1q-depleted serum and the use of blocking antibodies to C1q. 
The activation of the classical pathway was mediated by IgM through interaction 
with modified phosphomonoesters exposed on hypoxic PTEC. Studies with 
different human sera showed a strong correlation between IgM binding to 
hypoxic human PTEC and the degree of complement activation. These results 
demonstrate important species-specific differences in complement activation by 
hypoxic PTEC and provide clues for directed complement inhibition strategies in 
the treatment and prevention of IRI in the human kidney. 
 
INTRODUCTION
Ischemia/reperfusion injury (IRI) occurs upon reperfusion of vascularized 
tissue after an extended period of ischemia. It is an inevitable event in organ 
transplantation. Clinical and experimental studies have shown that renal IRI has 
a major impact on short- and long-term graft survival after organ transplantation 
and accounts for delayed graft recovery and associated morbidity and mortality 
(1;2). Restoration of blood flow to ischemic tissue initiates a cascade of 
inflammatory events including endothelial dysfunction, neutrophil sequestration 
and complement activation (C-activation) which all contribute to post ischemic 
injury (3).
The complement system is a complex cascade of proteins that can be activated 
by three different pathways (4). Each pathway is activated by a different set 
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of pattern recognition molecules. The classical pathway (CP) is initiated by 
direct binding of C1q to e.g. apoptotic cells, or by binding to antigen-antibody 
complexes. The lectin pathway of complement (LP) is activated by interaction 
of Mannan-binding lectin (MBL) or ficolins with sugar moieties. CP and LP 
activation both lead to deposition of C4 and C2 which result in the generation 
of the classical C3 convertase that is able to cleave C3. The alternative pathway 
(AP) is continuously activated at a low level (so-called tickover), does not require 
C4 and is tightly regulated by membrane-bound and soluble complement 
regulators. Furthermore, properdin can act as a focal point of AP mediated 
C-activation upon binding to its ligand (5). All pathways converge at the level 
of C3 and further downstream activation leads to formation of the membrane 
attack complex C5b-9 (MAC) (4).
Complement activation is a key feature of renal IRI, as has been demonstrated 
both in the clinical setting as well as in experimental models (6). Moreover, 
interference with C-activation reduces IRI. Studies in mice have suggested that 
the AP is predominantly activated in IRI. Mice deficient in factor B (7), an crucial 
constituent of the AP, or mice treated with anti-factor B antibodies (8) show 
reduced injury, whereas C4-deficient mice were shown to be as susceptible to 
renal IRI as wildtype mice (9). Nevertheless, other pathways of C-activation have 
also been implicated. Deposition of MBL was observed in mouse kidneys after 
renal IRI (10) and also deficiency of MBL partially protects mice against renal IRI 
(11). In pigs, different components of the CP and LP were detected after renal 
ischemia and therapeutic intervention with C1INH, which interferes with both 
the LP and CP, was successful (12).
In the heart, muscle and the intestine, C-activation after ischemia depends on 
naturally occurring IgM antibodies to intracellular antigens which are externalized 
upon ischemia (13-15). The role of these antibodies in renal IRI is controversial 
(16;17).
Both endothelial and epithelial cells in the kidney seem to be targets for 
C-activation following IRI. In the kidney, several studies have implicated the 
cortico-medullary proximal tubular epithelial cell (PTEC) as an important target 
(9;18). Renal IRI is associated with a reduction in membrane-bound complement 
regulators on PTEC (18). Moreover PTEC interact with properdin (19), which can 
serve as a focus for AP activation (5). 
So far, in human renal IRI the activation pathways by PTEC are still incompletely 
elucidated. In the present study, we developed an in vitro model to induce 
hypoxia/reoxygenation and investigated the subsequent effects on C-activation 
by hypoxic human and mouse PTEC. We specifically focused on the question 
which pathways of C-activation are initiated by the PTEC after hypoxic stress. 
We demonstrate that C-activation by human PTEC as a result of hypoxia/
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reoxygenation primarily occurs via the CP of complement, and is dependent 
on both IgM antibodies and C1q. In contrast, hypoxia-induced C-activation by 




Immortalized human renal proximal tubular epithelial cells (HK-2, kindly provided 
by M. Ryan, University College Dublin, Ireland)(20) were grown in serum-free 
DMEM/HAM-F12 (Bio-Whittaker, Walkersville, US) supplemented with 100 U/
ml penicillin, 100 µg/ml streptomycin (Invitrogen, Breda, the Netherlands), 
insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 ng/ml), tri-iodothyronine 
(40 ng/ml), epidermal growth factor (10 ng/ml) and hydrocortisone (36 ng/
ml, all purchased from Sigma, Zwijndrecht, the Netherlands). Primary human 
PTEC were isolated from pre-transplant biopsies or from kidneys not suitable for 
transplantation and cultured as described earlier (21). 
Immortalized mouse renal proximal tubular epithelial cells (IM-PTEC, kindly 
provided by Dr. G. Stokman, Gorlaeus Laboratories Leiden, Netherlands) were 
derived from a single proximal tubular epithelial cell of an Immorto mouse 
(Charles River, Maastricht, The Netherlands) based on the double expression 
of aquaporin-4 and CD10/neprilysin. Immorto mice express a temperature 
sensitive, interferon gamma dependent variant of the SV40 large T antigen. 
Cells are grown under permissive conditions at 33°C in DMEM/HAM-F12 (Bio-
Whittaker,) supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 
100 µg/ml streptomycin (Invitrogen), insulin (5 µg/ml), transferrin (5 µg/ml), 
selenium (5 ng/ml), tri-iodothyronine (40 ng/ml), prostaglandin E1 (5 ng/ml), 
hydrocortisone (36 ng/ml, all purchased from Sigma), mouse IFN-gamma (10 
ng/ml; R&D systems, Uithoorn, The Netherlands) and maintained for at least 
one week under restrictive conditions at 37°C in the absence of IFN-gamma to 
ensure re-differentiation.
Induction of hypoxia/reoxygenation and necrosis
To simulate an ischemic event, cells were grown to confluence in 24-well culture 
plates at 37 °C and subjected to normoxia (21% O2 and 5% CO2) or hypoxia 
(5% C02 and 95% N2) for 48 hours in a humidified modular incubator chamber 
(Billups-Rothenberg, Del Mar, US). Since it is known that cultured PTEC are 
resistant to hypoxia in high glucose levels (22), culture medium of the HK-2 cells, 
primary cultured human PTEC and mouse IM-PTEC was replaced by identical 
culture medium, but only containing 2 mM glucose, before induction of hypoxia. 
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To simulate the reperfusion phase, cells were washed and reoxygenated in 5% 
or 30% pooled human serum (NHS) or mouse serum (NMS) respectively, diluted 
in DMEM/HAM-F12 for 1h at 37 °C. As a control, cells were reoxygenated in 
medium without serum. Finally cells were washed in PBS, harvested with non-
enzymatic dissociation buffer (Sigma) and resuspended in FACS-buffer (1% 
BSA, 0.02 % sodium azide and 2,5 mM CaCl2 in PBS). Necrosis was induced by 
incubating fresh HK-2 cells and IM-PTEC at 56°C for 30 minutes, after which the 
cells were incubated with 5% NHS or 5% NMS for 1h at 37 °C. 
Analysis of complement activation pathways 
In order to elucidate which pathways of complement are involved in C-activation 
by hypoxic cells, several complement inhibitors were evaluated. EDTA, at a final 
concentration of 5 mM, was used to inhibit all pathways of C-activation. MgEGTA, 
at 5 mM, was used to block both the CP and LP. To further assess the role of the 
LP, D-Mannose (200 mM; Sigma) or increasing doses of mAb 3E7 (anti-MBL mAb 
kindly provided by Dr. T. Fujita, Fukushima, Japan), which both inhibit the binding 
of MBL to its ligands, were used. To assess the role of the CP, increasing doses 
of mAb85 (mAb anti-human C1q, kindly provided by Prof. C. E. Hack, Sanquin, 
Amsterdam, the Netherlands) were used. MAb85 is directed against the globular 
head regions of C1q and inhibits binding of C1q to activators such as IgM and 
aggregated IgG (23). To further study CP activation the binding of IgM (5-100 µg/
ml) to normoxic and hypoxic HK-2 cells was assessed. Functional consequences 
of IgM binding to hypoxic HK-2 cells were studied using 5% or 30% C1q- or IgM-
depleted human serum. As a control the serum was reconstituted with purified 
C1q (50 µg/ml) or IgM (100 µg/ml) respectively. IgM-dependent C-activation 
by mouse PTEC was studied by incubating hypoxic mouse IM-PTEC with 5% 
serum derived from immunoglobulin-deficient RAG -/- mice. Furthermore, 
the role of IgM in C-activation was studied using the phosphatemonoester 
phosphorylcholine (Sigma), an antigen for natural IgM. Phosphorylcholine 
(20mM) was first preincubated with 5% NHS for 15 min at room temperature 
and next incubated with hypoxic HK-2 cells for 1h at 37 °C. Binding of serum IgM 
and deposition of C3, C4 and C5-b9 on normoxic and hypoxic human PTEC was 
studied using 5% NHS from eleven healthy donors diluted in serum-free DMEM/
HAM-F12 culture medium and incubated on the cells for 1 h at 37 °C. 
FACS analysis
After incubation with purified IgM or serum as a source of complement, cells 
were washed in PBS, harvested with non-enzymatic dissociation buffer (Sigma) 
and resuspended in FACS-buffer (1% BSA, 0.02 % sodium azide and 2,5 mM 
CaCl2 in PBS). Depositions of C3, C4, C5b-9 and binding of IgM on human 
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PTEC were detected using mouse monoclonal antibodies against human C3 
(RFK22, Laboratory of Nephrology, Leiden, the Netherlands), human C4 (C4-4A, 
anti-C4, kindly provided by Prof. C. E. Hack,), human C3d (Quidel, San Diego, 
USA), human C4d (Quidel), human C5b-9 (mAb AE11, kindly provided by Dr T. 
E. Mollnes, Nordland Central Hospital, Bodo, Norway) and human IgM (HB57, 
hybridoma obtained from the American Type Culture Collection, Manassas, VA) 
respectively, followed by RPE-conjugated polyclonal goat anti-mouse Ig (DAKO, 
Glostrup, Denmark,). Deposition of C3 on mouse PTEC was detected using a 
rabbit polyclonal antibody anti-mouse C3 (in house generated) (24), followed by 
RPE-conjugated polyclonal goat anti-rabbit Ig (DAKO). All antibody incubations 
were performed on ice for 30 min. Cell surface staining was assessed using a 
FACScalibur flow cytometer (Becton Dickinson, Mountain View, CA). Propidium 
iodide (PI, 1µg/ml, Molecular Probes, Leiden, the Netherlands) and Annexin 
V-FITC (25 µg/ml, VPS Diagnostics, Hoeven, the Netherlands) was used for 
exclusion of apoptotic and necrotic cells. 
Assessment of functional lectin pathway activity by ELISA
Functional activity of the LP was assessed using mannan-coated plates as 
previously described (25). Shortly, NHS preincubated with L- or D-Mannose 
(Sigma) was incubated for 1 hour at 37°C to allow C4 and C3 deposition in the 
well. The plates were washed and incubated with dig-conjugated C4-4A (anti-
human C4) or RFK22 (anti-human C3), followed by HRP-conjugated F(ab’)2 from 
goat IgG anti-dig (Boehringer Mannheim, Mannheim, Germany). After washing, 
C3 deposition was quantified with ABTS (Sigma). The OD at 415 nm was measured 
using a microtiter plate reader.
Complement and serum reagents
All samples were collected and experiments were performed according to the 
guidelines of the ethics committee of the Leiden University Medical Center. As a 
source of complement, pooled normal human serum (NHS) from healthy donors 
and pooled mouse serum from C57BL/6 (NMS) and RAG-/- mice was divided 
into aliquots and stored at -80°C until used. Human C1q-depleted serum was 
generated as previously described(25). The C1q-depleted serum showed normal 
LP and AP activity in hemolytic assays and could be completely restored with 
purified C1q. Human IgM-depleted serum was generated by immune adsorption 
using Biogel-coupled anti-human IgM monoclonal antibodies (HB57) at a high 
salt concentration to prevent C-activation during the procedure and showed 
normal activity in all three complement pathways. Human C1q (26) and IgM (25) 
were purified as previously described. 
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Figure 1. Induction of 
hypoxic stress. HK-2 cells 
were subjected to normoxic 
or hypoxic conditions for 
48 hours. Photographs (20x 
magnification) showing 
normoxic (a; left) and hypoxic 
cells HK-2 cells which are 
stressed, rounded and have 
lost their tight junctions with 
neighboring cells (a; right). 
Cells were stained with PI 
and Annexin V and apoptotic/
necrotic cells were excluded 
from further analyses (b). C3 
deposition was determined by 
FACS after 1 hour reoxygenation 
of cells in 30% NHS (c).
Statistical analysis
Correlation analysis between variables was performed by linear regression and 
the significance of differences between groups was calculated by Student’s t-test 
using GraphPad Prism software (GraphPad Software, San Diego, CA). Differences 
with P<0.05 were considered significant.
 
RESULTS
Complement activation by hypoxic HK-2 cells and primary human PTEC
In order to establish an in vitro model to simulate IRI on PTEC we cultured HK-2 
cells under normoxic or hypoxic conditions. Forty-eight hours of hypoxia were 
required to induce hypoxic stress which was accompanied by morphological 
changes with rounding of cells and loss of tight junctions (Fig. 1A). Despite 
these changes, the vast majority of both hypoxic and normoxic cell populations 
(respectively >75% and > 90%) were still viable at this time point, as determined 
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with Propidium iodide and Annexin-V staining (Fig. 1B). In all cases, apoptotic 
and necrotic cells were excluded from the analysis.
Reoxygenation of the cells in 30% normal human serum (NHS) resulted in 
extensive C-activation by hypoxic HK-2 cells (Fig. 1C). In line with our previous 
findings, a low level of C-activation was also observed on normoxic cells (19). 
C-activation by hypoxic HK-2 cells was not restricted to deposition of C3 only (Fig. 
2B), but was accompanied by deposition of C4 (Fig. 2A) up to the level of C5b-9 
(Fig. 2C). Moreover, using monoclonal antibodies to neoepitopes on C4d and 
C3d, we demonstrated that the detected C3 and C4 on the cell surface reflects 
activated C-fragments (Fig. 2D, E). Furthermore, in all cases, C-activation could 
be completely blocked using EDTA, showing that the deposition of C4, C3 and 
C5b-9 was the result of activation of the complement system (Fig. 2A-E).   
In addition to the HK-2 cell line, also primary human PTEC derived from 
different donors (n=5) were subjected to 48 hours of hypoxia followed by 1 
hour reoxygenation in 5% serum (Fig. 3A, B). While normoxic PTEC induced low-
grade C-activation, hypoxia/reoxygenation of these cells resulted in a significant 
Figure 2. Complement activation by hypoxic HK-2 cells. Normoxic (white bar) and 
hypoxic (grey bar) HK-2 cells were reoxygenated in 30% NHS and stained for C4 (a), 
C3 (b), C5b-9 (c), C4d (d) and C3d (e) deposition. As a control complement activation 
was blocked using EDTA. Dotted lines represent background staining. Results given 
are the mean (+SD) MFI of triplicate cultures and are representative of 3 independent 
experiments. 
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increase of C-activation and deposition of C3. Interestingly, there was some 
variance in the degree of C-activation between the five different PTEC (Fig. 
3A), indicating that some PTEC were more prone to activate complement after 
hypoxia/reoxygenation than others. Titration of serum showed that similar 
complement activation was observed when comparing 5 or 30% serum as 
a source of complement (data not shown), therefore 5% serum was used for 
further experiments.
A prominent role for alternative pathway activation by hypoxic mouse, 
but not human PTEC
Although the activation of complement and deposition of C4 on human PTEC 
(Fig. 2A) already suggested involvement of the CP or LP, most mouse studies of 
renal IRI have implicated a dominant role for the AP (7;8). Therefore, similar as 
with the human PTEC, mouse PTEC were cultured under hypoxic conditions for 
48 hours and reoxygenated in normal mouse serum (NMS) in the presence or 
absence of MgEGTA, which blocks both the CP and LP but leaves the AP intact. 
Indeed, C3 deposition on hypoxic mouse PTEC was not affected by the addition 
of MgEGTA, indicating that the AP is the predominant pathway activated by 
hypoxic mouse PTEC (Fig. 4A). In contrast, incubation of hypoxic human HK-2 or 
hypoxic primary human PTEC with 5% serum in the presence of MgEGTA, almost 
completely prevented deposition of C3 (Fig. 4A), indicating a major involvement 
of the CP or LP.
Necrotic human cells are known to bind different complement components, 
leading to activation of the complement system. To study whether C-activation by 
necrotic human and mouse PTEC also follow different pathways of C-activation, 
these cells were rendered necrotic and incubated with human or mouse serum 
respectively in the presence or absence of MgEGTA. Indeed, mouse PTEC again 
exclusively activate the AP as MgEGTA did not have any inhibitory effect (Fig. 4B). 
Under these conditions human necrotic PTEC now also show some activation 
Figure 3. Complement 
activation by hypoxic 
primary PTEC. Primary 
human PTEC (n=5) were 
subjected to normoxic or 
hypoxic conditions for 48 
hours and reoxygenated 
in 5% serum for 1 hour. C3 
deposition was determined 
by flow cytometry (a,b). 
White dots represent 
normoxic and dark grey 
dots hypoxic conditions.
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of the AP. These data show that hypoxic and necrotic mouse PTEC exclusively 
activate the AP, while hypoxic human PTEC primarily activate the CP/LP and 
necrotic human PTEC activate both the AP and CP/LP.
No contribution of lectin pathway activation by hypoxic human PTEC 
Several studies in mice and humans have shown a role for the LP, which can be 
activated by MBL, in renal IRI (10-12). To study the contribution of the LP on 
C-activation by hypoxic human PTEC, these cells were incubated with NHS in 
the presence or absence of an inhibiting monoclonal antibody to MBL (Fig. 5A). 
Inhibition of MBL did not affect C3 or C4 deposition, indicating that the LP is not 
involved. In line with these findings, blockade of the LP using D-Mannose, a ligand 
for MBL, did not affect C3 or C4 deposition (Fig. 5B). To show that D-Mannose is 
able to inhibit the LP of complement, we applied an ELISA system with mannan-
Figure 4. In contrast to mouse, hypoxic human PTEC hardly activate the alternative 
pathway. (a) To study the contribution of the alternative pathway human (HK-2) and 
mouse PTEC (IM-PTEC) were rendered hypoxic (a) or necrotic (b) and incubated with 5% 
NHS or NMS respectively, in the presence or absence of MgEGTA, to block classical and 
lectin pathway activation. C3 deposition was determined using flow cytometry. White 
bars represent normoxic and grey bars hypoxic conditions. Results given are the mean 
(+ SD) MFI of triplicate cultures and are representative of 3 independent experiments. 
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coated plates which specifically activate the LP. C-activation in this assay could 
be completely blocked using D-Mannose, while L-Mannose, which does not bind 
MBL, had no effect (Fig. 5C). Together 
these data show that inhibition of the 
LP had no effect on C-activation by 
hypoxic human PTEC, indicating that 
there is no involvement of the LP. 
IgM binds to hypoxic human 
PTEC and contributes to classical 
pathway activation
The studies above indicate that hypoxic 
human PTEC exclusively activate the 
CP in human serum. To obtain more 
detailed insight in the mechanisms of 
CP activation by hypoxic human PTEC, 
we assessed the effect of inhibition of 
the CP using a monoclonal antibody 
directed against the C1q-globular 
head domains. Blockade of the CP 
using this antibody resulted in a dose-
dependent inhibition of both C3 and 
C4 deposition on hypoxic HK-2 cells 
(Fig. 6A) and primary PTEC (data not 
shown). Moreover, incubation of 
hypoxic HK-2 cells in C1q-deficient 
serum resulted in an almost complete 
abrogation of C3 and C4 deposition 
and reconstitution with purified C1q 
restored C-activation (Fig. 6B). 
The CP can be activated by binding of 
C1q to different cellular ligands, but 
also to cell-bound immunoglobulins 
like IgM. Indeed, we could show a 
dose-dependent binding of purified 
IgM to hypoxic human cells (Fig. 7A). 
Exposure of hypoxic human PTEC to 
serum depleted of IgM resulted in 
an almost complete abrogation of C3 
deposition, whereas reconstitution of 
Figure 5. No involvement of lectin pathway 
of complement. The lectin pathway was 
studied by (a) incubating hypoxic HK-2 
cells with 5% NHS with an increasing dose 
of blocking antibodies to MBL (mAb 3E7). 
White dots represent C3 and grey dots C4 
deposition. Besides, hypoxic HK-2 cells (b) 
or mannan coated plates (c) were incubated 
with NHS in the presence or absence of 
200 mM L-mannose (light grey bar) or 
D-mannose (dark grey bar) after which C3 
and C4 deposition was determined. White 
bars represent the condition with NHS only. 
Results given are the mean (+ SD) MFI of 
triplicate cultures and are representative of 
3 independent experiments.
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this serum with purified IgM fully restored C-activation. (Fig. 7B), indicating a 
major role for IgM and subsequent C1q on C-activation by hypoxic human PTEC.
In contrast to human PTEC, incubation of hypoxic mouse PTEC with serum 
derived from RAG -/- mice, which lack immunoglobulins, still resulted in extensive 
C-activation (Fig. 7C) to a similar level as normal mouse serum.
Recent studies have shown that the binding of IgM to apoptotic cells is mediated 
for a major part by lyso-phosphatidyl derivatives and that this binding can be 
blocked using phosphorylcholine (27;28). Indeed, C-activation by hypoxic human 
PTEC was blocked significantly by 20 mM phosphorylcholine (Fig. 7D), suggesting 
that natural IgM antibodies can bind to phospholipid neo-epitopes exposed on 
hypoxic cells and subsequently function as a focus of CP activation by hypoxic 
human PTEC.
Correlation between IgM levels and complement activation by hypoxic 
human PTEC
Eleven sera derived from healthy individuals all induced significant C3, C4 and 
C5b-9 deposition on hypoxic HK-2 cells, compared to normoxic cells (Fig. 8A-C). To 
determine whether there was an association between IgM binding and classical 
C-activation we assessed in parallel the binding of IgM and the deposition of 
C3, C4 and C5b-9 on hypoxic PTEC (Fig. 8D-F). We found a significant correlation 
between IgM binding and C4 (r2=0.643), C3 (r2=0.572) and C5b-9 deposition 
(r2=0.570), indicating that IgM binding to hypoxic human PTEC plays an important 
role in activation of the CP of complement after hypoxic stress.
Figure 6. Prominent role for the classical pathway of complement. To study the 
contribution of the classical pathway, hypoxic HK-2 cells were incubated with 5% 
NHS with an increasing dose of blocking antibodies to C1q (mAb 85), after which C3 
(white dots) and C4 (grey dots) deposition was determined. (a) Hypoxic HK-2 cells were 
incubated with 5% C1q-deficient serum (white bars), or this serum was reconstituted 
with purified C1q (100 µg/ml)(grey bar) (b). Results given are the mean (+ SD) MFI of 
triplicate cultures and are representative of 3 independent experiments.
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Figure 7. In contrast to 
mouse PTEC, complement 
activation by hypoxic human 
PTEC is IgM-dependent. 
To establish if complement 
activation was dependent on 
bound immunoglobulins, the 
binding of purified IgM (a) to 
normoxic and hypoxic HK-2 
cells was assessed. To study 
functional consequences of 
IgM binding, hypoxic HK-2 cells 
were incubated with 5% IgM-
deficient serum. As a control 
serum was reconstituted with 
purified IgM (100 µg/ml) (b). 
IgM-dependent complement 
activation by mouse PTEC was 
studied by incubating hypoxic 
IMPTEC with 5% NMS or RAG -/- 
serum after which C3 deposition was determined (c). Results given are the mean (+ SD) 
MFI of triplicate cultures and are representative of 3 independent experiments. Dotted 
lines represent background staining. Hypoxic HK-2 cells were incubated with 5% NHS in 
the presence of 20 mM phosphorylcholine (PC) and C3 deposition was determined (d). 
Results given are the mean (+ SD) MFI of triplicate cultures and are representative of 2 
independent experiments.
DISCUSSION
Several lines of evidence support an important role for the AP of C-activation 
by proximal tubular cells in in vivo mouse models of renal IRI. However, it is 
still unclear whether similar pathways of C-activation are involved in the human 
setting. Therefore we studied hypoxia-induced C-activation by human and mouse 
PTEC. Complement activation by hypoxic mouse PTEC was mainly dependent on 
the AP, compatible with the in vivo observations. In contrast, hypoxic human 
PTEC primarily activated complement through the CP, with a major involvement 
of natural IgM antibodies. These results reveal important species-specific 
differences which might have important implications for complement directed 
therapies in renal IRI.
As an in vitro model of renal IRI, both primary human PTEC and HK-2 cells were 
cultured under hypoxic conditions and reoxygenated in human serum. This 
resulted in extensive C-activation by the tubular cells and deposition of C4 and C3 
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up to the level of C5b-9. Complement activation could be completely abrogated 
using EDTA, showing that the deposition of complement factors on the hypoxic 
cells was the result of activation of the complement system. 
In our model, normoxic human PTEC showed some deposition of complement, 
as described before (29), which is partially mediated through binding of 
properdin (19). Nevertheless, in our model C-activation was markedly increased 
as a result of hypoxia/reoxygenation compared to the basal level of C-activation. 
Furthermore, using MgEGTA which blocks the CP and LP, C-activation could be 
completely abrogated to levels of complement deposited on normoxic PTEC, 
indicating that the increased deposition of complement on hypoxic cells does 
not depend on the AP. 
Studies with MBL knockout mice have shown a protective effect of MBL 
deficiency in the setting of renal IRI (11), and also renal deposition of MBL has 
been demonstrated (10). Moreover, we have previously demonstrated that 
renal allograft recipients with low MBL levels show a better graft survival (30). 
However, we could not show a role for MBL in our in vitro model using hypoxic 
human PTEC. Blocking antibodies to MBL or inhibition with D-mannose did not 
have any effect on C-activation. Although C-activation in the ischemic kidney 
is largely localized to the tubular epithelium, low grade C-activation on the 
endothelium could result in activation of the endothelium and extravasation 
of serum constituents in the interstitium which could lead to C-activation on 
Figure 8. Hypoxia induces IgM-mediated complement activation. Normoxic (white bar) 
or hypoxic (grey bar) HK-2 cells were incubated with 5% serum derived from eleven 
different healthy volunteers, and C4 (a), C3 (b) and C5b-9 (c) deposition was determined. 
Simultaneously, binding of IgM was measured by FACS analysis and correlated to the C4 
(d), C3 (e) and C5b-9 (f) deposition. P values and correlation coefficients are given in the 
graphs.
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tubular epithelial cells. Therefore we hypothesize that MBL is mainly involved 
in LP activation on endothelial cells as shown before (31;32), or has effector 
functions that are still unknown. 
Using C1q-depleted serum or blocking antibodies to C1q we could reduce 
C-activation by hypoxic human PTEC to basal levels indicating that the 
complement system is mainly activated via the CP. Interestingly, C-activation by 
hypoxic cells that were annexin-V and PI positive, and thus were excluded from 
analysis, also occurred via the CP, suggesting that hypoxia-induced apoptotic 
PTEC expose similar ligands as the hypoxic, but still viable cells. 
It is known from several studies that late apoptotic and necrotic cells bind 
natural IgM antibodies which will lead to activation of the CP (27;33). We could 
also demonstrate such a binding of IgM to hypoxic PTEC. Using IgM-deficient 
serum we showed that C-activation by hypoxic cells also occurs via binding of 
IgM, probably via binding of IgM to phosphorylcholine residues exposed on 
hypoxic cells as shown by inhibition of C-activation using phosphorylcholine. 
Furthermore, we could show a high correlation between IgM binding and C4, C3 
and C5b-9 deposition using sera from different donors, suggesting a prominent 
role for IgM in activation of the CP. It has been proposed that I-PLA2 activation 
during apoptosis promotes the exposure of membrane lysophosphatidylcholine 
leading to binding of natural IgM antibodies and subsequently C-activation(34). 
It is tempting to speculate that a similar process may be involved on hypoxic 
human PTEC. 
Data from studies in mice indicate that C-activation due to IRI in skeletal muscle 
(13), heart (14), intestine (35) and limb (28) occurs through binding of natural 
IgM. However, in renal IRI in mice it has been shown that immunoglobulins do 
not play a role (17). These findings are in line with reports showing that C4-
deficient mice were not protected against renal IRI (9), so it appears that in 
mice IRI can proceed independently of C4 and immunoglobulins. To confirm 
this in our model we used mouse PTEC which were rendered hypoxic and were 
incubated with normal mouse serum supplemented with MgEGTA to block CP 
and LP activation. Additionally we also used serum from RAG -/- mice which 
lack immunoglobulins. Indeed, C-activation still proceeded in the absence of 
immunoglobulins or an active CP and LP, indicating that the AP plays an important 
role in mice. These data are in contrast to hypoxic human PTEC which primarily 
activate the CP via IgM but in agreement with in vivo studies in mice (7;8). Also 
in a pig model, it was recently shown that the CP and LP of complement were 
involved in renal IRI (12). Importantly, these authors showed reduced ischemic 
injury when pigs were treated with C1INH, a specific inhibitor of both the CP 
and LP (36;37). Interestingly, this study (12) also demonstrated that these two 
pathways were activated in renal transplant recipients suffering from delayed 
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graft function (DGF). The co-localization of C4d with both C1q and MBL in graft 
biopsies obtained from these patients indicated that both these pathways 
were activated on peritubular capillaries, within the interstitium, and on the 
glomerular endothelium.
The potential difference in the mechanisms of C-activation by mouse and human 
cells, as presented in the current manuscript, has important implications for the 
interpretation of experimental data obtained in mice. To successfully develop 
therapeutic interventions targeted towards C-activation, it is essential to 
establish the validity of murine data relative to what takes place in the human 
situation. Because this study is limited to an in vitro model, further studies are 
needed to delineate the role of natural IgM and complement in the human 
situation following renal I/R. 
From the results above, we conclude that hypoxia-induced C-activation by 
human PTEC primarily occurs via the CP of complement, which is dependent on 
the binding of IgM. This is in contrast to hypoxic mouse PTEC which primarily 
activate the AP of complement. Together these data provide new clues about 
the pathways of complement that should be targeted after renal IRI in humans, 
however further studies in humans are needed.
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ABSTRACT
Background: Ischemia/reperfusion (I/R) injury has a major impact on kidney 
graft function and survival. Animal studies have suggested a role for complement 
activation in mediating I/R injury, however results are not unambiguous. Whether 
complement activation is involved in clinical I/R injury in humans is still unclear. 
Methods: In the present study, we assessed the formation and release of 
C5b-9 during early reperfusion in clinical kidney transplantation in both living, 
brain dead and cardiac dead donor kidney transplantation. By arteriovenous 
measurements and histological studies, local terminal complement activation in 
the reperfused kidney was assessed. 
Results: There was no release of sC5b-9 from living donor kidneys, nor was there 
a release of C5a. In contrast, instantly after reperfusion, there was a significant 
but transient venous release of soluble C5b-9 from the reperfused kidney graft 
in brain dead and cardiac dead donor kidney transplantation. This short-term 
activation of the terminal complement cascade in deceased donor kidney 
transplantation was not reflected by renal tissue deposition of C5b-9 in biopsies 
taken 45 minutes after reperfusion. 
Conclusions: This systematic study in human kidney transplantation shows an 
acute but non-sustained sC5b-9 release upon reperfusion in deceased donor 
kidney transplantation. This instantaneous, intravascular terminal complement 




Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ 
transplantation and a major determinant of patient and graft survival (1-3). 
Current therapy is supportive and there are no specific therapeutical options 
yet. The pathophysiology of I/R injury is complex and incompletely understood. 
The innate immune system has been suggested to play an important role in 
potentiating an injurious reaction upon reperfusion since it is prone to recognize 
not only pathogens but also ‘damaged self’ (4). 
The complement system is one of the fastest responding basal defense 
mechanisms of the innate immune system. Activation of either the classical, 
alternative, or Mannan-binding lectin pathway ultimately leads to the formation 
of C5b-9, otherwise known as the terminal complement complex or membrane 
attack complex (MAC). Release of soluble (s)C5-9 has been described in a variety 
of renal disorders, such as lupus nephritis, Henöch-Schonlein Pupura and aHUS, 
Acute but transient release of C5b-9 after kidney transplantation   •   67
   3
and has been shown to be a sensitive marker in assessing disease activity (5-8). 
Renal I/R affects the endothelial as well as the epithelial compartment and might 
activate the complement cascade leading to deposition of C5b-9 or release of 
non-lytic sC5b-9.
Animal studies of renal I/R injury generally show that complement inhibition 
reduces post-reperfusion damage (9-11). Zhou et al more specifically 
demonstrated the involvement of terminal complement complex C5b-9 (12). 
However, in recent rat experiments by our group, inhibition of complement 
activation did not reduce kidney damage and only 24 hours after reperfusion the 
first signs of complement activation were observed. Moreover, Mannan-binding 
lectin itself appears to exert cytotoxic effects on the tubular epithelium early 
after reperfusion, far before first complement deposition was observed (13). 
These recent findings raise questions about the contribution of complement 
activation as initiator of I/R injury.
Despite the extensive number of animal experiments, studies on the involvement 
of complement in human I/R injury are scarce. Studies in the human heart 
have suggested a role for complement activation in I/R-induced tissue damage 
(14,15). However, the diverse studies on experimental anti-complement therapy 
in human myocardial I/R injury did not lead to major improvements yet (16-21). 
To address the recent contradictory findings in animals and the lack of 
evidence for involvement of complement in human I/R injury, we investigated 
the role of complement activation in the initiation of clinical renal I/R injury. 
I/R-induced complement activation may take place in both the tubular and 
vascular compartment (10,22,23). Therefore, we systematically measured 
terminal complement activation during early reperfusion in human kidney 
transplantation in both the tubular compartment by immunohistochemistry and 
the intravascular compartment by selective arteriovenous measurements over 
the transplanted kidney.    
METHODS
Patient population
Twenty-four patients undergoing renal allograft transplantation were included 
for arteriovenous sampling; 8 patients receiving a kidney from a living donor, 9 
patients receiving a kidney from a brain dead donor and 7 patients receiving a 
kidney from a cardiac dead donor (patient and transplantation characteristics 
are in table 1), as previously described (29). Brain dead and cardiac dead donors 
together were referred to as deceased donors. For technical reasons (renal vein 
sampling) only patients receiving a left kidney were included. In another 33 
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patients (13 living donor, 10 brain dead donor, and 10 cardiac dead donor kidney 
recipients) renal biopsies were collected. The study protocol was approved 
by the local ethics committee, and informed consent was obtained from each 
patient.
Operation and materials
Kidney transplantations were performed according to local standardized protocol. 
In living donors minimally invasive nephrectomy was performed and Custodiol® 
Histidine–tryptophan–ketoglutarate solution (HTK) solution (Tramedico, Weesp, 
The Netherlands) was used for cold storage of the kidney. Brain dead and 
cardiac dead donor kidneys were perfused and stored with either University of 
Wisconsin solution (UW) or HTK. The immunosuppressive regimen was based 
on tacrolimus or cyclosporine A in addition with mycophenolate mofetil and 
steroids in all groups. 
Arterial and renal venous blood samples were obtained as described before in 
detail (25). A schematic drawing of the arteriovenous sampling method is shown 
in figure 1. In short, via a small catheter placed in the renal vein blood aliquots 
were sampled at 0, 3, 10 and 30 min. after reperfusion. Paired arterial blood 
samples were obtained at 0, 3, 10 and 30 min. after reperfusion. All samples 
were collected in tubes containing EDTA and immediately placed on ice. Blood 
samples were centrifuged (1,550 g, 20 min, 4°C) and the derived plasma was re-
centrifuged (1,550 g, 20 min, 4°C) to deplete it from leukocytes and thrombocytes. 
Material was aliquotted and stored at -70ºC until assayed.
In another 33 patients (13 living donor, 10 brain dead donor, and 10 cardiac dead 
donor kidney recipients) renal biopsies were collected. A renal cortical biopsy 
Figure 1. Schematic 
representation of the 
arteriovenous sampling 
method over the reperfused 
kidney by simultaneous 
blood collection from 
the renal artery and vein. 
Illustration by Manon 
Zuurmond© (www.
manonproject.com)
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was obtained after cold storage, and a second biopsy of the same kidney was 
collected 45 minutes after reperfusion. 
sC5b-9 and C5a plasma measurements
sC5b-9 and C5a levels were assessed by sandwich ELISA. In short, 96-well ELISA 
plates (Nunc Bioscience, Belgium) were coated with a monoclonal antibody (mAb) 
to a neo-epitope on C5b-9 (aE11; Hycult Biotechnology, Uden, Netherlands) or 
C5a (mAb 2952; Hycult Biotechnology). Plasma was incubated in the coated 
wells and bound sC5b-9 or C5a was detected with a biotin-labeled mAb to C6 
(9C4; in-house made) or C5a (mAb 561; Hycult Biotechnology) respectively, 
followed by detection with streptavidin–poly-horseradish peroxidase (Sanquin, 
Amsterdam, The Netherlands). Enzyme activity was detected using 2,2′-azino-
bis (3-ethylbenzthiazoline-6-sulphonic acid) (Sigma Chemical Co., St. Louis, MO). 
The optical density was measured at 415 nm using a microplate reader (Model 
680; Biorad, Philadelphia, USA). The detection limits for C5a and C5b-9 were 
1.95 ng/ml and 0.01 U/ml, respectively.
Immunohistochemistry
Sections (4 µm) of paraffin embedded, formaldehyde fixed biopsies were 
deparaffinized and treated with 0.1% protease (type XXIV pronase, Sigma) for 
antigen retrieval. Endogenous peroxidase activity was blocked with 0.1% H2O2 
and 0.1% NaN3. Consequently, C5b-9 deposition was assessed using a mAb to 
a neoepitope on C5b-9 (aE11, Hycult Biotechnology) followed by anti-mouse 
peroxidase-conjugated EnVisionTM (DAKO, Glostrum, Germany). The staining 
was visualized using Nova RED (Vector Labs, Peterborough, United Kingdom). 
Sections were counterstained with hematoxylin (Merck, Darmstadt, Germany). 
As a positive control, a renal biopsy of a patient with acute graft rejection was 
used. 
 
Data collection and statistical analysis
Clinical donor data were retrieved from Eurotransplant. Outcome measures were 
creatinine clearance at 30 days after transplantation, presence and duration of 
delayed graft function (DGF) and patient and graft survival. DGF was defined 
as need for dialysis within 7 days post-transplantation. Statistical analysis was 
performed using SPSS 16.0 statistical analysis software (SPSS Inc, Chicago, Ill). 
Wilcoxon signed ranks test was used for paired non-parametric data, the Mann-
Whitney test for unrelated non-parametric data, i.e. comparison of different 
donor types. Graph points represent the median and error bars represent the 
interquartile range. A p-value of less than 0.05 was considered significant.
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LD BDD CDD
N 8 9 7
Donor age: mean (SD) 43.9(10.6) 54.1(17.1) 52.7(15.3)
Donor gender (M:F %) 75:25% 44:56% 43:57%
Duration ICU stay in h. (SD) N/A 126 (211) 107 (139)
Duration of BD in h. (SD) N/A 14.7(9.7) N/A
Preservation fluid (n) HTK (8) UW (9) UW(2),HTK (5)
WIT1 in min. (SD) N/A N/A 23.1(7.7)
CIT in h. (SD) 3.0(0.3) * # 19.7(6.2) 17.3(2.6)
WIT2 in min. (SD) 34.0(6.3) 33.0(6.1) 34.1(6.4)
Recipient age: mean (SD) 41.1(10.5) 55.1(13.5) 54.0(11.2)
Recipient gender (M:F %) 38:62% 44:56% 71:29%
Preemptive transplantation (n) 1 0 0
Creatinine clearance day 30 in       
ml/min (SD)
73.3 (20.5) * # 49.3(15.3) # 27.1(10.3)
DGF (%) 0% 56% 86%
DGF: dialysis after                            
transplantation in days (SD)
0 (0) * # 7.0 (5.3) # 17.2 (7.2)
Table 1: Transplantation and outcome characteristics of patients undergoing 
arteriovenous measurements. Groups undergoing living donor (LD), brain dead donor 
(BDD) and cardiac dead donor (CDD) kidney transplantation were compared. Intensive 
care unit (ICU) stay: the period the donor was admitted to intensive care unit, BD: the 
total duration of brain dead of the donor, WIT1: first warm ischemia time, CIT: cold 
ischemia time, WIT2: second warm ischemia time, DGF: delayed graft function. *p<0.05 
compared to BDD, # p<0.05 compared to CDD.
 
RESULTS 
Donor and transplant characteristics
Recipient and donor age and gender were similar in living donor, brain dead 
donor and cardiac dead donor groups (Table 1). As expected, warm and cold 
ischemia times differed between the groups, with shorter cold ischemia times 
in living donor kidney transplantation. The immunosuppressive regimen did 
not differ between groups. A significantly higher rate of delayed graft function 
(DGF) was observed in brain dead donor and cardiac dead donor as compared 
to living donor kidney transplantation. Brain dead donor and cardiac dead donor 
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transplantation were equal in occurrence, but not in duration of DGF. All kidneys 
were still functioning at 1 year post-transplantation, except for one kidney (the 
recipient was not compliant with immunosuppressive medication). 
Early release of soluble complement complex C5b-9 from the kidney 
into the circulation
Activation of the terminal complement cascade during reperfusion was 
assessed by measuring the release of soluble (s)C5b-9 complex from the kidney 
by arteriovenous measurements (Figure 1). Immediately at reperfusion there 
was an acute but transient release of sC5b-9 from deceased donor kidneys, 
which was not observed from living donor grafts (LD p=0.46, BDD p=0.011, CDD 
p=0.028; Figure 2). There was no release of sC5b-9 at later timepoints, at 3 (LD 
p=0.31, BDD p=0.77, CDD p=0.06), 10 (LD p=0.48, BDD p=0.68, CDD p=0.08) or 
30 minutes (LD p=0.12, BDD p=0.78, CDD p=0.74) after reperfusion. Soluble C5a, 
as an alternative sign of complement activation, was measured in arteriovenous 
samples in living donor kidneys. In accordance with sC5b-9 measurements, there 
was no difference in arterial and renal venous C5a levels (p=1.00 at 5 minutes, 
p=0.29 at 30 minutes after reperfusion, data not shown). Differences in the net 
release of sC5b-9 from the kidney for the total of 30 minutes were assessed 
by comparing arterial and venous area under the curve. For living (p=0.87) and 
brain dead donor grafts (p=0.26) no net release was observed from the kidney. 
Cardiac dead donor kidneys, however, showed a significant release of sC5b-9 
from the kidney for the total first half hour after reperfusion (p=0.018). Baseline 
(t=0) arterial values of sC5b-9 were not different between LD, BDD and CDD 
recipients (p=0.08). 
Figure 2. sC5b-9 concentration in arterial and venous blood samples in living donor 
(LD), brain dead donor (BDD) and cardiac dead donor (CDD) kidney transplantations in 
the first 30 minutes of reperfusion. There was a significant release of sC5b-9 within sec 
after reperfusion (first time point) from BDD kidney grafts (n=9, p=0.011) and from CDD 
grafts (n=7, p=0.028), but not from LD grafts (n=8, p=0.46). At later time points there was 
no significant difference anymore. Graphs show median and interquartile range. 
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No increase in local, tissue-bound complement complex C5b-9 after 
reperfusion
The acute but transient release of soluble C5b-9 into the circulation might be 
accompanied by local C5b-9 deposition in the kidney, and local deposition 
could contribute to the absence of circulating C5b-9. Therefore, presence and 
localization of C5b-9 in pre- and post-reperfusion kidney biopsies was assessed. 
Whereas the renal biopsy of acute rejection tissue showed extensive C5b-9 
positivity, staining for C5b-9 revealed no vascular or tubular depositions of C5b-
9 before or after reperfusion in any of the three donor types (Figure 3).
DISCUSSION
I/R injury is one of the main causes of delayed graft function in transplantation. 
Studies in mice have suggested a predominant role for complement activation 
in renal I/R injury. However, in our recent study we show that not complement 
activation, but rather direct cytotoxic effects of circulation derived Mannan-
binding lectin initiate tissue injury in rat renal I/R experiments (13). Studies on 
timing and role of complement activation in human renal I/R injury are scarce and 
inconclusive. Therefore, we set out to assess the role of terminal complement 
activation in the initiation of renal I/R injury in humans. Our data show that 
there is acute, non-sustained terminal complement activation upon reperfusion 
in deceased donor kidney transplantation. 
Figure 3. Representative sections showing distribution of C5b-9 staining in a pre- and 
post-transplantation biopsies of living donor (LD), brain dead donor (BDD) and cardiac 
dead donor (CDD) kidneys. There were no C5b-9 depositions in any of the biopsies (LD 
n=13, BDD n=10, CDD n=10). In contrast, the positive control biopsy of a kidney graft 
with acute rejection showed massive peritubular and tubular C5b-9 depositions. Original 
magnification, x200. 
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We concentrated on measurement of sC5b-9 as it is the common end-point 
of both the classical, alternative and Mannan-binding lectin pathway of the 
complement cascade. Moreover, in mice it is suggested that specifically C5b-9 is 
essential in the induction of tubular damage in renal I/R injury (12). By measuring 
arteriovenous differences over the reperfused organ, we were able to obtain 
very specific data on local venous release of sC5b-9 from the human kidney. In 
a previous study involving living donor kidney transplantations only, we found 
no release of sC5b-9, but rather an early and vast release of interleukin-6 from 
the kidney (24). In the current study the group is expanded with kidneys from 
brain dead and cardiac dead donors which are more severely affected by I/R. We 
show that from these deceased donor kidney grafts sC5b-9 is indeed released 
directly after reperfusion, indicative of intravascular terminal complement 
activation. Since sC5b-9 is released transiently, directly after reperfusion, this 
may result from a wash out effect. The complement system may be triggered 
upon encounter with intravascular cellular debris accumulated during the 
cold ischemic period or by encounter with hypoxic or injured endothelium 
(23,25). Studies in other human organs, such as the heart confirm complement 
activation in I/R injury (14,15), although these observations may be influenced 
by complement activating effects of the cardiopulmonary bypass machine (26). 
Besides the intravascular sC5b-9 formation, C5b-9 could be formed locally in the 
tissue without any release into the circulation. To assess this tubular activation, 
tissue content and distribution of C5b-9 was assessed in kidney biopsies collected 
before and after reperfusion. There was no deposition of C5b-9 in the kidney 
after reperfusion in both living and deceased donor kidney transplantation. This 
is confirmed by a study of Haas et al. where in post transplantation biopsies no 
complement depositions as consequence of reperfusion were detected either 
(27). In contrast, renal tissue of a patient with acute graft rejection showed 
extensive C5b-9 deposition in the tubular compartment. 
Finally, the possibility remained that the complement cascade is activated in 
living donor kidneys as well, without leading to terminal complement activation. 
Therefore, release of C5a from the reperfused kidney was assessed because C5a 
is more upstream in the complement cascade than the terminal complex C5b-
9 is. In agreement with sC5b-9 measurements, there was no C5a release from 
living donor kidneys. This excludes complement activation after reperfusion in 
living donor kidneys and also excludes early involvement of C5a, which has also 
been ascribed a harmful role in I/R injury (9). 
A limitation of our study was the fact that the sampling time was restricted to 
maximally 30 minutes following reperfusion. Although complement activation 
in this study was only observed instantly after reperfusion, mouse experiments 
show membrane attack complex elements C6 and C9 later on, at 12 and 24 
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hours after reperfusion, respectively (28). Furthermore, one may consider the 
sample size as a limitation. However, as the goal of this study was to assess the 
basic pathophysiological role of complement activation in I/R injury, instead of 
correlating findings to clinical outcomes, small patient numbers were sufficient. 
Finally, only cortical biopsies could be collected, as deeper puncture holds a high 
risk of bleeding and calycal injury and was considered unsafe. 
In summary, this systematic study in human kidney transplantation shows 
acute, non-sustained intravascular terminal complement activation during early 
reperfusion of deceased donor kidney grafts, likely to be initiated by contact 
with intravascular cellular debris and injured or hypoxic endothelium. 
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ABSTRACT
Local activation of the complement system has been associated with ischemia/
reperfusion injury following kidney transplantation and tubular injury under 
proteinuric conditions. The soluble terminal complement complex sC5b-9 is a 
stable end-product of the complement cascade, and as such a promising urinary 
biomarker. In the early post-transplant period we found high urinary levels of 
sC5b-9, significantly correlating with the degree of proteinuria, suggesting 
activation of filtered complement components at the tubular epithelial surface 
of the kidney. However, when mimicking proteinuria in vitro by exposing serum 
(or blood) to urine (both negative for sC5b-9), we found extensive generation 
of sC5b-9 in urine. This process was inhibited by EDTA, confirming activation of 
the complement system. In conclusion, although sC5b-9 is an attractive urinary 
biomarker, one should be aware of the risk of extra-renal complement activation 
independent of a renal contribution. This may be of special interest when 
measuring urinary sC5b-9 following kidney transplantation in which procedure-
related (microscopic) hematuria and proteinuria are common. 
 
BRIEF COMMUNICATION
Complement activation at the tubular epithelial surface of the kidney, which 
lacks several important complement regulators (CD46, CD55) (1), is considered 
to be a mediator of tubular injury in the proteinuric condition. In proteinuria, 
complement proteins, which normally are retained in circulation, are able to pass 
the glomerular filter barrier, end up in the tubular lumen and are activated by 
the unprotected epithelial surface of the tubuli (2-4). To this end, the detection 
of soluble (s)C5b-9 in urine is widely considered as a clinical indicator of tubular 
complement activation (5-7). 
The complement system, a set of circulating proteins of the innate immune system 
that forms a biochemical cascade, is activated by the binding of complement 
recognition molecules (e.g. C1q, MBL or properdin) to their respective target (e.g. 
pathogens or apoptotic cells). Three activation pathways have been recognized, 
namely the classical, lectin and alternative pathway, which all converge at the 
level of complement component C3. Subsequent downstream activation of 
the complement cascade leads to formation of the lytic terminal complement 
complex C5b-9, which is able to damage and lyse target cells. Recently, it was 
shown that complement activation and deposition of C5b-9 on tubular epithelial 
cells is mediated by binding of properdin, the initiator of the alternative pathway 
of complement (8).
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Increased glomerular permeability to large plasma proteins (proteinuria) is 
common in the early period following renal transplantation, with a prevalence 
of 15% to 30% at 1 year post-transplantation (9). Activation of filtered or locally 
produced complement components is likely to be involved in tubulotoxicity 
of proteinuria (2;3). 
Complement activation 
products indeed are 
detectable in the urine 
of patients with different 
proteinuric renal diseases 
(10;11) and are believed 
to be one of the possible 
candidates mediating 
tubular injury in the 
proteinuric condition (2;3). 
However, in the days after 
transplantation, not only 
glomerular damage may be 
responsible for proteinuria, 
but also a procedure-related 
(microscopic) hematuria.
In the present study we confirm the relation of urinary sC5b-9 and proteinuria 
in a renal transplantation cohort and we investigated the possibility whether in 
proteinuric urine sC5b-9 can be generated independent of a renal contribution. 
In a cohort of deceased cardiac dead donors (Table 1), high levels of urinary 
sC5b-9 were detected (Fig 1A) at day 2 after transplantation, which decreased 
Figure 1. Urine from recipients of a renal allograft were collected at day 2, 10 and 42 
after transplantation and assessed for sC5b-9 (A) and proteinuria (B). Levels of sC5b-9 at 
day 2, 10 and 42 (C) were correlated to the measured proteinuria. 
Table 1. Donor, recipient and graft characteriscrtics.
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slowly after 10 and 42 days. Although urinary output was still variable at day 2, 
almost all patients showed normal diuresis at day 10. Most patients suffered 
from proteinuria (Fig 1B), and the degree of proteinuria strongly correlated with 
the urinary sC5b-9 levels (Fig 1C). 
To assess whether this observed complement activation may be an extra-renal 
phenomenon, the proteinuric condition was mimicked in vitro. Seven urine 
samples from healthy volunteers, all free of sC5b-9, were incubated with a 
small amount of freshly drawn blood from the corresponding individuals, which 
strikingly resulted in extensive generation of sC5b-9 in urine (Fig 2A). In contrast, 
levels of sC5b-9 remained low when the same amount of blood was added to 
PBS instead of urine, indicating that complement can be activated in urine ex 
vivo, independent of any renal contribution. To assess whether this effect was 
due to the presence of blood cells (12) (e.g. in hematuric conditions), similar 
dilutions of human serum in urine were tested. This also resulted in an extensive 
generation of sC5b-9 (Fig 2B), ruling out any effect of blood cells on the observed 
complement activation. 
The active process of complement activation in the urine samples in vitro 
was confirmed by the complete abolishment of complement activation when 
EDTA was added before incubation (Fig 2C). Since EDTA chelates calcium and 
magnesium needed for complement activation, measured urinary sC5b-9 must 
be formed by active complement activation in vitro in urine. 
The urinary protein content in the transplantation patients varied from 0 to 
10 mg/ml (Fig 1C). In an additional experiment, this range was approached 
by serially diluting serum (normal serum protein content is 60-80 mg/ml) 4 to 
32 times (Fig 3A). Even when serum was 32 times diluted in urine (reflecting a 
urinary protein content of 1.8-2.5 mg/ml), significant levels of sC5b-9 could be 
Figure 2. Blood (A) or serum (B, C) from seven healthy volunteers was 1:4 diluted in 
the corresponding urines or PBS and incubated for 60 minutes at 37°C followed by 
assessment of sC5b-9. Additionally, 10mM EDTA was added to the serum/urine to block 
complement activation (C). ** P < 0.01; *** P<0.001.
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detected. This indicates that also in less severe proteinuric conditions, sC5b-9 
can be generated without any renal contribution. 
Urine, even from healthy subjects, often contains viable or apoptotic renal cells 
and cellular debris (13;14), as turnover or injury to epithelial cells lining the 
urinary tract results in shedding of these cells into urine which potentially could 
lead to activation of complement proteins present in proteinuric urines (15;16). 
To investigate such an involvement, the urine was filtered with a 0.2 µm filter to 
remove cells and cellular particles which possibly remained after centrifugation. 
Next, the corresponding serum was added to the filtered or unfiltered urine to 
allow sC5b-9 generation (Fig 3B). Removal of remaining cells and cellular debris 
reduced the sC5b-9 generation in the urine by half, suggesting that sC5b-9 
generation in proteinuric urine is partially caused by cellular debris and apoptotic 
epithelial cells. The remaining complement activation observed after filtration, 
may be explained by high urinary levels of ammonia (17;18) or low urinary pH 
(12), which have been shown to favor urinary complement activation.
After renal transplantation, proteinuria is a common event, with a prevalence of 
15% to 30% at 1 year after transplantation (9). Here, we show that after renal 
transplantation, urinary sC5b-9 can be detected in the majority of renal allograft 
recipients and significantly correlates with the degree of proteinuria. This would 
classically be interpreted as activation of complement by the tubular epithelial 
Figure 3. Serum from a healthy volunteer was serially diluted in the corresponding urine 
and incubated for 60 minutes at 37°C followed by assessment of sC5b-9. Represented 
data are true sC5b-9 concentrations, uncorrected for dilution. sC5b-9 levels in the diluted 
serum were compared to undiluted serum. * P < 0.05; ** P < 0.01; *** P<0.001 (A).
Urine from 4 healthy volunteers was filtered with a 0.2 µm filter to remove any remaining 
cells or cellular debris. Subsequently, corresponding sera were 1:4 diluted in the filtered 
and unfiltered urine for 60 minutes after which sC5b-9 generation was assessed. ** P < 
0.01 (B).
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surface (8;19). However, in this study we show that, independent of a renal 
contribution, presence of blood or serum constituents in urine form healthy 
subject could lead to complement activation and generation of sC5b-9 in vitro. 
This implies that following transplantation, proteinuria and procedure-related 
(microscopic) hematuria may cause urinary complement activation resulting 
in high urinary sC5b-9 levels. Centrifugation or filtration following collection of 
patient urines would not prevent this, since urinary complement activation most 
probably occurs in the urinary tract.
We would like to conclude that urinary sC5b-9 measurement is troubled by extra-
renal or even ex vivo complement activation in case of hematuric or proteinuric 




Twenty-four patients undergoing a renal allograft transplantation receiving a 
kidney from a deceased cardiac death donors in the period between August 
2005 and September 2006 were recruited (Table 1). The study protocol was 
approved by the local ethics committee, and informed consent was obtained 
from each patient. 
Operation and materials 
Donor kidney transplantations were performed according to the local protocol. 
From allograft recipients, urine was collected at consecutive days after 
transplantation. Urine samples were centrifuged at 2500g at 4° Celsius for 10 
minutes, aliquotted and stored at −80° C for later complement measurements.
Urine measurements
Soluble C5b-9 was measured by ELISA using an antibody to a neoepitope on C5b-
9 (AE11) (20). Total protein was measured by a colorimetric method. 
Urinary complement activation
Whole blood or serum from 7 healthy volunteers was 1:4 or serially diluted 
in their corresponding urine or PBS, and incubated for 60 minutes at 37°C 
(mimicking the hematuric or proteinuric condition, respectively). Additionally, 
the process of complement activation was prevented by adding 10 mM EDTA. 
To investigate any involvement of remaining renal cells or cellular debris, urine 
from 4 healthy volunteers was filtered with a 0.2 µm filter (GE Healthcare, Little 
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Chalfont, UK). Subsequently, corresponding sera were 1:4 diluted in the filtered 
and unfiltered urines and incubated for 60 minutes at 37°C. After incubation, 
in all samples further complement activation was blocked by adding 10mM 
EDTA. Samples were then immediately processed for sC5b-9 measurement as 
described. 
Statistics
Correlation analysis between variables was performed by linear regression and 
the significance of differences was calculated by a Mann-Whitney test using 
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ABSTRACT
Ischemia/reperfusion injury (IRI) remains a major problem in renal 
transplantation. Clinical studies have identified that high serum levels of 
Mannan-binding lectin (MBL), the initiator of the lectin pathway of complement 
activation, are associated with inferior renal allograft survival. Using a rat model, 
we identified an entirely novel role for MBL in mediating renal IRI. Therapeutic 
inhibition of MBL was protective against kidney dysfunction, tubular damage, 
neutrophil and macrophage accumulation, and expression of proinflammatory 
cytokines and chemokines. Following reperfusion, exposure of tubular epithelial 
cells to circulation-derived MBL resulted in internalization of MBL followed by the 
rapid induction of tubular epithelial cell death. Interestingly, this MBL-mediated 
tubular injury was completely independent of complement activation since 
attenuation of complement activation was not protective against renal IRI. Our 
identification that MBL-mediated cell death precedes complement activation 
strongly suggests that exposure of epithelial cells to MBL immediately following 
reperfusion is the primary culprit of tubular injury. In addition, also human 
tubular epithelial cells in vitro were shown to be susceptible to the cytotoxic 
effect of human MBL. Taken together, these data reveal a crucial role for MBL in 
the early pathophysiology of renal IRI and identify MBL as a novel therapeutic 
target in kidney transplantation. 
INTRODUCTION
Ischemia/reperfusion injury (IRI) is a key event in clinical conditions such as 
infarction, sepsis and organ transplantation. Restoration of blood flow to 
ischemic tissue paradoxically exacerbates tissue damage by initiating a cascade 
of inflammatory events including release of pro-inflammatory cytokines and 
chemokines, recruitment of leukocytes and activation of the complement 
system (1-3). Numerous clinical and experimental studies have shown that 
renal IRI profoundly impacts short-and long-term graft survival following kidney 
transplantation, and is strongly associated with delayed graft function (DGF) and 
clinical morbidity and mortality (3-5). DGF results in oliguria, increased allograft 
immunogenicity and risk of acute rejection episodes (5) and is associated with 
extensive loss of the cortico-medullary proximal tubular epithelial cells (PTEC), 
often referred to as acute tubular necrosis (ATN). To date, no effective therapy or 
treatment for renal IRI in the clinic exists.
Renal ischemia is accompanied by a reduction of membrane-bound complement 
regulators on PTEC, rendering these cells susceptible to complement activation 
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following reperfusion (6). Activation of the complement system has been 
documented as one of the hallmarks of renal IRI (6-8). The complement system 
is a central component of innate immunity and consists of three pathways of 
activation, namely the classical, alternative and lectin pathway. The complement 
cascade is activated by the binding of recognition molecules, such as C1q and 
MBL, to their respective target, e.g. pathogens, apoptotic or necrotic cells (9). All 
three pathways converge at the level of complement factor C3, which is cleaved 
and subsequently deposits as C3b on target cells resulting in opsonization 
and clearance by phagocytic cells. In absence of effective clearance, further 
activation of the complement cascade leads to generation of the membrane 
attack complex (MAC) C5b-9 and lysis of target cells. 
MBL is the major recognition molecule of the lectin pathway of complement 
activation. Single-nucleotide polymorphisms in both structural and regulatory 
parts of the MBL gene have been found to lead to large interindividual variations 
in the concentration of functional MBL in serum (0-4 µg/ml) (10). Previously, 
we have shown that low pre-transplantation levels of MBL are associated with 
better graft survival after deceased-donor kidney transplantation. These findings 
identify MBL as a potential risk factor for graft and patient survival in renal 
transplantation (10;11). In rodents, MBL exists in two distinct isoforms, namely 
MBL-A and –C (12). Nevertheless, specific inhibition of MBL-A in myocardial 
infarction in rats has been shown to be effective in reducing post ischemic damage 
(13). Modulation of the complement system has been recognized as a promising 
strategy in drug discovery, and a large number of therapeutic modalities have 
been developed (14;15), suggesting that therapeutic strategies could be 
employed to improve clinical outcomes following renal IRI. In the present study 
we examined the role of MBL in the pathophysiology of renal IRI and explored 
the therapeutic targeting of MBL in a rat model of renal IRI. We identified an 
entirely novel role for MBL in mediating reperfusion-induced kidney injury 




The Animal Care and Use Committee of the Leiden University Medical Center 
approved all experiments. Eight-week-old male Lewis rats (200–250 gram) 
purchased from Harlan (Horst, The Netherlands), were housed in standard 
laboratory cages and were allowed free access to food and water throughout 
the experiments. Unilateral ischemia was induced by clamping of the left renal 
pedicle for 45 minutes using a bulldog clamp (Fine Science Tools, Heidelberg, 
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Germany). During clamping the contralateral kidney was removed. Sham-treated 
rats had identical surgical procedures except for clamping of the left kidney but 
including removal of the contra-lateral kidney. Before induction of ischemia, rats 
were treated with anti-rat MBL-A mAb (IgG1; P7E4; 1 mg/kg), anti-rat C5 mAb 
(IgG2b; 18A; 20 mg/kg) or as a control anti-human fibronectin mAb (IgG1; 1 mg/
kg or 20 mg/kg respectively) (13;16). To deplete rats (n=5 per group) of C3, cobra 
venom factor (CVF, 2 mg/kg; Sigma-Aldrich, Zwijndrecht, The Netherlands) or 
PBS as a control, was administered intraperitoneally 19 hours before induction 
of ischemia. To prevent CVF-induced C5 activation, rats were pretreated with 
anti-rat C5 mAb (18A; 20 mg/kg). 
Assessment of kidney function 
Renal function was determined by measuring creatinine and urea in serum 
samples using standard autoanalyzer methods by our hospital research services.
Renal histology
Histological evaluations were performed in a blinded manner by a single 
pathologist. Formalin-fixed kidneys embedded in paraffin were sectioned and 
stained with silver by standard methods. 
 
Renal immunostaining
Rat kidney sections (4 µm) of snap-frozen kidneys were air dried and acetone-
fixed. Neutrophil (PMN) and macrophage (Mph) accumulation was assessed 
using digitonin (DIG)-conjugated mAbs against CD43 (W3/13) and CD68 
(ED-1) respectively, followed by horseradish peroxidase (HRP)-conjugated 
sheep anti-DIG (Roche Diagnostics, Mannheim, Germany). The staining was 
visualized using Nova RED (Vector Labs, Peterborough, United Kingdom). Rat 
C3 deposition was assessed by direct staining using a fluorescein isothiocyanate 
(FITC)-conjugated rabbit polyclonal to rat C3 (made in-house). Quantification 
of immunohistochemistry was performed in a blinded manner by assessing 10 
consecutive high power fields (HPFs; magnification ×200) of the outer medulla 
and cortico-medullary junction on each section. Using image J software, the 
positive area in each image (expressed in pixels) was quantified. Deposition of rat 
or human MBL was assessed using anti-rat MBL (mAb 14C3) or anti-human MBL 
(mAb 3E7; Hycult Biotech, Uden, The Netherlands) respectively, followed by HRP-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc). 
The staining was visualized using tyramide labeled with tetramethylrhodamine-
5-(and 6)-isothiocyanate (Sigma-Aldrich). Nuclei were stained using Hoechst 
(Molecular Probes, Leiden, The Netherlands). Fluorescent micrographs were 
made using confocal laser scanning microscopy (LSM 510, Zeiss, Germany).
MBL mediates I/R injury independent of complement activation  •   91
   5
RNA isolation and Real-Time PCR
Rat kidney RNA was extracted from snap frozen renal tissue and purified using an 
RNeasy Mini isolation Kit according to the manufacturer’s instructions (Qiagen, 
Hilden, Germany). Specific rat primers for Kidney injury molecule (KIM)-1, 
Neutrophil gelatinase-associated lipocali (NGAL), Macrophage chemoattractant 
protein (MCP)-1, macrophage inflammatory protein (MIP)-2 and ribosomal 
protein S-15 (RPS-15, housekeeping gene), were designed using Oligo Explorer 
and obtained from Biolegio (Nijmegen, The Netherlands). The primer sequences 
were as follows: KIM-1 (forward, 5′- TACCAACATCAACCAGAGTCTC -3′; reverse, 5′- 
ACATAGAAGCCCTTAGTCGG - 3′), NGAL (forward, 5′- CGATGAACTGAAGGAGCGATTC 
-3′; reverse, 5′- TGGCAACAGGAAAGATGGAG - 3′), MCP-1 (forward, 5′- 
GCCCAGAAACCAGCCAAC -3′; reverse, 5′- GCCAGTGAATGAGTAGCAGC - 3′), MIP-2 
(forward, 5′- TCAATGCCTGACGACCCTAC -3′; reverse, 5′- GAGCCCATGTTCTTCCTTCC 
- 3′) and RPS-15 (housekeeping gene): forward 5’ CGTCACCCGTAATCCACC-3’ and 
reverse 5’-CAGCTTCGCGTATGCCAC -3’). PCR was performed using SYBR Green 
PCR mastermix (Biorad). Data were analyzed using Gene Expression Analysis for 
iCycler Real-Time PCR Detection System (Biorad). Expression of each gene was 
normalized against mRNA expression of the housekeeping gene Rsp-15. RT PCRs 
were performed in duplicate.
Immunohistochemistry 
Functional activity of the lectin pathway in rat serum was assessed by detection of 
C3 deposition on mannan-coated plates as previously described (17). Hemolytic 
activity of rat serum was assessed in an AP50 hemolytic assay as previously 
described (18).
Cell culture
Immortalized human PTEC (HK-2) (18) were grown as previously described 
(19). Primary PTEC from pre-transplant biopsies (20) and human umbilical vein 
endothelial cell (HUVEC) (21) were isolated and cultured as described. Primary 
cells were used at passage 3 or less.
Flow cytometry 
Cells were fixed using 1% paraformaldehyde (Pharmacy) and permeabilized using 
0.1% saponin (Sigma-Aldrich). Internalized MBL was detected using anti-human 
MBL (mAb 3E7; Hycult Biotech) followed by RPE-conjugated goat anti-mouse 
IgG (Southern Biotechnology Associates, Birmingham, USA). MBL staining was 
assessed using a FACScalibur flow cytometer (Becton Dickinson, Mountain View, 
CA). MBL binding and subsequent internalization was inhibited using 10 mM 
EDTA (Sigma Aldrich).
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Fluorescence microscopy
Cells were fixed using cold methanol (Pharmacy) and stained with anti-human 
MBL (mAb 3E7; Hycult Biotech) and rabbit polyclonal anti-human protein 
disulfide isomerase (PDI, Cell Signaling Technology, Danvers, MA, USA) followed 
by alexa-488 conjugated goat anti-mouse IgG (Molecular Probes) and alexa-568 
conjugated goat anti-rabbit IgG (Molecular Probes), respectively. 
Viability assays
Cell viability was assessed by FACS analysis using propidium iodide (PI; Molecular 
Probes, Leiden, The Netherlands) and Annexin V-FITC (VPS Diagnostics, Hoeven, 
The Netherlands). Cell viability was also assessed by counting Hoechst-positive, 
but PI-negative cells using fluorescence microscopy. Inhibition studies were 
done using D- or L-mannose (Sigma-Aldrich) or a blocking antibody to MBL (3F8). 
Preparation of human MBL
MBL was purified from human serum as previously described (22).
Statistical analysis
All data are presented as mean ± standard error of the mean (SEM) and subjected 
to nonparametric statistical analysis using one- and two-factor ANOVA or Mann-




Inhibition of MBL preserves renal function after ischemia/reperfusion 
To therapeutically target MBL in renal IRI we used a mAb to MBL-A (P7E4) which 
previously has been shown to effectively reduce post-ischemic damage following 
myocardial infarction in rats (13). Five minutes before induction of ischemia 
rats were treated with anti-MBL-A resulting in a transient inhibition of lectin 
pathway activity that normalized 24 hours afterwards (Fig 1A), while classical 
pathway activity was unaffected (data not shown). The lectin pathway activity 
in rats receiving the isotype-matched control antibody was unaffected (Fig 1A). 
Induction of ischemia for 45 minutes followed by reperfusion resulted in a marked 
impairment of renal function in control treated rats as measured by serum levels 
of creatinine (Fig 1B) and urea (Fig 1C) with levels rising within 24 hours and 
remaining high until 72 hours after reperfusion. In contrast, rats receiving the 
blocking antibody to MBL-A were protected against renal dysfunction, with 
serum levels of creatinine and urea close to the normal range (Fig 1B and C). 
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Furthermore, renal dysfunction in control-treated rats was accompanied by a 
significant decrease in weight at 72 hours after reperfusion, compared to sham 
or anti-MBL treated rats (Fig 1D). Despite the transient inhibition of MBL-A, the 
protection against renal IRI was almost complete, indicating that MBL-A exerts 
its harmful effects relatively short after reperfusion. 
Anti-MBL treatment reduces tubular injury and leukocyte infiltration 
Ischemia/reperfusion resulted in extensive ATN (Fig 2A) leading to tubular cast 
formation and obstruction of tubules (Fig 2E). These events were significantly 
reduced by inhibition of MBL-A (Fig 2B,F), with a reduction of 70% in ATN (Fig 
2C) and 66% in tubular cast formation (Fig 2G). Assessment of renal mRNA levels 
of KIM-1 and NGAL, both markers of tubular injury, revealed significantly lower 
KIM-1 expression (Fig 2D) in the anti-MBL treated group. NGAL expression had a 
tendency to decrease (Fig 2H). 
Figure 1. Inhibition of MBL-A protects against renal ischemia/reperfusion injury. 
Before induction of unilateral ischemia and removal of the contralateral kidney, rats 
received anti-MBL-A or an isotype-matched control mAb (1 mg/kg). Before and following 
reperfusion blood samples were drawn at consecutive time points to determine lectin 
pathway activity (A). Renal function was assessed by measuring serum creatinine (B) and 
urea (C) levels. After 72 hours of reperfusion rats were weighted and compared to pre-IRI 
weight to calculate weight loss (D). Data are shown as mean ± SEM, n= 6 per group. The 
comparison between groups is indicated by asterisks. * P < 0.05; ** P<0.01;***P<0.001.
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Tubular injury after reperfusion was accompanied by extensive infiltration of 
PMN (Fig 3A) and Mph (Fig 3E) in the outer medullary zone. Inhibition of MBL-A 
significantly reduced accumulation of PMN (Fig 3B, C) and Mph (Fig 3F, G), and 
chemokine expression of MIP-2 (Fig 3D) and MCP-1 (Fig 3H).
Figure 2. Tubular injury is significantly reduced by inhibition of MBL-A. Silver staining 
of renal sections from control (A, E) and anti-MBL (B, F) treated rats 72 hours following 
reperfusion showing ATN (A) and tubular cast formation (E) (original magnification 
x200). ATN (C) and tubular cast formation (G) were analyzed semi-quantitatively. Renal 
mRNA expression of injury markers KIM-1 (D) and NGAL (H) in renal tissue at 72 hours 
following reperfusion was assessed. Data are shown as mean ± SEM (n= 6 per group). The 
comparison between groups is indicated by asterisks. * P < 0.05; ** P<0.01;***P<0.001.
Figure 3. Macrophage and neutrophil accumulation was significantly reduced by 
inhibition of MBL-A. Renal sections from control (A, E) and anti-MBL (B, F) treated rats 
72 hours following reperfusion were stained for PMN (A, B) and Mph (E, F) (original 
magnification x200). Infiltrates of PMN (C) and Mph (G) were quantified using digital 
image analysis. Renal mRNA expression of the chemokines MIP-2 (D) and MCP-1 (H) in 
renal tissue at 72 hours following reperfusion was assessed. Data are shown as mean ± 
SEM (n= 6 per group). The comparison between groups is indicated by asterisks. * P < 
0.05; ** P<0.01.
Immunohistochemistry
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Induction of reperfusion injury is independent of complement activation
In mice it has been shown that the MAC (C5b-9) plays an important role in the 
induction of tubular injury following renal IRI (6). To dissect the role of C5 (which 
is downstream of MBL and C3) in our renal IRI model, we applied an anti-rat C5 
antibody (mAb 18A), which was previously shown to significantly reduce injury 
in a rat myocardial IRI model (16). Injection of anti-rat C5 before induction of 
ischemia resulted in complete inhibition of the terminal pathway of complement 
for at least 24-48 hours, whereas the control antibody had no effect (Fig 4A). 
However, despite this relative long-term inhibition of C5, rats were not protected 
against renal dysfunction, showing equally high creatinine levels as compared to 
control-treated rats (Fig 4B). Furthermore, there was no significant difference 
in tubular injury (Fig 4C) and cast formation (Fig 4D) suggesting that the tubular 
injury is not induced by C5 activation in this model. Moreover, assessment of 
Mph and PMN influx revealed an extensive influx of inflammatory cells in both 
the anti-C5 and control-treated group (Fig 4E, F).
Immunohistochemistry
Figure 4. Inhibition of C5 does not ameliorate renal ischemia/reperfusion injury. Before 
induction of unilateral ischemia and removal of the contralateral kidney rats received 
anti-rat C5 or a control mAb (20 mg/kg). Before and after reperfusion blood samples 
were drawn at consecutive time points to determine the inhibitory capacity of anti-rat 
C5 mAb by measuring serum hemolytic activity in an AP50 hemolytic assay (A). Renal 
function was assessed by measuring serum creatinine levels (B). Using silver staining, 
ATN (C) and tubular cast formation (D) was assessed semi-quantitatively at 72 hours 
after reperfusion. Renal sections were stained for Mph (E) and PMN ( F) infiltrate and 
analyzed quantitatively. Data are shown as mean ± SEM (n= 6 per group). The comparison 
between groups is indicated by asterisks. ** P<0.01.
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Since inhibition of MBL-A was shown to be very effective in reducing renal IRI, 
whereas inhibition of C5 was not, we set out to dissect the role of C3. Depletion 
of C3 was achieved using cobra venom factor (CVF) and was preceded by 
administration of anti-C5 to prevent excessive C5 cleavage and generation of 
C5a. Injection of anti-C5 abrogated terminal complement activity (Fig 5A) and 
subsequent administration of CVF completely depleted the pool of C3 for at least 
48 hours after reperfusion (Fig 5B). Despite depletion of C3 and inhibition of C5, 
this did not result in protection against renal IRI but even tended to an increased 
impairment of renal function (Fig 5C). CVF did not affect kidney function, since 
sham operated rats which also received CVF and were uninephrectomized, 
showed stable serum creatinine levels (Fig 5C). Also the influx of Mph (Fig 5D) 
and PMN (Fig 5E) at 48 hours was not reduced, indicating that not solely C3a or 
C5a were responsible for the influx of inflammatory cells into the renal tissue. 
Figure 5. Depletion of C3 does 
not protect against renal 
ischemia/reperfusion injury. 
Twenty-four hours before 
induction of ischemia, all 
groups received anti-rat C5 (20 
mg/kg). Five hours afterwards 
and 19 hours before induction 
of ischemia, rats received 
CVF to deplete C3. Sham-
operated rats also received 
CVF, while the control group 
received PBS. Blood samples 
were drawn at consecutive 
time points to determine 
hemolytic activity in an AP50 
assay (A) and C3 activation in 
a lectin pathway activation 
assay (B). Renal function was 
assessed by measuring serum 
creatinine levels (C). Renal 
sections following 48 hours of 
reperfusion were stained for 
Mph (D) and PMN ( E) infiltrate 
and analyzed quantitatively. 
Data are shown as mean ± SEM 
(n= 5 per group). 
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Complement is activated in a late phase following renal ischemia/
reperfusion and is preceded by deposition of MBL and tubular injury 
Taken together, these findings led us to question the contribution of different 
complement components in the early induction of renal IRI. Therefore, we 
further investigated the kinetics of tubular injury and complement activation 
in our model. Signs of ATN, including loss of tight junctions and epithelial 
sloughing, were early events (within 2-5 hours after reperfusion; Fig 6A) and were 
accompanied by deposition of MBL (Fig 6B). At this stage however, deposition 
of C3 (Fig 6C) and C5b-9 (Fig S1) was completely absent, implying that tubular 
injury could not be caused by activation of complement and generation of the 
lytic C5b-9 complex. Only from 24 hours onwards, C3 deposition was observed 
on injured MBL-positive tubular cells (Fig 6D). This delayed appearance of C3 
could not be explained by a change in local expression, as C3 expression even 
decreased from 5 hours onwards (Fig S2). Together, these findings suggest a 
differential role for MBL and complement activation in renal IRI. 
Figure 6. Complement is activated in a late phase following reperfusion and is preceded 
by deposition of MBL and tubular injury. Silver staining (A) of renal sections from rats 
(n=6 per group) sacrificed prior to, 2, 5 or 24 hours after reperfusion showing early loss 
of tight junctions and cell adherence at 2 and 5 hours followed by ATN at 24 hours. 
Renal sections were triple stained (D) for MBL (B; red), C3 (C; green) and Hoechst (blue) 
(original magnification x200).
98   •  Chapter 5 
Upon reperfusion MBL leaks from circulation and is internalized by 
tubular epithelial cells
This prompted us to seek for alternative effector functions than activation of 
complement by which MBL potentially could injure tubular cells. First we studied 
the localization and deposition of MBL following reperfusion in more detail. 
Staining of kidneys for rat MBL-A, showed minor staining in the peritubular 
capillaries of sham operated rats (Fig 7A), reflecting circulating MBL. In contrast, 2 
hours after reperfusion we observed an interstitial staining for MBL, surrounding 
the basolateral side of the tubuli (Fig 7B). Even more, also an intracellular staining 
of MBL-A in tubular epithelial cells was observed (Fig 7C), suggesting that MBL 
Figure 7. Following reperfusion MBL leaks from circulation and is internalized by 
tubular epithelial cells. Renal sections from sham operated (A) and ischemic rats (B, C) 
2 hours following reperfusion, were stained for rat MBL (red). Nuclei (blue) were stained 
using Hoechst. To discriminate between locally expressed or circulation-derived MBL, 
rats were injected with human MBL and sacrificed 3 hours after reperfusion. Sections 
from the right control kidney (D) or left ischemic kidney (E, F) were stained for human 
MBL (red). Presence of intracellular human MBL (red) was confirmed using confocal 
scanning laser microscopy (G), showing MBL staining in the same Z-plane (marked by 
asterisks) near the nuclei (blue). To study the interaction of human MBL with human 
PTEC in vitro, HK-2 cells were incubated with purified human MBL (0-20 µg/ml) for 30 
minutes at 4°C, followed by flow cytometry analysis (H, I). To study internalization of 
MBL, PTEC were incubated with 10 µg/ml human MBL at 4 or 37°C and intracellular 
MBL staining was assessed using flow cytometry (J). Values shown are mean ± SEM of 
triplicate determinations from a single experiment and are representative of 3 similar 
experiments. Dotted line represents background staining. Furthermore, internalization 
of MBL by cultured human PTEC was assessed using fluorescence microscopy (K). Human 
PTEC (HK-2) were incubated with 10 µg/ml human MBL for 60 min at 37°C and stained 
(n=5) for intracellular MBL (green), ER-marker PDI (red) and nuclei (blue) (original 
magnification x200 for A, B, D, E; x400 for C, F, K).
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from circulation had been internalized. However, assessment of MBL-A mRNA 
revealed local MBL-A expression in the kidney (Fig S2), leaving the option that 
intracellular MBL might be the result of local production. 
To discriminate between locally expressed or circulation-derived MBL, we 
intravenously administered human MBL (50 µg) shortly after reperfusion 
resulting in a serum concentration of 2 µg/ml human MBL (data not shown). 
Specific staining for human MBL of the reperfused kidney 3 hours following 
reperfusion revealed an intense staining surrounding (Fig 7E) and inside tubular 
cells (Fig 7F), which was absent in the contralateral control kidney (Fig 7D). 
Intracellular MBL was further demonstrated using confocal microscopy (Fig 7G), 
showing MBL staining (red) in the same plane (Z-plane) in between the nuclei 
(blue). This confirms that upon reperfusion of the ischemic kidney, MBL from 
circulation leaks into the interstitium where it is internalized by tubular cells. 
This staining was most pronounced in the cortico-medullary border, the region 
mostly damaged. 
To further study whether MBL is able to interact with tubular cells, we cultured 
and exposed human PTEC to human purified MBL in vitro, which resulted in dose-
dependent binding of MBL as determined by flow cytometry (Fig 7H, I). To study 
internalization of MBL by tubular cells as observed in vivo following reperfusion, 
human PTEC were incubated with MBL at 4 or 37°C followed by an intracellular 
FACS staining (Fig 7J). We observed an increased staining at 37°C, indicating that 
MBL was indeed internalized. Incubation of MBL in presence of EDTA, which 
chelates calcium needed for binding, largely inhibited binding and subsequent 
internalization of MBL. These data were confirmed by immunofluorescence 
using an intracellular staining method, showing a perinuclear staining pattern of 
human MBL (Fig 7K), indicating that binding of MBL is followed by internalization. 
Together these data show that MBL specifically binds to PTEC which is followed 
by internalization.
MBL induces tubular epithelial cell death
To study the functional consequence of MBL binding and internalization, human 
PTEC were incubated with different concentrations of purified MBL (0-10 µg/ml) 
for different time points. Strikingly, already within 5 hours of MBL incubation 
(10 µg/ml) alterations in cell morphology were observed. Tubular epithelial cells 
start shrinking and rounding, followed by detachment from the plate within 
24 hours of incubation with MBL (Fig 8A), resembling the situation observed 
in vivo upon IRI. FACS staining of PTEC for PI and Annexin V after 24 hours of 
incubation with MBL (10 µg/ml) revealed that most cells were in an early (25%) 
or late apoptotic (44%) phase (Fig 8C), whereas untreated cells (90%) remained 
viable (Fig 8B). This cytotoxic effect was time- and dose-dependent and was 
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Figure 8. MBL induces tubular epithelial cell death. Human PTEC (HK-2) were incubated 
with 2.5, 5 or 10 (A) µg/ml human MBL for 2-48 hours. Wells were photographed (A, 
magnification ×200) and cell viability was assessed by counting Hoechst-positive, but 
PI-negative cells in the well using fluorescence microscopy (D). Cell viability at 24 
hours incubation with 0 (B) or 10 (C) µg/ml MBL was assessed by FACS analysis using 
propidium iodide (PI) and Annexin V-FITC. HK-2 cells were incubated with 10 µg/ml MBL 
in the presence of D- or L-mannose (200 mM) for 2-48 hours (E) and cell viability was 
determined using PI and Annexin V. HK-2 cells were incubated with 10 µg/ml MBL in 
the absence or presence of an inhibitory mAb to MBL (25 µg/ml; 3F8) for 24 hours (F). 
Primary HUVEC were incubated with 2.5, 5 or 10 µg/ml human MBL for 2-48 hours (G). 
Primary PTEC were incubated with 10 µg/ml MBL in the presence of D- or L-mannose 
(200 mM) for 24 hours (H). Cell viability was assessed by counting Hoechst-positive, but 
PI-negative cells (F-H). 
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accelerated at higher doses of MBL (Fig 8D), and even at a physiologic MBL 
concentration of 2.5 µg/ml this effect was clearly present. To show specificity, 
MBL was preincubated with D-mannose (a ligand for MBL) which resulted in a 
very effective inhibition of MBL-induced cell death, as assessed with Annexin 
V and PI (Fig 8E). In contrast, incubation with L-mannose, which does not bind 
MBL, showed no inhibition indicating that binding through the lectin domain of 
MBL is involved in exerting this cytotoxic effect. Prolonged incubation with MBL 
in the presence of D-mannose still resulted in complete inhibition of cell death, 
showing that D-mannose not only delayed, but actually prevents MBL-induced 
cytotoxicity. These data were confirmed using a blocking antibody to MBL (3F8) 
recognizing an epitope on the carbohydrate recognition domain resulting in an 
almost complete inhibition of MBL-induced cell death (Fig 8F). The cytotoxic 
effect was specific for epithelial cells, since HUVEC were not affected by MBL 
(Fig 8G). All PTEC experiments were performed using a PTEC cell line (HK-2). 
Therefore, we confirmed these observations by exposing primary human PTEC 
to MBL, which again resulted in MBL-induced cell death. Also here, this cell 
death could be prevented by the addition of D-, but not L-mannose (Fig 8H).
 
DISCUSSION
In the present study we identified a novel role for MBL in the pathogenesis of 
renal IRI. In a rat model of renal IRI, we demonstrated that therapeutic inhibition 
of MBL is protective against renal IRI. Following reperfusion, exposure of 
tubular epithelial cells to circulation-derived MBL resulted in internalization of 
MBL followed by the rapid induction of tubular epithelial cell death. This MBL-
mediated tubular injury was completely independent of complement activation 
since interference with C3 or C5 was not protective against renal IRI. MBL-
mediated cell death preceded complement activation strongly suggesting that 
exposure of epithelial cells to MBL immediately following reperfusion is the 
primary culprit of tubular injury, and not the lytic C5b-9 complex. 
Several studies, mainly performed in mice, have shown an important role for 
complement in the induction of renal IRI. A study using C3, C5 and C6 deficient 
mice showed a predominant role for C5b-9 in renal IRI (6), and also inhibition of 
C5 with monoclonal antibodies was protective (23). In contrast to these data, 
others have shown that gene knock-out (24), inhibition (24) or depletion of C3 
(25) was not protective against renal IRI. In our model deposition of C3 and 
C5b-9 following reperfusion was observed, although this was in a relatively late 
phase (24 hours onwards). A similar late kinetics of C5b-9 deposition has also 
been shown in a mouse IRI model (23), although this model was characterized 
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by an early increase in deposition of C3 (2 hours). We did not observe early C3 
deposition, indicating possible differences in kinetics and pathogenesis of renal 
IRI among species. Differences in organ size and metabolism between species 
could play a role in the observed differences, given that in mice clamping times 
of usually 20-25 minutes are needed to induce renal injury, while in rats 45-60 
minutes of clamping time is needed to induce substantial IRI. Also, difference 
in relative strength of complement activation pathways could be of influence. 
In this respect, it has been shown that serum complement activity even among 
rat strains are varying (26), explaining why in certain rat strains complement 
activation could be more involved.
Despite the fact that complement activation was not involved in the induction 
of renal IRI in our model, we did find a pivotal role for MBL in the pathogenesis 
of renal IRI, since transient inhibition of MBL-A in the early phase following 
reperfusion was completely protective. Studies in MBL-deficient mice, which 
are protected against renal IRI, confirm these findings (27). It is tempting to 
speculate that these mechanisms might contribute to our previous observation 
that genetically determined high levels of MBL were an important risk factor for 
renal graft loss following kidney or simultaneous pancreas kidney transplantation 
(10;11). 
Deposition of MBL has been observed in human biopsies early after 
transplantation (28) and in pigs following renal IRI (14), and is classically linked 
to activation of the lectin pathway of complement. Interaction of MBL with 
meprins expressed on tubular epithelial cells was shown to be the initial step 
for complement activation (29;30).  However, for the first time we here show a 
differential role for MBL in renal IRI, independent of its capacity to activate the 
complement system. MBL is able to directly induce renal tubular epithelial cell 
death in the complete absence of complement activation. 
Recently, in intestinal IRI in man it was shown that MBL null alleles were 
associated with preserved epithelial cell integrity (31). Interestingly, also here no 
signs of complement activation were observed, suggesting that also in intestinal 
IRI, MBL might have a cytotoxic effect on epithelial cells.
In oncology, MBL has been shown to bear anti-tumor activity which has been 
termed MBL-dependent cell-mediated cytotoxicity (32). However, to the best 
of our knowledge, our studies are the first to identify a direct cytotoxic effect 
of MBL on non-malignant cells. Recently, an intracellular form of MBL has been 
described which possibly functions as a cargo transport lectin facilitating ER-to-
Golgi traffic in glycoprotein quality control (33). Exogenous MBL internalized by 
tubular epithelial cells potentially could overload and dysregulate this system 
leading to induction of epithelial cell death, however more research is required 
to unravel the exact mechanism involved in MBL-induced tubular cell death. 
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In summary, our results document the important role of MBL in the early 
pathogenesis of renal IRI and suggest that therapeutic intervention at the level 
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SUPPLEMENTARY MATERIAL
The following supplementary material is available for this article:
Figure S1. C5b-9 deposits in a late phase following renal ischemia/reperfusion. 
Deposition of C5b-9 in the cortico-medullary region at consecutive time points after 
reperfusion (A). C5b-9 deposition was assessed using a mAb to a neoepitope on rat C5b-
9 (2A1, Hycult Biotechnology, Uden, The Netherlands) followed by HRP-conjugated goat 
anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). The 
staining was visualized using tyramide labeled with fluorescein (tyramide-FITC, Sigma-
Aldrich-Aldrich). C5b-9 deposition was quantified using digital image analysis (B).
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ABSTRACT
Ischemia/reperfusion injury (IRI) is a key event in kidney transplantation and 
is characterized by tubular epithelial cell injury. Recently, we demonstrated a 
crucial role for Mannan-binding lectin (MBL) in the pathogenesis of renal IRI. 
MBL, activator of the lectin pathway of complement, was shown to be directly 
cytotoxic to tubular cells independent of complement activation.
Here, we demonstrate that exposure of tubular cells to MBL in vitro mediates 
endoplasmic reticulum (ER)-stress. Assessment of ER-stress markers sXBP-
1 and CHOP revealed a potent ER-stress response with a twenty- and tenfold 
induction respectively, accompanied by a strong IL-6 expression. Strikingly, ER-
stress was followed by an excessive ATP production, loss of the mitochondrial 
membrane potential and production of mitochondrial superoxide. Confocal 
microscopy revealed a strong colocalization of internalized MBL with ER-stress 
sensor GRP78 and mitochondria, suggesting that interaction of MBL with GRP78 
and mitochondria is detrimental to cellular homeostasis. 
Assessment of sXBP-1 following renal ischemia/reperfusion in rats revealed an 
extensive induction of ER-stress within 2 hours, accompanied by an elevated 
IL-6 expression. Interestingly, assessment of GRP78 protein expression revealed 
a complete loss of GRP78 in the cortico-medullary region already 2 hours after 
reperfusion followed by tubular injury and abundant KIM-1 expression within 24 
hours. Importantly, therapeutic inhibition of MBL completely prevented loss of 
GRP78, diminished IL-6 expression and protected against tubular injury. 
In conclusion, we demonstrated that MBL mediates ER-stress and affects 
mitochondrial homeostasis in tubular cells. Interaction with GRP78 might be 




In kidney transplantation, ischemia/reperfusion (I/R) is an inevitable event and 
associated with extensive injury to the renal proximal tubular epithelial cells 
(PTEC). Numerous clinical and experimental studies have shown that renal 
IRI profoundly impacts short- and long-term graft survival following kidney 
transplantation, and is strongly associated with delayed graft function and 
clinical morbidity and mortality (1-3). To date, no effective therapy or treatment 
for renal IRI in the clinic exists.
Hypoxia/reoxygenation during renal ischemia/reperfusion (I/R) is a complex 
stress, characterized by interconnected cellular processes such as ATP depletion, 
MBL mediates ER-stress in tubular cells through GRP78   •   109
   6
protein misfolding, generation of reactive oxygen species (ROS), and elevation 
of intracellular calcium. PTEC are highly metabolic active and equipped with a 
vast amount of mitochondria, and are therefore particularly sensitive to these 
processes. 
The ER is the major intracellular calcium storage site and high lumenal calcium 
is essential for normal ER function. ATP shortage during ischemia results in a 
calcium leak from the ER, which impairs the activity of molecular chaperones 
and maturation of native proteins. These events result in accumulation of mis- 
and unfolded proteins in the lumen of the ER leading to ER-stress (4-6). 
Calcium flux from the ER into the cytosol is buffered to some degree by 
mitochondrial calcium uptake stimulating mitochondrial ATP production. 
However, once a continuous increase in cytosolic calcium exceeds the buffering 
capacity, mitochondria become dysfunctional and mitochondria-mediated 
apoptotic pathways are activated leading to cell death (7;8). Various adaptive 
responses to maintain homeostasis and survival are therefore employed, 
including the activation of the ER-stress response. 
The glucose-regulated proteins (GRPs), a family of molecular chaperones and 
calcium-binding proteins located in ER are induced by ER-stress. Induction of 
GRPs by ER-stress protects cells against oxidative stress and ischemia-related 
processes. The concept of ischemic preconditioning is based on this concept 
where a mild insult is sufficient to induce GRP expression and renders cells 
tolerant to a subsequent lethal insult (9;10). GRP78, a molecular chaperone 
also known as BiP or immunoglobulin heavy chain binding protein, is the 
master modulator of the ER-stress response and under physiologic conditions is 
associated with three resident ER transmembrane proteins, Upon dissociation 
and binding of GRP78 to misfolded proteins, these transmembane proteins are 
activated which leads to a variety of cellular responses to restore normal ER 
function (4-6). 
Recently, we demonstrated a crucial role for Mannan-binding lectin (MBL) in the 
pathogenesis of renal IRI (11). MBL, an innate immune protein and activator of 
the lectin pathway of complement, was shown to be directly cytotoxic to tubular 
epithelial cells independent of complement activation. Upon reperfusion of the 
ischemic kidney, vascular leakage exposes tubular epithelial cells to circulation-
derived MBL, which contributed to tubular injury. Considering the important 
protective role of GRPs in renal IRI, we hypothesize that MBL might interfere 
with GRPs leading to tubular cell death. 
Here, we demonstrate that renal I/R is accompanied by ER-stress and loss of 
GRP78 in the most affected cortico-medullary region of kidney. Therapeutic 
targeting of MBL in vivo protects tubular cells located in this region from loss 
of vital GRP78 and consequent tubular injury. In vitro, we demonstrated that 
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basolateral internalization of MBL by tubular cells induces ER-stress accompanied 
by excessive ATP production, loss of the mitochondrial membrane potential and 




The Animal Care and Use Committee of the Leiden University Medical Center 
approved all experiments. Eight-week-old male Lewis rats (200–250 gram) 
purchased from Harlan (Horst, The Netherlands), were housed in standard 
laboratory cages and were allowed free access to food and water throughout 
the experiments. Unilateral ischemia was induced by clamping of the left renal 
pedicle for 45 minutes using a bulldog clamp (Fine Science Tools, Heidelberg, 
Germany). During clamping the contralateral kidney was removed. Sham-
treated rats had identical surgical procedures except for clamping of the left 
kidney but including removal of the contra-lateral kidney. Before induction of 
ischemia, rats were treated with anti-rat MBL-A mAb (IgG1; P7E4; 1 mg/kg) (11) 
or as a control anti-human fibronectin mAb (IgG1; 1 mg/kg). Rats were sacrificed 
2, 5 or 24 h following reperfusion.
Assessment of kidney function  
Renal function was determined by measuring creatinine and urea in serum 
samples using standard autoanalyzer methods by our hospital research services.
Renal histology
Histological evaluations were performed on formalin-fixed kidneys embedded 
in paraffin, which were sectioned and stained with silver by standard methods. 
Renal immunostaining
Rat kidney sections (4 µm) of snap-frozen kidneys were air dried and acetone-
fixed. Kidney sections were stained with digitonin (DIG)-conjugated mAb against 
CD43 (W3/13; macrophages), goat pAb against rat Kidney-injury molecule 
(KIM)-1 (R&D systems, Abingdon, UK) or rabbit pAb against rat GRP78 (Abcam), 
followed by horseradish peroxidase (HRP)-conjugated sheep anti-DIG (Roche 
Diagnostics, Mannheim, Germany), rabbit anti-goat (DAKO, Glostrup, Denmark) 
or goat anti-rabbit pAb (DAKO), respectively. The staining was visualized using 
Nova RED (Vector Labs, Peterborough, United Kingdom). Quantification of 
immunohistochemistry was performed in a blinded manner by assessing high 
power fields (HPFs; original magnification ×200) of the complete rat kidney using 
MBL mediates ER-stress in tubular cells through GRP78   •   111
   6
a slide scanning microscope (Leica, Rijswijk, The Netherlands). Using imageJ 
software, the positive area in the outer medulla and cortico-medullary junction 
(expressed in pixels) was quantified.
RNA isolation and real-time PCR
RNA was extracted from snap frozen renal rat tissue or cultured human PTEC (HK-
2) and purified using an RNeasy Mini isolation Kit according to the manufacturer’s 
instructions (Qiagen, Hilden, Germany). Specific rat primers for GRP78, CHOP 
and ribosomal protein S-15 (RPS-15, housekeeping gene), and specific human 
primers for spliced XBP-1 (12) and CHOP were designed using Oligo Explorer 
and obtained from Biolegio (Nijmegen, The Netherlands). The primer sequences 
were as follows: rat KIM-1 (forward, 5’-TACCAACATCAACCAGAGTCTC-3’; 
reverse, 5’-ACATAGAAGCCCTTAGTCGG-3’), rat CHOP (forward, 5’- 
GAGTCTAATACTCGATCATACC-3’; reverse, 5’-TTGATTCTTCCTCTTCGTTCC-3’), 
rat GRP78 (forward, 5’-GAGATTGTTCTGGTTGGCGGATCTACTC-3’; 
reverse, 5’-CCATATGCTACAGCCTCATCTGGGTT-3’), rat RPS-15 
(housekeeping gene: forward 5’-CGTCACCCGTAATCCACC-3’ and 
reverse 5’- CAGCTTCGCGTATGCCAC-3’), human CHOP (forward, 5’- 
GGAGCATCAGTCCCCACTT-3’; reverse, 5’-TGTGGGATTGAGGGTCACATC-3’), 
human sXBP-1 (forward, 5’-TGCTGAGTCCGCAGCAGGTG-3’; 
reverse, 5’-GCTGGCAGGCTCTGGGGAAG-3’), human IL-6 
(forward, 5’- AAGCCAGAGCTGTGCAGATGAGTA-3’; reverse, 5’- 
AACAACAATCTGAGGTGCCCATGC-3’) and human GAPDH (housekeeping 
gene: forward 5’-TTCCAGGAGCGAGATCCCT-3’ and reverse 
5’-CACCCATGACGAACATGGG-3’). PCR was performed using SYBR Green PCR 
mastermix (Biorad). Data were analyzed using Gene Expression Analysis for 
iCycler Real-Time PCR Detection System (Biorad). Expression of each gene was 
normalized against mRNA expression of the housekeeping gene rat RPS-15 or 
human GAPDH. RT PCRs were performed in duplicate.
XBP1 PCR splicing analysis  
ER-stress-induced processing of rat XBP1 mRNA was evaluated by 
PCR and restriction site analysis. Primer for rat XBP-1, encompassing 
the IRE1 cleavage site of XBP1, was amplified using the rat XBP-1 
primer (forward, 5’- AAACAGAGTAGCAGCGCAGACTGC-3’; reverse, 5’- 
GGATCTCTAAAACTAGAGGCTTGGTG-3’) resulting in a 601-bp PCR product. 
PCR products were subsequently incubated with PstI at 37°C for 5 h followed 
by separation on 2% agarose gels. sXBP-1 lacks the PstI restriction site, which 
results in a larger PCR product. Upper bands representing spliced XBP-1 were 
quantified using image J software. 
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Cell culture
Immortalized human PTEC (HK-2) were grown as previously described (13). Cells 
were grown and exposed to MBL in 48-wells culture plates. To study basolateral 
exposure of MBL, cells were grown to 95% confluency in a transwell system (0,4 
µM polyester membrane 12 mm inserts; Corning Life Sciences, New York, USA) 
IL-6 ELISA
Secreted IL-6 in culture supernatants was measured using a commercial 
IL-6 sandwich ELISA (Sanquin, Amsterdam, Netherlands) according to the 
manufacturer’s instructions.
Fluorescence microscopy
HK-2 cells were fixed using cold methanol or 1% paraformaldehyde (both from 
Pharmacy) and stained with mAb against human MBL (mAb 3E7; Hycult Biotech) 
and a rabbit pAb against human golgin-97 (Invitrogen, Carlsbad, USA), mitofilin 
(Abcam, Cambridge, UK) or GRP78 (Abcam) followed by alexa-488 conjugated 
goat anti-mouse IgG (Molecular Probes) and alexa-568 conjugated goat anti-
rabbit IgG (Molecular Probes), respectively. 
Mitochondrial assays
Mitochondrial membrane activity and mitochondrial superoxide production 
were assessed using MitoTracker Red and MitoSOX Red (both from Invitrogen), 
respectively. PTEC were exposed to MBL for consecutive time points followed by 
15 minutes incubation with Mitotracker Red, MitoSOX Red was incubated during 
MBL exposure. Consequently, red fluorescence was assessed using fluorescence 
microscopy.
ATP measurement
Intracellular ATP was measured using a commericial ATP bioluminescent assay kit 
(Sigma Aldrich, Zwijndrecht, The Netherlands) according to the manufacturer’s 
instructions. 
Viability assays
HK-2 cells were washed and permeabilized using cold methanol and nuclei were 
stained using Hoechst. Viability was assessed by counting Hoechst-positive cells 
using fluorescence microscopy. 
Preparation of human MBL
MBL was purified from human recalcified plasma as previously described (14;15).
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Statistical analysis
All data are presented as mean ± standard error of the mean (SEM) and subjected 
to nonparametric statistical analysis using one- and two-factor ANOVA or Mann-
Whitney test using GraphPad Prism software. A value of P < 0.05 was considered 
statistically significant.
RESULTS
Basolateral interaction with MBL is cytotoxic for human tubular cells
Recently, we demonstrated direct cytotoxicity of MBL towards tubular cells 
following renal I/R (11). In the present study we set out to dissect the mechanism 
by which MBL mediates tubular cell death. First, the in vivo condition following 
renal I/R was mimicked by exposing human PTEC (HK-2) to purified human 
MBL. Exposure to MBL at 4°C for 1 h resulted in extensive binding of MBL as 
assessed by fluorescence imaging and FACS analysis (Fig 1A). Incubation at 
37°C, which allows internalization, revealed that MBL was internalized within 
minutes and trafficked to a perinuclear region (Fig 1B). Prolonged incubation 
with MBL resulted in extensive vacuolization after 8 h followed by rounding and 
detachment of cells within 24 h (Fig 1C). Vascular leakage following reperfusion 
results in exposure of tubular cells to MBL from the basolateral side, from where 
MBL should be subsequently internalized (11). To mimic this process in our in 
vitro model, we made use of a transwell system and exposed PTEC from the 
upper (apical) or lower (basolateral) compartment. Only basolateral exposure 
of PTEC to human MBL induced cell death, whereas apical exposure only had 
minimal effect (Fig 1D). This suggests that a basolateral membrane protein or 
internalization process is involved in this MBL-mediated cell death.
Internalized MBL colocalizes with the endoplasmic reticulum and 
mitochondria
Subsequently, intracellular trafficking of MBL was studied. No colocalization of 
MBL with the Golgi was found, whereas staining for GRP78 (Fig 2), an ER-residing 
protein, revealed a strong colocalization suggesting trafficking of MBL to the ER. 
GRP78 is a stress-inducible-ER chaperone, which serves as a master modulator 
of the ER-stress response. Recently, it was shown that GRP78 under stress 
conditions also traffics to mitochondria (16). Staining for MBL and a mitochondrial 
marker (mitofilin) indeed revealed a partial colocalization, suggesting that MBL 
might interacts with GRP78-positive mitochondria. Colocalization of MBL with 
GRP78 or mitofilin was subsequently confirmed by confocal microscopy. 
114   •  Chapter 6 
MBL induces ER-stress in human tubular cells
GRP78 has been shown to prevent oxidative stress, calcium disturbances and 
cell death in PTEC and is indispensable for tubular cell homeostasis (17-19). To 
study the functional consequences of MBL internalization and interaction with 
GRP78, several ER-stress markers were assessed following exposure to MBL. 
Splicing of mRNA sXBP-1 by IRE1, expression of CHOP as a consequence of PERK 
and eIF2a phosphorylation, and IL-6 expression induced by JNK-pathway were 
assessed as markers for ER-stress and revealed a twenty- and tenfold induction 
of sXBP-1 (Fig 3A) and CHOP (Fig 3B) respectively. sXBP-1 and CHOP expression 
occurred within 30 minutes indicating that ER-stress mediated by MBL is one of 
Figure 1. Basolateral interaction with MBL is cytotoxic for human tubular cells. Human 
PTEC (HK-2) were incubated with 10 µg/mL MBL for 1 h at 4°C (A) or 10 and 60 min 
at 37°C (B). Cells were stained extracellular (A) or intracellular (B) for MBL (green) and 
cells were photographed using a fluorescence microscope (original magnification ×200) 
or analysed by flow cytometry (A). Nuclei (blue) were stained using Hoechst (B). Cells 
were incubated with 10 µg/mL human MBL for 8 or 24 h at 37°C (C) and cells were 
photographed (original magnification ×200). To study apical or basolateral exposure to 
MBL (D), cells were cultured in a transwell system and exposed to 10 µg/mL MBL from the 
upper (apical) or lower (basolateral) compartment for 24 h. Cell viability was assessed by 
counting Hoechst-positive, but PI-negative cells in the well using fluorescence microscopy 
(original magnification ×100). Values shown are mean ± SEM of triplicate determinations 
from a single experiment and are representative of two similar transwell experiments. 
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the first consequences of MBL exposure. ER-stress following MBL exposure was 
accompanied by a strong and dose-dependent IL-6 protein expression (Fig 3C). 
Exposure to 10 or 20 µg/mL MBL induced a rapid cell death within 12 h, which 
might explain the lower levels of IL-6 in these conditions.
MBL affects mitochondrial homeostasis
ER-stress results in calcium flux from the ER into the cytosol, which is buffered to 
some degree by mitochondrial calcium uptake. Increased mitochondrial calcium 
stimulates oxidative metabolism and ATP production. This prompted us to study 
whether MBL-mediated ER-stress might influence mitochondrial homeostasis. 
Assessment of cellular ATP levels revealed that ER-stress was followed by an 
Figure 2. Intracellular trafficking of internalized human MBL. PTEC (HK-2) were exposed 
to MBL for 1, 2 or 4 h at 37°C, fixed and stained (A) for MBL (green) and a marker (red) 
for the golgi (golgin), endoplasmic reticulum (GRP78) or mitochondria (mitofilin). Nuclei 
(blue) were stained using Hoechst. Double staining (yellow) was found for MBL with 
GRP78 or mitochondria, but not with golgin. Cells were photographed using fluorescence 
microscopy (original magnification x600). PTEC (HK-2) were exposed to MBL for 4 h at 
37°C, fixed and stained for MBL (green) and a marker (red) for the endoplasmic reticulum 
(B, GRP78) or mitochondria (C, mitofilin). Nuclei (blue) were stained using Hoechst. 
Colocalization (yellow) was assessed by confocal microscopy.
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excessive ATP production in the first hours of MBL exposure. Ablation of ATP 
production at 24 h was accompanied by tubular cell death. (Fig 4A). 
Prolonged ER-stress might lead to mitochondrial injury induced by excessive 
calcium influx into the mitochondria. Strong calcium entry activates mitochondrial 
superoxide generation and collapse of the mitochondrial membrane potential. 
In addition, mitochondrial GRP78 has been shown to stabilize Raf-1 to maintain 
mitochondrial permeability and to protect cells from ER-stress-induced apoptosis 
(20). This prompted us to more in-depth study mitochondrial homeostasis. 
Figure 3. MBL induces ER-stress in human PTEC. PTEC (HK-2) were incubated with 10 µg/
mL MBL for consecutive time points. Subsequently, mRNA was harvested and expression 
of spliced (s)XBP1 (A) and CHOP (B) was assessed by RT-PCR. PTEC were incubated with 
MBL (0-10 µg/mL) for 24 h. Culture supernatants were collected and secreted IL-6 
content was measured by an IL-6 sandwich ELISA (C). 
Figure 4. 
MBL affects 
m i t o c h o n d r i a l 
homeostasis.
PTEC (HK-2) were 
exposed to 10 µg/
mL MBL for 0-24 
h, after which 
intracellular ATP 
content was 
measured (A). PTEC (HK-2) were exposed to 10 µg/mL MBL for 4 h (B, C). To assess the 
mitochondrial membrane potential (B), cells were incubated with MitoTracker Red for 15 
min after MBL exposure. Cells were fixed and nuclei (blue) were stained using Hoechst. 
To assess superoxide production (C), cells were incubated with MitoSOX Red during 
4h MBL exposure. Cells were photographed using a fluorescence microscope (original 
magnification x600). 
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Active mitochondria were stained using MitoTracker Red, which accumulation 
in mitochondria is dependent on the mitochondrial membrane potential. 
Normal PTEC showed active mitochondria, however exposure to MBL for 4 h 
dramatically reduced the mitochondrial membrane potential (Fig 4B). Loss of 
membrane potential was accompanied by mitochondrial superoxide production, 
as assessed by MitoSOX Red which specifically is targeted to active mitochondria 
and upon oxidation by mitochondrial superoxide produces red fluorescence (Fig 
4C). The massive increase in ATP production, loss of mitochondrial membrane 
potential and ROS formation were preceded by a period of extensive ER-stress 
(Fig 3), suggesting that mitochondrial alterations are the result of the initial ER-
stress induced by MBL. 
Figure 5. Renal I/R is accompanied by ER-stress and tubular injury. Lewis rats (n=6 per 
group) underwent unilateral ischemia for 45 min and removal of the contralateral kidney. 
Rats (n=6 per group) were sacrificed at consecutive time points and renal sections were 
stained for Kidney-injury molecule (KIM)-1 (A, original magnification x200) or processed 
for silver staining (B, original magnification x400). KIM-1 was quantified using digital 
image analysis (C). Following reperfusion or in sham (sh) operated rats, blood samples 
were drawn at consecutive time points to assess renal function by measuring serum 
creatinine (D). Renal mRNA expression of rat spliced (s)XBP-1 (E,F). CHOP (G) and IL-6 (H) 
was assessed in renal tissue at consecutive time points following reperfusion or in sham 
(sh) operated rats. Data are shown as mean ± SEM, n = 6 per group. The comparison 
between groups is indicated by asterisks. *p<0.05; **p<0.01; ***p<0.001.
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Renal I/R is accompanied by ER-stress and tubular injury
To study the in vivo relevance of these findings, we assessed the role of MBL 
in ER-stress in a rat model of renal IRI. Firstly, tubular injury and occurrence 
of ER-stress was assessed. Clamping of the renal pedicle for 45 minutes and 
removal of the contralateral kidney resulted in severe renal dysfunction (Fig 5D) 
within 24 h, which was accompanied by extensive protein expression of Kidney-
injury molecule (KIM)-1 within 5 h upon reperfusion (Fig 5A, C). A silver staining 
revealed that tubular alterations and loss of tight junctions already occurred 
within 2 h upon reperfusion (Fig 5B). Interestingly, this injury was accompanied 
by a significant splicing of XBP-1 (Fig 5E, F), expression of CHOP (Fig 5G) and IL-6 
(Fig 5H) 2 h after reperfusion. 
Renal I/R is accompanied by loss of ER-stress sensor GRP78 
Staining for KIM-1 revealed that mainly the tubuli in the corti-medullary transition 
were injured and extensively expressed KIM-1 at 24 h after reperfusion (Fig 6A). 
Strikingly, staining for GRP78 revealed that particularly in this region, tubular 
GRP78 protein expression was lost (Fig 6B) already 2 h after reperfusion. While 
some tubuli normally expressed GRP78, others completely lost expression (Fig 
Figure 6. Renal I/R is accompanied by loss of ER-stress sensor GRP78 in the cortico-
medullary tubular cells. Renal sections (n=6 per group) from sham operated rats or rats 
sacrificed 2, 5 or 24 h after reperfusion were stained for KIM-1 (A) or GRP78 (B). Sections 
were photographed and photographs were digitally stitched and analyzed (C) using 
digital image. GRP78 staining in the cortico-medullary region (D, original magnification 
x400) was digitally quantified (E). GRP78 mRNA expression (F) was assessed in total renal 
tissue at consecutive time points following reperfusion or in sham (sh) operated rats. 
Data are shown as mean ± SEM, n = 6 per group. The comparison between groups is 
indicated by asterisks. *p<0.05; **p<0.01; ***p<0.001.
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6D), which might result in extensive ER-stress in these cells. Quantification (Fig 
6C, E) showed that most staining was significantly lost within 2 h upon reperfusion 
which was accompanied by an increased mRNA expression of GRP78.
Inhibition of MBL prevents loss of ER-stress sensor GRP78
To assess the role of MBL in this, we therapeutically target MBL using the 
protective and blocking mAb (P7E4) to MBL (11). Inhibition of MBL following I/R 
significantly protected against renal dysfunction (Fig 7A). Importantly, inhibition 
of MBL completely prevented the loss of tubular GRP78 early after reperfusion, 
whereas control-treated animals lost their GRP78 protein expression in the 
cortico-medullary tubular cells (Fig 7B). Loss of GRP78 was accompanied by an 
extensive expression of IL-6, which might be related to ER-stress and loss of 
GRP78. In addition, anti-MBL treatment also significantly reduced IL-6 expression 
Figure 7. Inhibition of MBL prevents loss 
of ER-stress sensor GRP78 and subsequent 
IL-6 expression. Before induction of 45 
min of unilateral ischemia and removal 
of the contralateral kidney, rats received 
anti-MBL-A or an isotype-matched control 
mAb (1 mg/kg). Before and following 
reperfusion blood samples were drawn 
at consecutive time points to assess renal 
function by measuring serum creatinine 
(A) Renal sections (n=6 per group) from 
sham operated, control-treated or anti-
MBL treated rats sacrificed 2, 5 or 24 h 
after reperfusion were stained for GRP78. 
Staining in the cortico-medullary region was 
subsequently digitally quantified (B). IL-6 
mRNA expression (C) was assessed in renal 
tissue at consecutive time points. Data are 
shown as mean ± SEM, n = 6 per group. The 
comparison between groups is indicated by 
asterisks. *p<0.05; **p<0.01; ***p<0.001.
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early after reperfusion (Fig 7D), suggesting that MBL plays an important role 
in early tubular ER-stress following reperfusion. These findings await further 
studies on the role of MBL in tubular mitochondrial homeostasis in vivo which 
might be closely related to this process.
 
DISCUSSION
Recently we demonstrated a pivotal role for MBL in the pathogenesis of renal 
IRI (11). MBL has cytotoxic effects towards PTEC independent of complement 
activation contributing to tubular injury following reperfusion. Here, we 
demonstrate that MBL interacts with GRP78 in PTEC, mediates ER-stress 
and affects mitochondrial homeostasis. Therapeutic inhibition of MBL in vivo 
protected tubular cells from loss of vital GRP78 and consequent tubular injury
GRP78 is a constitutively expressed molecular chaperone, however expression 
is enhanced under a variety of stressful conditions including hypoxia, glucose 
deprivation, alterations in intracellular calcium and oxidative stress (21), events 
that take place during renal I/R. Induction of GRP78 is critical for maintaining 
viability of cells that are subjected to such stresses and loss of GRP78 would 
therefore be detrimental. Here, we show that renal I/R is accompanied by ER-
stress and loss of GRP78 in the cortico-medullary region of kidney, the region 
that is mostly affected. Importantly, therapeutic inhibition of MBL protected 
tubular cells located in this region from loss of vital GRP78 and consequent 
tubular injury, indicating that MBL might be injurious to tubular cells by 
interfering with GRP78. Expression of proinflammatory IL-6, a consequence of 
GRP78 degradation (22) and ER-stress (23;24), was also significantly reduced by 
inhibition of MBL following reperfusion. 
GRP78 has been shown to prevent oxidative stress, calcium disturbances and 
cell death in renal epithelial cells (17;25). Expression of antisense RNA, targeted 
to GRP78 sensitized tubular cells to oxidant-induced cell death (19), indicating 
that GRP78 is indispensable in tubular cells under oxidative stress. 
Internalization of circulation-derived MBL in vivo was shown to be the process 
by which tubular epithelial cells following renal I/R might be injured (11). By 
exposing tubular cells in vitro to MBL, we here demonstrated that basolateral 
internalization of MBL by tubular cells induced a potent ER-stress response 
which was accompanied by an excessive ATP production, a subsequent loss 
of the mitochondrial membrane potential, production of mitochondrial 
superoxide followed by induction of cell death. Internalized MBL colocalized 
with mitochondria and GRP78. Although GRP78 is mostly known from its 
function as molecular chaperone in the ER, GRP78 has also been shown to be 
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present, although in low amounts, on mitochondria, in the cytoplasm, on the 
cell membrane and as a secreted form (16;26-30). Membrane-bound GRP78 
might be a possible candidate as a cellular receptor by which MBL is internalized. 
Indeed, it has been shown that MBL is able to interact with GRP78 in hepatic 
cells (31), suggesting that a detrimental interaction with GRP78 in tubular cells 
might be possible, however the mechanism by which MBL is internalized is still 
subject of investigation. Interestingly, overexpression of calreticulin, another ER 
chaperone also protected tubular cells against oxidative stress (18). Calreticulin 
has been described as the MBL receptor on phagocytosing cells (32;33), making 
this also a possible candidate by which MBL might be internalized.
The mechanism by which MBL affects mitochondrial homeostasis and ER-stress 
is still speculative since both processes are tightly intertwined. Depletion of 
cellular ATP as a consequence of ischemia or oxidative stress is known to induce 
ER-stress, since most GRP78 uses the energy from ATP hydrolysis to promote 
folding and prevent aggregation of proteins within the ER (34). Vice versa, ER-
stress enhances mitochondrial calcium to generate more ATP (35;36). However, 
excessive calcium flux from the ER to the mitochondria during prolonged ER-
stress will lead to mitochondrial injury and subsequent ATP depletion (7;37). 
GRP78 has been shown to be involved in both processes. First of all, GRP78 
prevents calcium flux from the ER (36), probably by interacting with the translocon 
calcium channel in the ER-membrane (8). In addition, GRP78 on mitochondria 
has been shown to stabilize the mitochondrial membrane potential by 
associating with raf-1 and cooperatively confer resistance to ER-stress induced 
cell death (20). Interference of MBL with GRP78 might affect both processes. 
Our data suggest that initially ER-stress is induced following MBL exposure, 
followed by disturbances in mitochondrial homeostasis. Release of calcium 
from ER stores might be the main cause of MBL-mediated ER-stress. An increase 
in cytosolic calcium in tubular cells then would lead to enhanced calcium influx 
into mitochondria, disrupting mitochondrial metabolism eventually leading to 
cell death. 
Recently is has been shown that ligation of cell-surface GRP78 on cancer cells also 
causes release of calcium from ER stores mediated via phospholipase C, thereby 
increasing cytosolic calcium (38). In line with this, it is known that especially 
tumor cells have increased levels of GRP78 on the cell surface. Importantly, is 
has been shown that MBL bears antitumor effects, which has been termed MBL-
dependent cell-mediated cytotoxicity (39). Since MBL is able to interact with 
GRP78, we speculate that, next to killing of tumor cells, the cytotoxic effect of 
MBL on tubular cells might also be mediated by signaling through cell surface 
GRP78. 
Under physiologic conditions GRP78 is hardly present on normal cells, however 
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induction of ER-stress has been shown to promote GRP78 localization on the 
surface of kidney cells (30). ER-stress induced by glucose deprivation during 
renal ischemia might be the initial trigger for GRP78 to traffic to the basolateral 
membrane of the tubular cells. Especially tubular cells in the cortico-medullary 
border are subjected to low oxygen and glucose levels during I/R, making these 
cells particular sensitive to ER-stress. It is therefore tempting to speculate that 
vascular leakage following reperfusion enables circulation-derived MBL to enter 
the interstium and bind to GRP78 on the cell surface of the tubular cells. Signaling 
to GRP78 might then have detrimental effects. Next to signaling, internalization 
of MBL might also be mediated by GRP78, since evidence has emerged that 
GRP78 also serves as a receptor for viral entry into host cells (40).
In this study we show that loss of GRP78 in vivo is tightly connected to MBL, 
because inhibition of MBL completely preserved GRP78 protein expression in 
the cortico-medullary tubular cells. However, the mechanism by which GRP78 
is degraded is still unknown. Recently, it was shown in macrophages that the 
mycotoxin deoxynivalenol induced ER-stress, which was accompanied by loss 
of GRP78 and high expression of IL-6(22). The authors suggested that the loss 
of GRP78 was related to an autophagic pathway. The process of autopahgy has 
also been described in renal IRI and might be involved in degradation of GRP78. 
In addition, it has been shown that cytosolic GRP78 might be secreted(26), 
however the mechanism involved requires further investigation. 
In summary, our results document the important role of MBL in renal IRI. 
We demonstrated that inhibition of MBL in vivo protected tubular cells from 
loss of vital GRP78 and consequent tubular injury. Basolateral internalization 
of MBL by tubular cells in vitro induced ER-stress accompanied by excessive 
ATP production, loss of mitochondrial membrane potential and production of 
mitochondrial superoxide followed by tubular cell death. These results indicate 
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ABSTRACT
Ischemia/reperfusion injury (IRI) is a key event in kidney transplantation and 
is accompanied by activation of the complement cascade. In addition, a novel 
and complement-independent role for Mannan-binding lectin (MBL), initiator of 
the lectin pathway of complement, was established in the pathogenesis of renal 
IRI. Recombinant human C1-inhibitor (rhC1INH), a serine protease inhibitor, 
inhibits complement activation and through its differential glycosylation might 
also directly interact with MBL. Therefore, application of rhC1INH might be a 
potential therapeutic option to prevent or reduce renal IRI. 
Here, we explored the therapeutic application of rhC1INH in a rat model of 
renal IRI and studied whether rhC1INH is able to attenuate MBL-mediated 
tubular injury. We demonstrate that rhC1INH was functionally active in rat 
serum and blocks both classical and lectin pathway activation in vitro. However, 
the therapeutic administration of rhC1INH in vivo did not attenuate renal 
dysfunction, tubular injury, inflammatory cell influx and complement cascade 
activation following reperfusion in rats. Kinetic studies revealed that rhC1INH 
was mostly cleared from the circulation within 2 hours, complement activity 
was only briefly reduced and circulating MBL levels were unaffected. In addition, 
we demonstrated that rhC1INH did not block the MBL-mediated cytotoxicity 
towards human tubular cells in vitro. 
Taken together, we demonstrate that rhC1INH is not protective in a rat model 




Ischemia caused by inadequate local blood supply, is an inevitable event in 
kidney transplantation. Restoration of blood flow to ischemic tissue during the 
transplantation procedure paradoxically exacerbates tissue damage by initiating 
a cascade of inflammatory events including endothelial dysfunction, formation 
of reactive oxygen species, neutrophil sequestration and complement activation, 
which all contribute to post-ischemic injury (1-3).
Numerous clinical and experimental studies have shown that renal IRI has a 
major impact on short- and long-term graft survival after kidney transplantation 
and usually accounts for delayed graft function and associated morbidity and 
mortality in the clinic (3-5). Complement activation is a key feature of renal 
ischemia/reperfusion injury (IRI) and has been demonstrated both in the clinical 
setting (6;7) as well as in experimental models (8-10). 
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The complement system is a complex cascade of around thirty plasma proteins 
that can be activated via either the classical pathway (CP), lectin pathway (LP) 
or alternative pathway (AP)(11). The CP is activated by binding of C1q to e.g. 
antigen-antibody complexes or apoptotic cells (12) which lead to activation of 
the associated serine proteases C1r and C1s. The LP is activated by binding of 
Mannan-binding lectin (MBL) or ficolins to sugar moieties which lead to activation 
of the MBL-associated serine proteases (MASPs). Activated serine proteases 
C1r/C1s or MASPs then cleave C4 and C2, which result in the generation of the 
classical C3 convertase. The alternative pathway (AP) is continuously activated 
at a low level (so-called tickover), does not require C4 and is tightly regulated by 
membrane-bound and soluble complement regulators. Furthermore, properdin 
can act as a focal point of AP-mediated complement activation upon binding to 
its ligand (13). All three pathways converge at the level of complement factor 
C3, which is cleaved and subsequently deposits as C3b on target cells resulting 
in opsonization and clearance by phagocytic cells. Further activation of the 
complement cascade leads to generation of the membrane attack complex 
(MAC) C5b-9 and lysis of target cells.
C1 esterase inhibitor (C1INH), a physiologic serine protease inhibitor belonging 
to the serpin superfamily, acts as a major inhibitor of complement system 
activation and prevents uncontrolled activation (14-16). It is an acute phase 
protein with a mean plasma level of 250 µg/ml, and is increasing up to 2.5-fold 
during inflammation. C1INH can inhibit both the classical and lectin pathway, 
and upon complement activation, C1INH binds to activated MASP or C1r and C1s 
to generate MASP(C1INH) (17) and C1rC1s(C1INH)2 complexes (18-20), which 
subsequently dissociate from the MBL or C1q molecule, respectively. These 
complexes are then rapidly cleared from the circulation. 
Renal IRI is associated with extensive loss of the cortico-medullary proximal 
tubular epithelial cells (PTEC), an event often referred to as acute tubular 
necrosis (ATN). Recently, we demonstrated that therapeutic inhibition of MBL 
with a monoclonal antibody was protective against renal IRI and more in-depth 
studies revealed a direct cytotoxic effect of MBL on tubular epithelial cells 
independent of complement activation (18). Upon reperfusion of the ischemic 
kidney, MBL from circulation leaks into the interstitium where it is internalized 
by tubular cells and contributes to tubular injury. Unfortunately, to date no anti-
MBL therapy or other treatments for renal IRI in the clinic exists. 
Recently however, several clinical possibilities of pharmacologic inhibition of 
complement, including C1INH have become available (21). C1INH might be a 
possible therapeutic candidate to prevent renal IRI given that C1INH regulates 
vascular permeability (22) and might prevent leakage of MBL in the interstitial 
compartment following reperfusion. Secondly, C1INH targets the MASPs, 
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which might be involved in the cytotoxic effect of MBL on tubular cells. Thirdly, 
complement that is activated at a later stage following reperfusion leading to 
exacerbation of tissue injury, might be inhibited. 
Recombinant human C1INH (Ruconest®), which recently has been registered for 
treatment of acute attacks in hereditary angioedema, is differentially glycosylated 
(23;24) with increased oligo-mannose structures and therefore, compared to 
plasma-derived C1INH, might include an additional inhibitory effect towards 
MBL recognizing mannose residues. 
In the present study, we explored the therapeutic application of rhC1INH 
(Ruconest®) in a rat model of renal IRI and studied whether rhC1INH is able to 
attenuate MBL-mediated tubular injury. We demonstrate that rhC1INH is not 
protective in a rat model of renal IRI and does not rescue human tubular cells 




The Animal Care and Use Committee of the Leiden University Medical Center 
approved all experiments. Eight-week-old male Lewis rats (200–250 gram) 
purchased from Harlan (Horst, The Netherlands), were housed in standard 
laboratory cages and were allowed free access to food and water throughout 
the experiments. Unilateral ischemia was induced by clamping of the left renal 
pedicle for 45 minutes using a bulldog clamp (Fine Science Tools, Heidelberg, 
Germany). During clamping the contralateral kidney was removed. Sham-treated 
rats had identical surgical procedures except for clamping of the left kidney but 
including removal of the contra-lateral kidney. Before induction of ischemia, 
rhC1INH (Ruconest®, 625 U/kg, equivalent to 100 mg/kg; Pharming Group NV, 
Leiden, The Netherlands) or as a control human serum albumin (HSA; 100 mg/
kg) was infused intravenously. Blood samples were collected at 1, 2, 5 or 24 
hours following reperfusion and processed as serum. Kidneys were harvested 24 
hours after reperfusion and subsequently animals were sacrificed.
Assessment of kidney function 
Renal function was determined by measuring creatinine and urea in serum 
samples using standard autoanalyzer methods by our hospital research services.
Renal immunostaining
Rat kidney sections (4 µm) of snap-frozen kidneys were air dried and acetone-
fixed. Kidney sections were stained with digitonin (DIG)-conjugated mAb 
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against CD68 (ED-1, macrophages) or goat pAb against rat KIM-1 (R&D systems, 
Abingdon, UK), followed by horseradish peroxidase (HRP)-conjugated sheep 
anti-DIG (Roche Diagnostics, Mannheim, Germany) or rabbit anti-goat (DAKO, 
Glostrup, Denmark), respectively. The staining was visualized using Nova RED 
(Vector Labs, Peterborough, United Kingdom). Rat C3 deposition was assessed 
by direct staining using a FITC-conjugated rabbit polyclonal to rat C3 (made in-
house). Quantification of immunohistochemistry was performed in a blinded 
manner by assessing 10 consecutive high power fields (HPFs; magnification 
×200) of the outer medulla and cortico-medullary junction on each section. 
Using image J software, the positive area (expressed in pixels) was quantified.
Rat serum complement activity measurements
Functional activity of the lectin and classical pathway were assessed using 
plates coated with mannan or IgM, as previously described (25), with minor 
modifications. Rat sera drawn at different time points after reperfusion or normal 
rat serum mixed with rhC1INH (Ruconest®, Pharming Group NV) were 1/50 
diluted in GVB++ (veronal buffered saline, 0.1% gelatin, 0.5 mM MgCl2, 2 mM 
CaCl2, 0.05% Tween 20) and incubated for 60 min at 37°C to allow C3 deposition 
in the well. The plates were washed with PBS/0.05%Tween and incubated with 
dig-conjugated mouse anti-rat C3 antibody (ED11, made in-house (26)), followed 
by HRP-conjugated sheep anti-DIG (Roche Diagnostics). After washing, C3 
deposition was quantified with 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic 
acid) (ABTS; from Sigma-Aldrich; 2.5 mg/ml in 0.1M Citrate/Na2HPO4 buffer, pH 
4.2) in the presence of 0.01% H2O2, for 30–60 min at room temperature. The OD 
at 415 nm was measured using a microtiter plate reader (Biorad).
Rat MBL ELISA
MBL levels in rat serum were assessed using a sandwich ELISA. In short, Nunc 
Maxisorb plates (Nunc, Roskilde, Denmark) were coated with a mAb against 
rat MBL (P7E4, kindly provided by G.L. Stahl Harvard Medical, School, Boston, 
USA) followed by rat serum incubation. Rat MBL binding was detected using 
DIG-conjugated mAb against rat MBL (P7E4). After washing, MBL binding was 
quantified with ABTS; (Sigma-Aldrich). The OD at 415 nm was measured using a 
microtiter plate reader (Biorad).
MBL-MASP complex ELISA
Human MBL-MASP complexes after MBL purification were assessed using 
a sandwich ELISA. In short, Nunc Maxisorb plates were coated with a pAb 
against MASP-2 (kindly provided by R. B. Sim, University of Oxford, Oxford, 
U.K.) followed by sample incubation. MBL-MASP complex binding was detected 
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using DIG-conjugated mAb against human MBL (3E7, Hycult Biotecht, Uden, 
Netherlands). After washing, MBL-MASP complex binding was quantified with 
ABTS; (Sigma-Aldrich). The OD at 415 nm was measured using a microtiter plate 
reader (Biorad).
RhC1INH ELISA
Circulating levels of rhC1INH before, 1, 2, 5, and 24 hours after reperfusion were 
assessed using a sandwich ELISA as previously described (24). 
 
Cell culture
Immortalized human PTEC (HK-2) were grown as previously described (27). 
Fluorescence microscopy
HK-2 cells were fixed using cold methanol and stained with mAb against human 
MBL (mAb 3E7; Hycult Biotech) followed by Alexa-488 conjugated goat anti-
mouse IgG (Molecular Probes). Nuclei were stained using Hoechst (Molecular 
Probes, Leiden, The Netherlands).
Viability assays
Cell viability was assessed using propidium iodide (PI; Molecular Probes, 
Leiden, The Netherlands). Following incubation with PI, cells were washed and 
permeabilized using cold methanol and nuclei were stained using Hoechst. 
Viable cell count was assessed by counting Hoechst-positive, but PI-negative 
cells using fluorescence microscopy. 
Preparation of human MBL and MASP-free MBL 
MBL was purified from human recalcified plasma as previously described (28). 
To yield a MASP-free MBL preparation, MBL was further purified by gel filtration 
using a Sepharose 6B column as previously described (29). In short, the purified 
MBL preparation was dialysed against 0.1 M acetic-acid containing 0.2 M NaCl 
and 5 mM EDTA at pH 5. Subsequently, the dialysed sample was subjected 
to size exclusion chromatography on a Superdex 200. This procedure results 
in dissociation of purified MBL–MASP complexes which were subsequently 
separated by size exclusion. 
Statistical analysis
All data are presented as mean ± standard error of the mean (SEM) and subjected 
to nonparametric statistical analysis using one- and two-factor ANOVA or Mann-
Whitney test using GraphPad Prism software. A value of P < 0.05 was considered 
statistically significant.
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RESULTS 
RhC1INH is functionally active in rat serum
Before therapeutic application rhC1INH (Ruconest®) in a rat model of renal IRI, 
functionality of rhC1INH in rat serum was tested in vitro, using a complement 
activation assay assessing classical and lectin pathway activity. Preincubation of 
rat serum with rhC1INH resulted in a dose-dependent inhibition of C3 deposition 
(Fig 1). The lectin pathway was more effectively inhibited by rhC1INH than the 
classical pathway (Fig 1B), with an IC50 of 1 and 5 U/ml, respectively. Maximum 
inhibition of lectin pathway activation was achieved at 10 U/ml. Therefore, 
a therapeutic dose of 625 U/kg was chosen for in vivo application in rats, 
corresponding to an estimated end concentration of at least 10 U/ml rhC1INH 
in circulation. 
RhC1INH does not preserve renal function after ischemia/reperfusion
Five minutes before induction of renal ischemia, rats (n=6) were infused with 
rhC1INH (625 U/kg) or as a control human serum albumin (HSA). Induction 
of ischemia for 45 min followed by reperfusion resulted in a significant renal 
dysfunction in control-treated rats as measured by serum levels of creatinine 
(Figure 2A) and urea (Figure 2B). Treatment with rhC1INH did not protect against 
renal dysfunction. Rats treated with rhC1INH even tended to show a higher 
increase in creatinine and urea (Fig 2B) compared to control treated animals at 
24 hours of reperfusion. 
RhC1INH does not reduce C3 deposition, cellular influx and tubular injury 
Rats were sacrificed at 24 hours of reperfusion and deposition of C3 was 
assessed. While kidneys from sham-operated rats showed a C3 staining with 
a typical half-moon distribution surrounding tubular cells, following IRI there 
Figure 1. RhC1INH inhibits 
complement activation in rat 
serum. Preincubation of rat 
serum with rhC1INH resulted 
in a dose-dependent inhibition 
of C3 deposition on mannan- 
(A) and IgM-coated plates (B). 
C3 deposition as a measure 
of complement activity was 
calculated as a percentage of 
C3 deposition in wells with 
untreated rat serum.
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was a significant increase in tubular C3 deposition (Fig 3A). Although rhC1INH 
was able to inhibit C3 deposition in vitro (Fig 1), administration in vivo did not 
reduce tubular deposition of C3. Also influx of macrophages (Fig 3B), which was 
apparent in the control treated animals, was not reduced in the rhC1INH-treated 
group. Expression of kidney injury molecule (KIM)-1, an early marker for tubular 
injury, was strongly expressed at 24 hours following reperfusion (Fig 3C) and was 
also not reduced by application of rhC1INH. 
 
Kinetics of rhC1INH in rats are unfavorable for effective protection
Assessment of complement activity in circulation revealed that 1 hour following 
reperfusion both the lectin and classical pathway were blocked efficiently by 
rhC1INH. However, this inhibitory effect was only short, since at 2 hours of 
reperfusion, complement activity of both lectin (Fig 4A) and classical (Fig 
4B) pathway was restored to basal levels. This prompted us to study the 
pharmacokinetics of rhC1INH in vivo. Measurement of rhC1INH levels following 
administration revealed a fast clearance of rhC1INH from circulation. One hour 
after reperfusion still sufficient rhC1INH levels (Fig 4C) for lectin and classical 
pathway inhibition in circulation (Fig 4A, B) were detected (10 U/ml) as was 
also calculated from the assay assessing rhC1INH functionality in rat serum in 
vitro (Fig 1). In contrast, rhC1INH levels at 2 hours were reduced by more than 
threefold and 5 hours after reperfusion almost undetectable. From this, a half-
life of approximately 30 minutes could be calculated. The data suggest that the 
Figure 2. RhC1INH does not preserve 
renal function after ischemia/
reperfusion. Before induction of 
unilateral ischemia and removal of 
the contralateral kidney, rats received 
rhC1INH (625 U/kg) or as a control 
human serum albumin (100 mg/kg). 
Before and following reperfusion, blood 
samples were drawn at consecutive 
time points to assess renal function by 
measuring serum creatinine (A) and 
urea (B) levels. Data are shown as mean 
± SEM, n = 6 per group. The comparison 
between groups is indicated by asterisks. 
*p<0.05; **p<0.01; ***p<0.001.
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rhC1INH concentrations at 2 and 5 hours of reperfusion were not sufficient for 
effective complement inhibition in the circulation.
RhC1INH does not inhibit MBL-mediated tubular cell death 
Recently we showed that inhibition of MBL by a monoclonal antibody is 
protective against renal IRI in rats (30). In addition, we showed that MBL directly 
induces tubular injury independent of complement activation. Assessment of 
circulating MBL levels after rhC1INH administration demonstrated that rhC1INH 
did not affect the levels of MBL in circulation (Fig 4D). Lectin pathway activity at 
1 hour reperfusion was efficiently blocked, indicating that rhC1INH only targets 
and dissociated the MASPs from MBL, but did not affect MBL itself. To assess 
whether rhC1INH was able to prevent MBL-mediated tubular injury, human 
tubular epithelial cells were incubated with purified MBL in vitro (Fig 5A), which 
resulted in an extensive induction of cell death within 24 hours. Preincubation of 
MBL with a dose response of rhC1INH (10-1000 µg/ml, Fig 5A, B), however, did 
not protect tubular cells from MBL-mediated cell death.
RhC1INH is a protease inhibitor and irreversibly binds to and inactivates MBL-
associated serine proteases (MASP)-1 and -2. To study whether these MASPs, 
Figure 3. RhC1INH does not reduce C3 deposition, cellular influx and tubular injury. 
Renal sections from control- (A), rhC1INH-treated (B) or sham-operated rats 24 h 
following reperfusion were stained for C3 deposition (A) macrophages (Mph; B) or 
kidney-injury molecule (KIM)-1 (C). C3 deposition, Mph infiltrate and KIM-1 expression 
were quantified using digital image analysis. Data are shown as mean ± SEM (n = 6 per 
group). Original magnification ×200. The comparison between groups is indicated by 
asterisks. *p < 0.05; **p<0.01; ***p<0.001.
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which are co-purified with MBL, might be involved in MBL-mediated tubular cell 
death, blocking antibodies to MASP-2 were applied. Exposure of tubular cells to 
MBL in the presence of MASP-2 antibodies did not prevent MBL-mediated cell 
death (Fig 5A, B). Since this strategy did not target MASP-1, MASP-free MBL was 
purified. Using a MBL-MASP complex ELISA, absence of MBL-MASP complexes 
was confirmed (Fig 5C). Incubation of MASP-free MBL on tubular cells still 
affected tubular cells (Fig 5B), indicating that MASPs are not involved in MBL-
mediated tubular injury. 
 
DISCUSSION
In the present study we demonstrated that rhC1INH is not protective in a rat 
model of renal IRI. Therapeutic administration of functionally active rhC1INH in 
vivo did not attenuate renal dysfunction following reperfusion, nor did it inhibit 
influx of inflammatory cells, tubular injury or complement cascade activation. 
Although rhC1INH inhibited complement activation in vitro, tubular C3 deposition 
at 24 hours following reperfusion was present in rhC1INH-treated animals at the 
same extent as control-treated animals. Recently, we and others have shown 
that activation of complement is a relative late event following reperfusion with 
the first signs of C3 deposition at 2 and 24 hours upon reperfusion in mice (7) and 
rats (30), respectively. In our rat model, kinetic analysis revealed that rhC1INH 
Figure 4. RhC1INH kinetics 
in rats are unfavorable for 
effective protection. Before 
induction of unilateral ischemia 
and removal of the contralateral 
kidney, rats received rhC1INH 
intravenously (625 U/kg). Before 
and following rhC1INH infusion, 
blood samples were drawn 
at consecutive time points to 
assess lectin (A) and classical (B) 
pathway activity and circulating 
levels of rhC1INH (C) and MBL 
(D). 
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only effectively inhibited complement activity in the first hour after reperfusion 
and that both classical as well as lectin pathway activity was fully restored in the 
next hour. This fast clearance of rhC1INH (Fig 4A) might explain the inability of 
rhC1INH to reduce complement deposition and complement-mediated injury. 
Castellano et al (6) showed that a comparable dose of rhC1-inhibitor infused 
in pigs significantly protected against renal IRI and reduced both lectin and 
classical pathway activation up to at least 240 minutes after infusion, indicating 
an important species difference in the clearance of and protection by rhC1INH. 
Another important difference between these two models is the presence of 
peritubular C4d staining in pigs following reperfusion (6), which is completely 
absent in rats (data not shown). This suggests that classical and/or lectin pathway 
activation by C1q and MBL leading to C4 deposition in the kidney following 
reperfusion is virtually absent in rodents. These data are in line with IRI studies 
in mice, in which C4-deficient animals are not protected (10). However, recently 
Figure 5. RhC1INH does not inhibit MBL-mediated tubular cell death. Human PTEC 
(HK-2) were incubated with or without 10 µg/ml human MBL (A, B) in the presence 
or absence of rhCINH (1 mg/ml) or blocking antibodies to MASP-2 (100 µg/ml) for 
24 h. Subsequently, wells were photographed (A; magnification ×200) and quantified 
(B). To assess the contribution of MASPs in MBL-mediated cell death, MASP-free MBL 
was generated (C) and incubated (D) in a dose response on human PTEC. Viable cells 
were assessed by counting Hoechst-positive, but PI-negative cells in the well using 
fluorescence microscopy.
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it was shown in several mouse models of IRI, that MBL in association with MASP-
2 (31) can bypass C4 and directly cleave C3 (32). Indeed, mice deficient for MBL 
were protected against renal IRI (33). Glycosylated tubular meprins, which bind 
MBL (34;35), were shown to be involved in the activation of complement in the 
kidney. Inhibition of MBL-MASP complexes by rhC1INH might therefore still be a 
therapeutic option, however the unfavorable fast clearance of rhC1INH does not 
warrant any protective effects in rodents.
We recently demonstrated an entirely new concept of lectin pathway participation 
in renal IRI. In a rat model we showed that MBL exerts direct cytotoxic effects to 
tubular epithelial cells in the complete absence of complement activation (30). 
Inhibition of MBL was almost completely protective against renal IRI, whereas 
downstream inhibition of complement was not. Because rhCINH targets the 
MBL-associated serine proteases (MASPs) (15), we examined whether MASPs 
might be involved in this MBL-mediated tubular cell death. However, blockade 
of MASP-2 or depletion of MASPs from MBL, did not abrogate the cytotoxic 
effect of MBL (Fig 5), suggesting that interference of rhC1INH with MASPs would 
not reduce the cytotoxicity of MBL towards tubular cells.
RhC1INH, in contrast to purified human C1INH, is known to be heavily 
glycosylated (23;24) and is therefore thought to have an additional inhibitory 
effect towards the lectin pathway of complement by directly binding MBL. Since 
rhC1INH was cleared quickly from circulation (Fig 4A), we considered whether 
this might affect circulating levels of MBL. This effect however was negligible 
since circulating MBL levels following reperfusion remained stable in the first 
hours following rhC1INH administration. Also in vitro, rhC1INH did not inhibit 
cytotoxic effects exerted by MBL towards human tubular cells, indicating that 
rhC1INH is not able to reduce the complement-independent effects of MBL.
Although an important function of C1INH is to regulate complement activation, it 
also inhibits proteases of the fibrinolytic, clotting, and kinin pathways. Deficiency 
of C1INH is associated with hereditary angioedema (22;36). Involvement of 
fibrinolytic and clotting pathways in renal IRI has been demonstrated (37-39), 
which also might be influenced by C1INH. In the past few years, it has become 
apparent that C1INH has additional anti-inflammatory functions independent of 
protease inhibition. These include interactions with leukocytes that may result 
in enhanced phagocytosis (40), with endothelial cells via E- and P-selectins 
that interfere with leukocyte rolling and in turn results in suppression of 
transmigration of leukocytes across the endothelium (41) and interactions 
with extracellular matrix components (42;43). In addition, C1INH has a direct 
anti-apoptotic activity on vascular endothelial and myocardial cells, associated 
with blocking of cytochrome c translocation and the inhibition of caspase-3 
activation by normalization of the pro-apoptotic Bcl-2/Bax expression ratio 
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(44;45). Altogether, these effects contribute to the protective effect of C1INH 
in reperfusion injury. Treatment with C1INH has been successfully performed in 
animal IRI models in the heart (44;46), intestine (47), skeletal muscle (48), liver 
(49) and brain (50;51). However in all these models, purified C1INH from human 
plasma was used. This might explain the discrepancy observed with our renal 
IRI model, in which the recombinant form of C1INH was used. Pharmacokinetic 
studies in rats revealed that the recombinant form was cleared from circulation 
within two hours. Timing of rhC1INH administration before the initiation of 
ischemia was therefore not optimal, since most rhC1INH has been cleared 
from the circulation by the time that it was actually needed and complement 
activation was most evident. Furthermore, the complement-independent MBL-
mediated cytotoxicity, which could not be inhibited by rhC1INH in vitro, may be 
more pronounced in the kidney than in other organs systems. 
Taken together, we demonstrated that rhC1INH is not protective against renal IRI 
in rats and does not rescue human tubular cells from MBL-mediated cytotoxicity 
in vitro.
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ABSTRACT
Introduction: Endothelial cells (ECs) are highly susceptible to hypoxia and easily 
affected upon ischemia/reperfusion (I/R) during renal transplantation. Pericytes 
and angiopoeitins play important role in modulating EC function. In the present 
study, we investigate the effect of renal I/R on dynamics of angiopoietin 
expression and its association with pericytes and fibrosis development.
Methods: Male Lewis rats were subjected to unilateral renal ischemia for 45 
minutes followed by removal of the contralateral kidney. Rats were sacrificed 
at different time points after reperfusion. Endothelial integrity (RECA-1), 
pericytes (PDGFRβ), Angiopoietin-2 (Ang-2)/Angiopoietin-1 (Ang-1) expression 
and interstitial collagen deposition (Sirius Red and α-SMA) were assessed using 
immunohistochemistry and RT-PCR. 
Results: Our study shows an increase in protein expression of Ang-2 starting at 
5 hours and remaining elevated up to 72 hours, with consequently higher Ang-
2/Ang-1 ratio after renal I/R (p<0.05 at 48 hours). This was accompanied by an 
increase in protein expression of the pericytic marker PDGFRβ and a loss of ECs 
(both at 72 hours after I/R, p<0.05). Nine weeks after I/R, when renal function 
was restored, we observed normalization of the Ang-2/Ang-1 ratio and PDGFRβ 
expression and increase in cortical ECs, which was accompanied by fibrosis.
Conclusions: Renal I/R induces a dysbalance of Ang-2/Ang-1 accompanied by 
proliferation of pericytes, EC loss and development of fibrosis. The Ang-2/Ang-1 
balance was reversed to baseline at 9 weeks after renal I/R, which coincided with 
restoration of cortical ECs and pericytes. Our findings suggest that angiopoietins 
and pericytes play an important role in renal microvascular remodeling and 
development of fibrosis.
INTRODUCTION 
Renal I/R is an inevitable consequence of renal transplantation causing significant 
graft injury (5;16;29). Renal I/R impairs the integrity of ECs and leads to loss 
of peritubular capillaries (6;9;17;19;25;32;36). Loss of integrity and function 
of the endothelial monolayer lead to renal hypoxia, which is suggested to be 
a major initiator of profibrotic changes and interstitial scar formation in the 
kidney (2;24). These microvascular changes and renal scarring eventually lead to 
a deteriorating of renal function and graft loss (26).
Pericytes play a critical role in the stabilization and proliferation of peritubular 
capillaries via interaction with ECs (1;20;30). This process is mediated by several 
angioregulatory factors, including Ang-1, produced by pericytes and Ang-
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2 produced by activated ECs (7;30;35). Angiopoietins are a group of vascular 
regulatory molecules that bind to the receptor tyrosine kinase Tie-2, which is 
predominantly expressed by vascular ECs. Ang-1 is a strong vascular protective 
agonist of the Tie-2 receptor responsible for suppressing vascular leakage, 
maintaining EC survival and inhibiting vascular inflammation. Ang-2 acts as an 
antagonist of Ang-1 and in a dose dependent manner promotes destabilization, 
vessel leakage and inflammation. By promoting pericyte dropout, Ang-2 will lead 
to loosening contacts between ECs and perivascular cells, with subsequent vessel 
destabilization and abnormal microvascular remodeling (7;14;15;35). Recent 
studies have shown that pericytes detach from the endothelium and migrate 
to the interstitium to become activated and differentiate into myofibroblasts 
contributing to renal fibrosis (10;12). Interestingly, treatment with cartilage 
oligomeric matrix protein (COMP)-Ang-1 in a mice model of renal I/R injury 
resulted in protection against peritubular capillary damage and decrease in 
inflammatory cells and renal interstitial fibrosis (19). 
However, dynamics and the time course of angiopoietin expression, its relation 
with EC and pericyte expression and development of fibrosis in the repair phase 
after renal I/R injury are unknown. Using an established rat model of renal I/R 
injury, we assessed the impact of I/R on Ang-2/Ang-1 balance and its effect on 
microvascular remodeling, pericytes and the formation of fibrosis up to 9 weeks 
after renal I/R injury. We hypothesize that I/R injury leads to activation of ECs 
with consequent elevation of Ang-2 levels, which may lead to proliferation of 
pericytes and loss of ECs, but may also induce fibrosis in the long term.
 
METHODS
Rat model of renal I/R injury
Renal I/R injury was induced as previously described (34). The Animal Care and 
Use Committee of the Leiden University Medical Center approved all experiments. 
Eight-week-old male Lewis rats (200–250 g) purchased from Harlan (Horst, The 
Netherlands) were housed in standard laboratory cages and allowed free access 
to food and water throughout the experiments. Unilateral ischemia was induced 
by clamping of the left renal pedicle for 45 min using a bulldog clamp (Fine 
Science Tools, Heidelberg, Germany). During clamping the contralateral kidney 
was removed. Sham-treated rats had identical surgical procedures except for 
clamping of the left kidney. Tail blood samples were taken before and at indicated 
time points after reperfusion and were kept on ice. Rats were sacrificed at 2, 5, 
24, 48 or 72 hours (hr) and 1, 6 and 9 weeks (wk) after reperfusion and kidneys 
were harvested for histological examination and immunohistochemical staining. 
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Renal function was assessed by measuring creatinine and urea (BUN) in serum 
samples using standard auto analyzer methods by our hospital research services.
Immunohistochemistry and immunofluorescent staining 
Rat kidney sections (4 µm) of snap-frozen kidneys were air dried and acetone 
fixed. Slides were incubated overnight with goat polyclonal IgG against Ang-1 
(N18) or Ang-2 (F18; both Santa Cruz Biotechnology), mouse monoclonal IgG 
against endothelial cells (RECA-1; Hycult Biotechnology, Uden Netherlands and 
CD31; Abcam, Cambridge, England), myofibroblasts (α-SMA, Progen, Heidelberg, 
Germany), inflammatory cells (OX42+ for monocytes, dendritic cells and 
granulocytes, and CD45 (BD Pharminghen, Breda Netherlands) for leukocytes) or 
rabbit polyclonal IgG against pericytes (PDGFRβ; Abcam, Cambridge, England). 
Antibody binding was detected with horseradish peroxidase (HRP)-labeled rabbit 
anti-goat IgG (DAKO, Glostrum, Germany), goat anti-mouse IgG (Jackson, Suffolk, 
England) or goat anti-rabbit IgG (DAKO), respectively. After washing, sections 
were incubated with tyramide-fluorescein isothiocyanate in tyramide buffer 
(NENTM Life Science Products, Boston, MA, USA), washed and incubated with 
HRP-labeled rabbit anti-fluorescein isothiocyanate (DAKO, Glostrum, Germany) 
and developed with 3,3’-Diaminobenzidine (DAB) (Sigma, St Louis, MO, USA). 
Sections were counterstained with haematoxylin (Merck, Darmstadt, Germany) 
and mounted with imsol (Klinipath, Duiven, the Netherlands). Quantification 
of immunohistochemistry was performed in a blinded manner by assessing 
consecutive high power fields (magnification, ×100) on each section from 
the cortex, outer and inner medulla. Using Image J software, the percentage 
of positivity per specific region of the kidney was determined, with exception 
of Ang-1 and Ang-2, which was only analyzed for the cortex. Glomeruli were 
excluded from all analyses of the cortex. Since the Ang-2/Ang-1 ratio, rather than 
the absolute expression of either angiopoietin is generally used to determine 
the functional status of the microvasculature (26), this ratio was calculated 
using the Ang-2 and Ang-1 quantification. Immunofluorescent double stainings 
were performed for ki-67 (cell proliferation marker) using polyclonal rabbit IgG 
(Abcam, Cambridge, England) and RECA-1 and Ang-2/RECA-1. Due to technical 
reasons double stainings with Ang-1/ PDGFRβ and RECA-1/ PDGFRβ could not 
be performed, therefore the pericyte marker NG2 (rabbit polyclonal IgG; BD 
Pharmingen, Breda, Netherlands) was used for these double stainings. Antibody 
binding was visualized using Alexa™ 488-labeled goat anti-rabbit IgG, Alexa™ 
568-labeled goat anti-mouse IgG (both Life science) and donkey anti-goat 
IgG (Jackson, Suffolk, England). Nuclei were stained using Hoechst (Molecular 
Probes, Leiden, the Netherlands). Micrographs were made using a fluorescence 
microscope (Leica, DMI6000, Rijswijk, the Netherlands).
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Histologic evaluation
Renal fibrosis was evaluated histologically by Sirius Red staining as described 
previously (27) on 4 µm paraffin slides of renal rat tissue. From each part of the 
kidney (cortex, outer and inner medulla) five random images were obtained. 
Image analyses was performed using Image J software. The amount of collagen 
deposition was measured and expressed as percentage of positivity per region 
of the kidney. In addition, all tissue specimens were scored for severity of 
fibrosis on a semi-quantitative scale (0-3) in a blinded manner by an experienced 
pathologist.
RNA isolation and Real-Time PCR 
RT-PCR was performed as described previously (34). Total RNA was extracted 
from snap frozen cross-section kidney slices using the RNeasy Mini isolation 
Kit according to the manufacturer’s instructions (QIAGEN, Hilden, Germany). 
cDNA was synthesized from 1 µg total RNA, using an oligo dT primer, RNase-
OUT, M-MLV reverse transcriptase, 0.1 M-DTT and buffers in a volume of 20 µL 
(all purchased from Invitrogen, Breda, The Netherlands). Quantitative real-time 
PCR was performed in duplicate by using iQ SYBR Green Supermix on iCycler 
Real-Time Detection System (BioRad). The amplification reaction volume was 
20 µL, consisting of 10 µL iQ SYBR Green PCR mastermix, 1 µL primers, 1 µL 
cDNA, and 8 µL water. Data were analyzed using Gene Expression Analysis for 
iCycler Real-Time PCR Detection System (Biorad). Expression of each gene was 
normalized against mRNA expression of the housekeeping gene Rsp-15. RT PCRs 
were performed in duplicate. The primer sequences are shown in table 1.
Table 1. Primer sequences used for quantitative real-time PCR
Gene Forward primer 5’->’3 Reverse primer 5’->’3 Supplier
RSP-15 CGTCACCCGTAATCCACC CAGCTTCGCGTATGCCAC Biolegio
ANG-1 TCTCTTCCCAGAAACTTCA TTTGATTTAGTACCTGGGTCTC Biolegio
ANG-2 TGCATCTGCAAGTGTTCCC GCCTTGAGCGAGTAACCG Biolegio
TIE-2 GTCCTATGGTGTATTGCTCTG TCTCTCATAAGGCTTCTCCC Biolegio
Statistical analyses
Data are reported as mean ± standard error of the mean (SEM). Statistical 
comparisons were performed using one-way ANOVA or Mann–Whitney test 
with GraphPad Prism software (GraphPad Software Inc., San Diego, CA, U.S.A.). 
A value of p < 0.05 was considered statistically significant. 
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RESULTS
Renal I/R induces transient deterioration of renal function, influx of 
inflammatory cells and interstitial fibrosis
In the current study we used a rat model of renal I/R resulting in extensive 
renal dysfunction, as shown by increased serum creatinine and BUN levels, but 
characterized by normalized renal function after 1 week following I/R (p<0.05, 
compared to 72 hr) (Fig. 1A, B). Renal dysfunction was accompanied by significant 
Figure 1. Renal I/R induces 
deterioration of renal function 
and influx of inflammatory 
cells. Serum creatinine 
levels (A) and BUN (B) were 
measured at consecutive 
time points after reperfusion. 
CD45+ leukocyte infiltrate was 
quantified using digital image 
analysis (C). Representative 
photomicrographs of kidney 
sections stained with CD45 
(D) from a sham-operated 
rat and a rat subjected to I/R 
and sacrificed at 72 hr after 
reperfusion. An overview of 
the division of the different 
regions (cortex, outer medulla 
and inner medulla) in a 
kidney section stained with 
OX42 (E). Representative 
photomicrographs of kidney 
sections stained with OX42+ 
from a sham-operated rat 
and rats subjected to I/R and 
sacrificed at 72 hr or 9 weeks 
after reperfusion (F). OX42+ 
infiltrate of sham-operated 
rats and rats subjected to I/R 
was quantified in the different 
areas using digital image 
analysis (G) and demonstrated 
as % of the depicted area. Data are shown as mean ± SEM (n= 5 rats per group). *P<0.05 
compared to corresponding sham controls. #P<0.05 compared to 72 hr or 1 wk rats. 
Original magnification of D, E and F, x200. C=cortex; OM=outer medulla; IM=inner 
medulla. 
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infiltration of OX42+ inflammatory cells in the cortex, outer and inner medulla 
at 72 hr (p<0.05), which peaked at 1 week compared to sham-operated rats (Fig. 
1E, F, G). A decrease in OX42+ inflammatory cells was observed at 6 and 9 weeks 
in the different parts of the kidney compared to 1 week following I/R (p<0.05). 
In the outer and inner medulla, the influx of OX42+ cells remained significantly 
increased up to 6 and 9 weeks (p<0.05), respectively, after renal I/R injury 
compared with sham-operated rats (Fig. 1G). Consistently, CD45 expression in 
the cortex showed a similar pattern as OX42+ staining (Fig. 1C, D).
One week after reperfusion, significant diffuse interstitial collagen deposition 
was observed in the cortex, outer and inner medulla compared to sham-operated 
rats (p<0.05) (Fig. 2A, B). After 9 weeks collagen deposition was significantly 
decreased in different regions of the kidney compared to 1 week following renal 
I/R injury (p<0.05), although kidneys were still characterized by focal areas of 
intense Sirius Red staining. The semi-quantitative analyses showed that fibrosis 
scores at 9 weeks were not statistically different from 1 week after I/R (data not 
Figure 2. Renal I/R induces 
interstitial fibrosis. Representative 
photomicrographs of Sirius Red 
stained kidney sections (A) of 
the cortex, outer medulla and 
inner medulla obtained from a 
sham-operated rat (sacrificed at 
1 week), and rats subjected to 
I/R and sacrificed at 1 or 9 weeks 
after reperfusion as indicated. 
Quantitative analysis of Sirius Red 
staining (B) and α-SMA staining 
(C) at different time points after 
reperfusion in sham-operated 
rats and rats subjected to I/R in 
the different regions as indicated. 
Quantification was performed 
by digital image analysis and 
is demonstrated as % of the 
depicted area. Data are shown 
as mean ± SEM (n= 5 rats per 
group). *P<0.05 compared to 
corresponding sham controls. 
#P<0.05 compared to 72 hr or 1 
wk rats. Original magnification 
of A, x200. C=cortex; OM=outer 
medulla; IM=inner medulla. 
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shown), which is probably due to the focal areas of fibrosis. Consistently, the 
α-SMA immunohistochemical staining revealed a significant increase of fibrosis 
in cortex and outer medulla at 72 hr (p<0.05) and at all parts of the kidney at 1 
week (p<0.05) following I/R injury compared with sham-operated rats (Fig. 2C, 
D). At 9 weeks, α-SMA staining was significantly decreased in the cortex, outer 
and inner medulla compared with 1 week after I/R injury (Fig. 2C).
Restoration of peritubular capillaries in the cortex after renal I/R
Since endothelial damage is an important hallmark of I/R injury, we assessed 
peritubular capillaries over time by staining for RECA-1. A significant reduction 
in RECA-1 expression was observed at 72 hr post I/R (p<0.05) in the cortex and 
Figure 3. Restoration of I/R-
induced peritubular capillary 
loss in the cortex late after 
reperfusion.
Representative images 
of kidney sections of the 
cortex, outer medulla and 
inner medulla stained for 
RECA-1 (A) obtained from a 
sham-operated rat and rats 
subjected to I/R and sacrificed 
at 72 hr and 9 weeks after 
reperfusion. RECA-1 was 
quantified using digital image 
analysis as indicated (B). 
Immunofluorescent double 
staining for RECA-1 (red) and 
Ki-67 (green) of representative 
kidney sections of a sham-
operated rat and rats sacrificed 
at 72 hr (C) or 9 weeks (D) 
after reperfusion. Insert is 
showing double positivity of 
RECA-1 and Ki-67 staining in 
yellow in kidney sections at 
9 weeks after reperfusion. 
Representative images of 
kidney sections of the cortex 
stained for CD31 (E) obtained 
from a sham-operated rat and rats subjected to I/R and sacrificed at 72 hr or 9 weeks 
after reperfusion. Data are shown as mean ± SEM (n= 5 rats in grouper group). *P<0.05 
compared to corresponding sham controls. #P<0.05 compared to 72hr. Original 
magnification of A, C and E, x200; insert at 9 weeks, x400.
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outer medulla and at 1 week in the inner medulla (p<0.05) compared with sham-
operated rats (Fig. 3A, B). Interestingly, we found a significant increase of RECA-
1 staining at 6 and 9 weeks in the cortex (p<0.05) following I/R compared to 
rats that were sacrificed at 72 hr (Fig. 3B). RECA-1 staining colocalized with the 
proliferation marker Ki-67, suggesting EC proliferation in peritubular capillaries 
within the renal cortex at 9 weeks after I/R (Fig. 3C). No proliferation of ECs 
was found in the glomeruli following renal I/R. In the outer and inner medulla a 
different pattern was found. Here, a significant reduction in RECA-1 expression 
was observed at 72 hr post I/R in the outer medulla (p<0.05) and at 1 week in the 
inner medulla (p<0.05) compared with sham-operated rats (Fig. 3B). In contrast 
to the cortex, RECA-1 staining in these areas showed a further decrease up to 
9 weeks after ischemic injury (p<0.05) (Fig. 3B). CD31 staining demonstrated a 
pattern comparable to the RECA-staining (Fig. 3E). 
Renal I/R induces a dysbalance in Ang-2/Ang-1 ratio at early time points 
and return to baseline after 6 weeks
In control kidneys of sham-operated rats, Ang-1 staining was observed in the 
glomeruli and in a capillary like pattern between the tubuli (Fig. 4A). Double 
staining of Ang-1 and the pericyte marker NG2 revealed colocalization, suggesting 
that Ang-1 is expressed by pericytes (Fig. 4C). Starting at 24 hr after renal I/R, 
a significant decrease in Ang-1 expression was observed (data not shown), 
reaching a maximal decrease at 72 hr (p< 0.05) (Fig. 4A, F). Ang-1 expression 
increased significantly at 9 weeks after renal I/R compared to 72 hr (p<0.05) 
(Fig. 4A, F). Additionally, RT-PCR analyses revealed a decrease in Ang-1 mRNA 
levels which reached significance at 1 week compared the sham-operated rats 
(p<0.05; Fig. 4I). In control rats, low levels of Ang-2 protein were observed in 
glomeruli, interstitial vessels and on brushborders of tubuli (Fig. 4B, G). Due to 
the apical and brush border expression on tubuli of Ang-2 in the medulla, it was 
technically not possible to distinguish between interstitial and tubular presence 
of Ang-2 (Fig. 4E). Therefore quantification of angiopoietins was only performed 
in the cortex. Additional double staining of Ang-2 and RECA-1 confirmed the 
expression of Ang-2 by ECs (Fig. 4D). Compared to sham-operated rats, Ang-2 
expression increased at 5 hr (data not shown) and remained elevated up to 72 
hr (p< 0.05) after I/R (Fig. 4G). Consequently higher Ang-2/Ang-1 ratios were 
observed after 48 hr and 72 hr (p<0.05) (Fig 4H). After 1 week, Ang-2 levels and 
Ang-2/Ang-1 ratio started to decrease, reaching significance at 6 and 9 weeks 
compared to 72 hr after renal I/R (Fig. 4B, G and H). Ang-2 mRNA levels did not 
confirm the observed changes at protein levels (Fig. 4J). Tie-2 mRNA expression 
showed a significant decrease at 1 week compared with sham-operated group 
and reversal to baseline levels at 9 weeks after I/R (Fig. 4K). 
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Renal I/R leads to proliferation of pericytes
Immunohistochemical staining revealed the presence of PDGFRβ positive cells 
in the mesangium, Bowman’s capsule, large vessels and peritubular capillaries 
(Fig. 5A). A significant increase of pericytes was observed at 48 hr upon I/R in 
all parts of the kidney compared with sham-operated rats, which persisted up 
to 72 hr in the cortex and up to 9 weeks in both the outer and inner medulla (p< 
0.05) (Fig. 5A, B). PDGFRβ expression showed normalization at the protein level 
in all regions of the kidney (p<0.05) at 9 weeks after renal I/R injury (Fig. 5A, 
B). To investigate the anatomical relation of ECs and pericytes double staining 
Figure 4. Renal I/R 
induces a dysbalance in 




kidney sections stained 
with Ang-1 (A) or Ang-2 
(B) in a sham-operated 
rat and rats subjected 
to I/R and sacrificed 
at 72 hr or 9 weeks 
after reperfusion. 
I m m u n o f l u o r e s c e n t 
double staining for Ang-
1/NG2 (C), RECA-1/Ang-
2 (D) and Ang-2/RECA-1 
(E) of representative 
kidney sections in a 
sham-operated rat. 
Arrows indicate double 
staining in yellow (C,D) 
and apical expression of 
Ang-2 (E). Quantitative 
analysis of cortical 
protein expression of 
Ang-1 (F), Ang-2 (G), 
and Ang-2/Ang-1 ratio 
(H) at consecutive time 
points after reperfusion. 
Quantitative analysis of RNA expression of Ang-1 (I), Ang-2 (J) and Tie-2 (K) at 
consecutive time points after reperfusion. Data are shown as mean ± SEM (n= 5 rats per 
group). *P<0.05 compared to corresponding sham controls. #P<0.05 compared to 72 hr. 
Magnification of A-E, x400.
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with RECA-1 and the pericyte marker NG2 were performed, which revealed 
expression of both markers in the glomeruli and peritubular space (Fig. 5C).
DISCUSSION
We performed a detailed kinetic analysis of angiopoietin and pericyte expression 
after renal I/R injury. We demonstrate that renal I/R induces a dysbalance in 
Ang-2/Ang-1 which is accompanied by a loss of ECs, proliferation of pericytes 
and development of fibrosis. At 9 weeks post I/R, we show reversal to baseline in 
Ang-2/Ang-1 balance, an increase in ECs and normalization of PDGFRβ expression 
in the cortex. Whereas renal function is fully restored at this time point, the 
renal tissue does still show signs of fibrosis.
It is postulated that loss of ECs is a central common pathway involved in 
organ failure that precedes and drives the profibrotic changes of the kidney 
parenchyma (2;3;24). Different reports using animal models have been 
Figure 5. Renal I/R induces proliferation of pericytes. Representative photo-micrographs 
of whole kidney sections stained for PDGFRβ (A) in a sham-operated rat and rats 
subjected to I/R and sacrificed at 72 hr or 9 weeks after reperfusion. Insert is showing 
peritubular and glomerular expression of PDGFRβ in sham-operated rats. Quantitative 
analysis of PDGFRβ 
protein expression (B) 
at consecutive time 
points after reperfusion. 
Fluorescent double 
staining for RECA-1 
(red) and NG2 (green) 
of representative 
kidney sections (C) 
in a sham-operated 
rat and rat subjected 
to I/R and sacrificed 
at 9 weeks after 
reperfusion. Data are 
shown as mean ± SEM 
(n= 5 rats per group). 
*P<0.05 compared to 
corresponding sham 
controls. #P<0.05 
compared to 72hr. 
Original magnification 
of A, x100; insert at 72hr 
and C, x200.
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published which demonstrate chronic deleterious effects of ischemic injury on 
long-term renal function and microvascular structure (2;6;16;17;29;36). Basile 
et al have shown that renal I/R in a rat model results in permanent damage to 
peritubular capillaries with development of tubulointerstitial fibrosis and decline 
in long-term renal function (2). In the present study, we also observed loss of 
peritubular capillaries and development of tubulointerstitial fibrosis following 
renal I/R, which were more severe and extensive in the outer and inner medulla 
than the cortex. The observed fibrosis at early time points after renal I/R injury 
in our study coincided with the influx of inflammatory cells. At later time points, 
we observed a different pattern of fibrosis, which was more dense and unrelated 
to the areas of inflammation. This ‘inflammatory fibrosis’ observed at early 
times has been reported to be important for restoration of the original tissue 
morphology and function (13). It is, however, also suggested that if repair is not 
efficient at early times, fibrosis at the repair phase cannot be prevented (9). In 
our study, at 9 weeks after reperfusion, restoration and proliferation of ECs was 
found in the cortex, but not in the outer and inner medulla. This could be caused 
by the anatomical relationship of capillaries and tubules in the outer and inner 
medulla, with consequently a greater impact of hypoxia- and leucocyte-induced 
EC damage than in the cortical peritubular capillaries (5). 
In contrast to the study of Basile et al, we found restoration and proliferation of 
ECs in the cortex in the repair phase (9 weeks after I/R). Possible explanations 
for this discrepancy between our study and the studies of Basile could be 
differences in clamping time (45 versus 60 minutes, respectively) and the 
removal of the healthy contralateral kidney in our study. In the study of Basile, 
additional experiments in which rats were subjected to 30 and 45 minutes of 
bilateral ischemia were performed, to assess whether the duration of ischemic 
injury affects damage to the renal microvasculature and function. Both renal 
function and capillary density were more disturbed in the 45 minutes group 
compared to the 30 minutes rats, which might implicate a “critical ischemia 
time” for endothelial repair (2).
The molecular mechanisms that lead to microvascular injury in organ failure 
are largely unknown. It has been suggested that several angioregulatory growth 
factors, including the angiopoeitins, play a central role in the loss of vascular 
integrity (18;36). In this regard, a study has shown that treatment with COMP-
Ang-1 (soluble, stable and potent form of Ang-1) in a mice model of renal 
I/R resulted in protection against peritubular capillary damage, decrease in 
interstitial inflammatory cells and renal interstitial fibrosis (5). Other investigators 
have demonstrated stabilization of peritubular capillaries along with increased 
fibrosis and inflammation after adenoviral Ang-1 treatment in a mouse model 
of folic acid-induced nephrotoxicity (37). These studies suggest that differences 
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in efficacy of Ang-1 in the kidney may be due to variation in potency of Ang-
1 and COMP-Ang-1 or difference in kidney disease models (5;12;37). Ang-2 
acts as an antagonist of Ang-1 and increases vessel leakage, inflammation and 
destabilization by promoting pericyte loss, therefore loosening contacts between 
ECs and pericytes (18;36).
An interesting observation in this study is the relation in time between Ang-2/
Ang-1 balance and microvascular integrity and pericytes in the cortex after I/R. 
Activation of ECs, reflected by increase in Ang-2 expression and consequently 
higher Ang-2/Ang-1 ratio, was accompanied by proliferation of pericytes, EC loss 
and development of fibrosis. This relation between EC loss and dysbalance in 
angiopoietins has also been demonstrated in a mouse model of anti-glomerular 
basement membrane glomerulonephritis, where glomerular capillary loss was 
associated with reduced Ang-1 and increased Ang-2 expression (38). In addition, 
in an animal model of diabetic retinopathy, Ang-1 was shown to have a profound 
effect in repairing integrity of the retinal EC permeability barrier (39). Moreover, 
injection of Ang-2 into the eyes of normal rats has been shown to induce a dose-
dependent pericyte loss (28). These findings suggest an important role for the 
angiopoeitins in generating a proangiogenic environment that is necessary for 
capillary repair.
Several studies have pointed at the critical importance of the interaction between 
pericytes and ECs in maintenance of the capillary network (1;30). Surprisingly, 
hardly any data are available on the relation between pericytes and loss of 
ECs in renal I/R. Only one study has shown an association between damage to 
peritubular capillaries and decreased number of pericytes in cadaveric renal 
allografts after I/R (21). Peritubular capillary integrity was better preserved and 
pericytes were more pronounced in patients who had a better recovery of their 
graft function compared to patients with sustained postischemic acute kidney 
injury (21). However, this study investigated the expression of pericytes at 
only one time-point early after renal I/R and did not investigate the relation to 
angiopoietins and development of fibrosis in a time course.
To investigate the role of pericytes in renal I/R injury, we used PDGFRβ as pericyte 
marker. PDGFRβ is a single-spanning transmembrane glycoprotein that binds to 
its dimeric ligand PDGF and a crucial receptor for recruitment and survival of 
pericytes by paracrine secretion of PDGFB by ECs (4;23;33). PDGFRβ has been 
shown in studies of obstructive and post-ischemic kidney injury to be expressed 
by pericytes and fibroblasts (8;22;23). Compared with other pericyte markers, 
PDGFRβ continued to be expressed after proliferation of pericytes and after 
transformation into myofibroblasts upon injury. Recently, Duffield et al provided 
evidence for the contribution of pericytes to the development of renal fibrosis 
(11;18;23;30). Using a transgenic mouse model of unilateral ureter obstruction 
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(UUO), expressing green fluorescent protein in cells producing the collagen 
type I, they demonstrated that pericytes are the main source for interstitial 
myofibroblasts during renal fibrosis (23). The same investigators showed 
migration of perivascular stromal cells from capillaries into the renal interstitium, 
within 9 hr after induction of ureter obstruction. After loosening contact from the 
capillaries, pericytes became activated and proliferated into collagen producing 
myofibroblasts contributing to fibrosis (23). PDGFRβ signaling has been reported 
to play an important role in the development of fibrosis. Blockade of PDGFRβ 
attenuated recruitment of inflammatory cells, loss of ECs and fibrosis in mice 
subjected to renal I/R injury and UUO (22). Also in our study we demonstrated 
proliferation of pericytes and loss of ECs which was accompanied by development 
of fibrosis. The pericytes may have responded to injury by detaching from the 
capillaries and becoming pathologic matrix depositing cells, that contribute to 
the population of α-SMA–positive cells in the fibrotic interstitial space observed 
in this study (8;31). The process of pericyte detachment has been suggested to 
be reversible, which could explain the observed decrease in PDGFRβ expression 
and the restoration of ECs in the cortex (22). However, in both the inner and outer 
medulla an increase of PDGFRβ cells was observed up to 9 weeks after renal I/R. 
Interestingly, these areas had no increase in EC staining and demonstrated a 
more profound fibrosis reaction compared to the less damaged cortex area. 
An important discussion point remains whether the decrease in RECA-1 in the 
cortex observed in our study is explained by EC loss or by interstitial edema 
and compression of peritubular capillaries. However, previous studies utilizing 
microfilm analyses and EC staining with CD31 confirmed the loss of ECs after I/R 
(2;3;17;19;32). Additional CD31 staining in this study revealed a similar pattern 
as observed with RECA-1. Although our study clearly suggests that angiopoietins 
are essential in renal microvascular remodeling in the cortex, we were not able 
to analyze the outer and inner medulla of Ang-2 staining. Ang-2 showed brush 
border and apical expression on tubules in the medulla, making it difficult to 
distinguish between interstitial and tubular presence of Ang-2. Therefore, we 
focused only on the cortex for angiopoietins staining. Furthermore, we observed 
a discrepancy in Ang-2 protein and mRNA expression, which could be explained 
by the use of whole kidney RNA extractions instead of a specific region as for 
immunohistochemistry or contribution of earlier produced Ang-2 by infiltrating 
cells, while lacking the detectable transcript (28). A therapeutic intervention 
would be required to prove a causal relationship between the functions of 
angiopoietins and pericytes and its role in EC stabilization and repair. 
In conclusion, our study demonstrates that renal I/R induces a dysbalance in 
angiopoietins, accompanied by proliferation of pericytes and development of 
fibrosis. These findings support the hypothesis that angiopoietins and pericytes 
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play an important role in renal microvascular remodeling. Since angiopoietins 
and pericytes are considered as important hallmarks of microvascular integrity, 
strategies to counteract microvascular destabilization after I/R may well improve 
long term graft function.
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9.1 INTRODUCTION
Ischemia/reperfusion (I/R) is an inevitable and injurious event in clinical 
conditions such as infarction, sepsis and solid organ transplantation. Ischemia 
occurs after insufficient local blood supply. Depletion of cellular energy (ATP) 
is the most prominent cause of cellular injury during ischemia. Reperfusion 
of ischemic tissue e.g. following transplantation provides oxygen as well as 
substrates that are necessary for tissue regeneration, restoration of energy 
levels and concurrent removal of toxic metabolites. Nevertheless, restoration 
of blood flow to ischemic tissue paradoxically exacerbates tissue damage by 
initiating a cascade of inflammatory events including release of reactive oxygen 
species (ROS), pro-inflammatory cytokines and chemokines, recruitment of 
leukocytes and activation of the complement system (1-4). Such deterioration of 
tissue function and integrity after reperfusion is defined as ischemia/reperfusion 
injury (IRI). Renal I/R is the major cause of acute kidney injury (AKI). AKI is a 
clinical syndrome characterized by a rapid decrease in renal function and plasma 
accumulation of creatanine, urea, metabolic acids, potassium and phosphate. 
AKI may not only occur in the context of kidney transplantation, in which I/R is 
inevitable, but is also a consequence of impaired kidney perfusion e.g. during 
major surgery or sepsis. Incidence of ischemic AKI varies from more than 5000 
cases per million people per year for non-dialysis-requiring AKI, to 295 cases per 
million people per year for dialysis-requiring disease (5). AKI has a frequency of 
1,9% in hospitalized patients (6) and is especially common in critically ill patients, 
in whom the prevalence of AKI is greater than 40% at admission to the intensive-
care unit if sepsis is present. 
In the renal transplant setting, ischemia during the transplant procedure, under 
toxic therapautical conditions or immunological injury, compromise tissue 
viability and promote alloimmunity. Therefore, AKI not only has a major impact on 
short-term but also on long-term graft survival following kidney transplantation 
and is strongly associated with delayed graft function (DGF), clinical morbidity 
and mortality (7-11). Ischemic AKI following renal I/R is characterized by injury 
to the proximal tubular epithelial cells (PTEC) mostly in the cortico-medullary 
junction. This process is called acute tubular necrosis (ATN). The injured tubular 
cells are important for tubular reabsorption, the process by which filtered 
metabolites e.g. salts, proteins and glucose, are reabsorbed from the primary 
filtrate via the brush border of these cells and transported back into the blood. 
During an ischemic event, there is shedding of the proximal tubular brush border 
within several minutes (13) and loss of polarity with mislocalization of adhesion 
molecules, complement regulators and other membrane proteins (12;13). In 
advanced ischemic injury, viable and necrotic tubular epithelial cells detach 
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from the basement membrane. These sloughed tubular cells, brush-border 
vesicle remnants and cellular debris form characteristic tubular casts, which 
might activate complement. The complement system is therefore an important 
contributor to inflammation after IRI. As a consequence of renal ischemia, there 
is an altered localization and expression of complement regulators on tubular 
cells (14), which makes these cells prone for complement activation. In addition, 
apoptotic as well as necrotic cells and tubular casts generated during I/R are 
potent activators of the complement system (15-18).
9.1.1 Scope of this thesis 
Several lines of evidence support an important role for complement in renal IRI. 
Most of this evidence however, is based on studies performed in mice, which 
demonstrate a predominant role for the alternative pathway of complement 
(19-21). In the kidney, the cortico-medullary junction harboring the proximal 
tubular cells (PTEC) is the region, where most complement activation and 
deposition of C3 and C5b-9 occurs. The loss of complement regulators at the 
basolateral surface of tubular cells allows complement activation following I/R 
on these cells. (14). Although complement activation is a clear hallmark of renal 
IRI in mice, the involvement of complement activation in human IRI remains to 
be explored. In addition, the contribution of the different complement pathways 
in human IRI has not been delineated. 
In the past, it has been shown that high levels of MBL are associated with worse 
allograft survival following clinical kidney transplantation, suggesting a harmful 
role for MBL and the lectin pathway of complement. Whether MBL might play 
a harmful role in the early phase of kidney transplantation during renal I/R, 
remains to be explored. Together, these subjects form the scope of this thesis. In 
the first part of the thesis (chapter 2-4) we focused on the role of complement 
and the activation pathways involved in human IRI. In addition, we made an 
approach to measure human complement activation locally in the renal tissue, 
in circulation and in the urine early following clinical kidney transplantation. In 
the second part (chapter 5-7) we focused on the role of MBL and a therapeutic 
approach to target MBL in the setting of renal IRI. Finally, we describe (chapter 8) 
how I/R and the mediators involved affect the endothelial compartment, which 
enables MBL to reach the tubular compartment and injure tubular cells.
9.2 COMPLEMENT IN HUMAN IRI
Most of the IRI studies performed in mice show a predominant role for the 
alternative pathway of complement (19-21). However, direct and in-depth 
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studies in humans confirming these findings are lacking and so far in human renal 
IRI, the activation pathways of complement by ischemic PTEC are incompletely 
elucidated. To successfully develop therapeutic interventions targeted towards 
complement activation in human, it is essential to establish the validity of murine 
data relative to what takes place in the human situation. 
9.2.1 Human complement activation in vitro
Thus far, it was unknown whether experimental data obtained in mice might 
be extrapolated to humans. This prompted us to study whether complement 
is activated and which pathways of complement activation are initiated by 
human PTEC following I/R and to compare these findings to mouse PTEC 
(chapter 2). For this purpose, we developed an in vitro model to induce hypoxia 
and subsequent reoxygenation to simulate I/R on human and mouse PTEC. 
Following reoxgygenation, we studied the role of the different pathways of 
complement activation. Exposure of human or mouse PTEC to hypoxia followed 
by reoxygenation in serum as a source of complement, resulted in extensive 
complement activation. Mouse PTEC exclusively activated complement via 
the alternative pathway, which was completely in line with in vivo IRI studies 
previously performed in mice (19;21). In contrast, complement activation by 
human PTEC was exclusively dependent on the classical pathway, supported by 
studies in C1q-depleted serum and use of blocking antibodies to human C1q. The 
activation of the classic pathway was mediated by IgM through interaction with 
modified phosphomonoesters exposed on human hypoxic PTEC. It is known from 
several studies that late apoptotic and necrotic cells bind natural IgM antibodies, 
which will lead to activation of the CP (22;23). We could demonstrate a similar 
binding of IgM to hypoxic human PTEC. Using IgM-deficient serum we showed 
that complement activation by hypoxic cells also occurs via binding of IgM, 
probably to phosphorylcholine residues exposed on hypoxic cells, as shown by 
inhibition of complement activation using phosphorylcholine. In line with these 
findings, it was recently shown that cultured pancreatic islets bind natural IgM 
and also activate the CP, probably caused by hypoxia or injury during the culture 
or harvesting procedure. 
Data from studies in mice but also human indicate that complement activation 
following I/R in skeletal muscle (24), heart (25), intestine (26) and limb (27) in vivo 
also occurs through binding of natural IgM. However, in renal IRI in mice it has 
been shown that immunoglobulins do not play such a role (28). These findings are 
in line with reports showing that C4-deficient mice were not protected against 
renal IRI (21), so it appears that in mice, renal IRI can proceed independently of 
C4 and immunoglobulins. The reason for this difference compared to human 
PTEC is unknown so far.
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In a pig model however, it was recently shown that the classical and lectin 
pathways of complement were involved in renal IRI (29). Importantly, this 
study demonstrated reduced ischemic injury when pigs were treated with C1 
inhibitor, a specific inhibitor of both the classical and lectin pathway (30;31). 
These porcine data are in line with our findings on human tubular cells, which 
activated the classical pathway of complement. Interestingly, this study (29) also 
demonstrated that the classical and lectin pathway were activated in human 
renal transplant recipients suffering from delayed graft function (DGF). The co-
localization of activated C4 with both C1q and MBL in graft biopsies obtained from 
these patients indicated that both these pathways were activated on peritubular 
capillaries, within the interstitium, and on the glomerular endothelium. However, 
in this study no C4 staining on tubular epithelial cells was observed, which could 
be explained by the fact that only cortical biopsies were taken, whereas tubular 
injury following reperfusion is mostly observed in the cortico-medullary junction 
of the kidney. In addition, biopsies were taken at 7-15 days after transplantation, 
in which tubular injury most probably has been cleared and repaired. Due to 
safety concerns however, biopsying early after reperfusion and specifically in 
the corticomedullary region is difficult. Previous studies on IRI in humans mostly 
relied on peripheral blood measurements, which lack sensitivity and do not 
discriminate between the release of factors from the allograft and systemically 
released factors. For these reasons, in-depth studies on the role and kinetics 
of reperfusion-induced complement activation in human have been hampered 
sofar. 
9.2.2 Human complement activation in circulation 
Recently, a renewing approach was established (32), which enabled us to 
measure circulating complement activation products directly released from the 
reperfused kidney and thereby avoiding the limitations of systemic measurements 
in human (chapter 3). Via a small catheter placed in the renal vein, blood aliquots 
were sampled at consecutive time points after reperfusion. In addition, paired 
arterial blood samples were collected. We concentrated on measurement of 
sC5b-9 because it is the common endpoint of all three pathways. Furthermore, 
it is suggested that in mice specifically C5b-9 is essential in the induction of 
tubular damage in renal IRI (21). For these reasons, arteriovenous concentration 
differences of terminal sC5b-9 were assessed directly over the reperfused organ 
to reveal the local activation of complement in human IRI. 
Release of sC5b-9 in living donor (LD), brain-dead donor (BDD), and cardiac dead 
donor (CDD) kidney transplantation were compared. A significantly higher rate 
of delayed graft function (DGF) was observed in BDD and CDD kidneys compared 
with LD kidneys. We demonstrated that mostly from CDD grafts, which are most 
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severely affected by I/R, sC5b-9 was released directly after reperfusion, indicative 
of intravascular terminal complement activation. sC5b-9 was released only very 
transiently, directly after reperfusion. This may represent a washout effect. The 
complement system may be triggered on encounter with intravascular cellular 
debris accumulated during the cold ischemic period or by encounter with hypoxic 
or injured endothelium (33;34). Intravascular thrombosis and clot formation 
during warm ischemia, especially in CDD kidneys might occur. The clotting and 
complement system are tightly intertwined (35-39). Activated thrombin as well 
as formed fibrin clots have been shown to activate complement leading to C5b-
9 formation. Indeed, potent thrombin activation was demonstrated directly 
following reperfusion by measuring prothrombin fragment (F)1 and 2 levels, 
indicative of conversion of prothrombin into thrombin by factor Xa (32). This 
thrombin activation might also be the cause of the transiently released sC5b-9 
observed directly after reperfusion.
A limitation of our study was the fact that the sampling time was restricted 
to maximally 30 minutes following reperfusion. Except for the very transient 
release of C5b-9 instantly after reperfusion, there was no release of C5b-9 
during the entire sampling period of 30 minutes. The absence of complement 
activation is in line with mouse IRI experiments, in which the first membrane 
attack complex elements C6 and C9 are observed only after 12 and 24 hours 
of reperfusion, respectively (40). Also in our rat IRI model, we observed the 
first signs of C5b-9 deposition after 24 hours of reperfusion (41), indicating that 
terminal complement activation is a relatively late event following reperfusion 
in human as well as in rodents.
Finally, the possibility remains that the complement cascade was transiently 
activated in living donor kidneys as well, without leading to terminal complement 
activation. Therefore, release of C5a from the reperfused kidney was assessed, 
because C5a is more upstream in the complement cascade than the terminal 
complex C5b-9 is. In agreement with C5b-9 measurements, there was no C5a 
release from living donor kidneys. This excludes early complement activation 
after reperfusion and also excludes early involvement of C5a, which has also 
been ascribed as harmful role in IRI (42). 
 
9.2.3 Human complement activation in renal tissue
Besides the intravascular sC5b-9 formation, C5b-9 could be also formed locally in 
the kidney without any release into the circulation. To assess local complement 
activation on tubular cells, tissue content and distribution of C5b-9 in needle 
biopsies collected before and after reperfusion was assessed. Surprisingly, the 
tubular surface, where C5b-9 is expected to deposit (21), showed no deposition 
of C5b-9 in LD, BDD or CDD kidneys after reperfusion. In contrast, renal tissue 
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of a patient with acute graft rejection showed extensive C5b-9 deposition in the 
tubular compartment. These findings were supported by a study of Haas et al. 
(43), where in 1 hour post-transplantation biopsies, no complement deposition 
as a consequence of reperfusion was detected either. However in this study, only 
cortical biopsies were collected, whereas complement activation on tubular cells 
deeper in the cortical-medullary region might have been missed. Therefore, in 
our study needle biopsies were taken, which make it possible to sample deeper 
into the kidney. Because these needle biopsies are relative thin, we cannot fully 
exclude a sampling error in which the most affected area still have been missed. 
Nevertheless, in more than thirty needle biopsies collected no C5b-9 deposition 
could be detected, making these findings quite reliable. 
9.2.4 Human complement activation in urine
The third approach we applied to study the role of complement in human 
renal IRI, was to assess complement activation products in the urine in the 
early post-transplant period. Increased glomerular permeability to large 
plasma proteins (proteinuria) is common in the early period following renal 
transplantation, with a prevalence of 15% to 30% at 1 year post-transplantation 
(44). Complement activation at the tubular epithelial surface of the kidney, 
which lacks several important complement regulators (CD46, CD55) (45), is 
considered to be a mediator of tubular injury in the proteinuric condition. In 
proteinuria, complement proteins, which normally are retained in circulation, 
are able to pass the glomerular filter barrier, end up in the tubular lumen and 
are activated by the unprotected epithelial surface of the tubuli (46-48). To 
this end, the detection of soluble (s)C5b-9 in urine is considered as a clinical 
indicator of tubular complement activation (49-51), however in the setting of 
renal IRI in human this has not been assessed before. Therefore, we collected 
urinary samples at consecutive days following kidney transplantation in a cohort 
of deceased cardiac dead donors and assessed protein and sC5b-9 content 
(chapter 4). In line with proteinuria studies, we were able to confirm the 
relation of urinary sC5b-9 and proteinuria. In the early post-transplant period 
we found high urinary levels of sC5b-9, significantly correlating with the degree 
of proteinuria, suggesting activation of filtered complement components at the 
tubular epithelial surface of the kidney. However, when mimicking proteinuria in 
vitro by exposing serum (or blood) to urine (both negative for sC5b-9), we found 
extensive generation of sC5b-9 in urine. This process was inhibited by EDTA, 
confirming activation of the complement system. Removal of remaining cells and 
cellular debris by filtering the urine reduced the sC5b-9 generation in the urine 
by half, suggesting that sC5b-9 generation in proteinuric urine is partially caused 
by cellular debris and dead epithelial cells. This implies that following kidney 
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transplantation, proteinuria but also procedure-related (microscopic) hematuria 
may cause urinary complement activation resulting in high urinary sC5b-9 levels. 
Centrifugation or filtration following collection of patient urines would not 
prevent this, since urinary complement activation is rapid and most probably 
already occurs in the urinary tract. So, although sC5b-9 is an attractive urinary 
biomarker, one should be aware of the risk of extra-renal complement activation 
independent of a renal contribution. Although urinary sC5b-9 was detected in 
the majority of renal allograft recipients and significantly correlates with the 
degree of proteinuria, the implications and clinical relevance of measured sC5b-
9 are rather unpredictable and therefore could not be used to draw any further 
conclusions from the urinary sC5b-9 measurements.
9.3 MBL IN RENAL IRI
Besides a predominant role for the alternative pathway of complement, also 
involvement of the lectin pathway, in particular by MBL, in the course of renal 
IRI in mice has been demonstrated. Mice subjected to renal I/R display evident 
renal MBL deposition on tubular cells which co-localizes with depositions of 
C3, C6 and C9. The degree of early deposition of MBL is associated with later 
complement activation, neutrophil influx and organ failure (40). Therefore, a 
role for MBL in complement activation following I/R was suggested. 
Also in human biopsies, deposition of MBL have been observed after kidney 
transplantation (29) and low pretransplantation levels of MBL are associated 
with better graft survival after deceased-donor kidney transplantation at the 
long term (52). Of interest, MBL-deficient mice are protected against renal IRI 
and MBL-deficient mice reconstituted with recombinant human MBL show a 
dose-dependent increase of renal injury comparable to the severity in wild-type 
mice (53). 
Remarkably in mice, the downstream classical and lectin pathway component C4 
is not involved in renal IRI, given that C4-deficient mice are not protected (21). 
These findings from MBL- and C4-defiicient mice have been a discrepancy for 
many years and suggest that other effector functions of MBL besides activation 
of the lectin pathway of complement might exist. Recently however, it was 
demonstrated that MBL is able to bypass C2 and C4 and directly activates C3. In 
different IRI models in mice it was shown that MBL/MASP-1 complexes directly 
might activate C3 in the absence of C2 and C4 (54), though this was not shown 
for renal IRI. In the mouse kidney, interaction of MBL with highly glycosylated 
meprins expressed and secreted by mouse PTEC has been suggested to be the 
initial step for MBL binding and subsequent complement activation (55), as 
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these meprins in vitro are able to bind MBL and activate complement. Although 
MBL/MASP-1 complexes are able to bypass C2 and C4 (56), its contribution to 
the degree of complement activation in vitro has been shown to be modest. 
Since MBL is a highly versatile protein, we cannot exclude that other effectors 
functions of MBL besides activation of the lectin pathway of complement might 
play a role in renal IRI. 
9.3.1 MBL-mediated tubular injury 
In chapter 5 we describe a novel role for MBL in the pathogenesis of renal 
IRI. Remarkably, this novel role was completely independent of complement 
activation. In a rat model of renal IRI, we demonstrated that therapeutic 
inhibition of MBL is protective against renal IRI and prevents kidney dysfunction, 
tubular damage, neutrophil and macrophage accumulation, and expression of 
proinflammatory cytokines and chemokines. Following reperfusion, vascular 
leakage resulted in extravasation of circulation-derived MBL in the interstitial 
space. Subsequent exposure of tubular epithelial cells to MBL resulted in 
internalization of MBL followed by the rapid induction of tubular epithelial 
cell death. This MBL-mediated tubular injury was completely independent of 
complement activation since inhibition of C3 or C5 was not protective against 
renal IRI. MBL-mediated cell death preceded complement activation, strongly 
suggesting that exposure of epithelial cells to MBL immediately following 
reperfusion is the primary culprit of tubular injury, and not the lytic C5b-9 
complex. 
Several studies, mainly performed in mice, have shown an important role for 
complement in the induction of renal IRI. A study using C3, C5 and C6 deficient 
mice showed a predominant role for C5b-9 in renal IRI (21), and also inhibition 
of C5 with monoclonal antibodies was protective (57). In contrast to these data, 
others have shown that gene knock-out (58), inhibition (58) or depletion of C3 
(59) was not protective against renal IRI. In our rat IRI model, deposition of C3 
and C5b-9 following reperfusion was observed, although this was in a relatively 
late phase (24 hours onwards). A similar late kinetics of C5b-9 deposition has also 
been shown in mouse IRI (57), although this mouse model was characterized by 
an early increase in deposition of C3 (2 hours). We did not observe early C3 
deposition, indicating possible differences in kinetics and pathogenesis of renal 
IRI among species. Differences in organ size and metabolism between species 
could play a role in the observed differences, given that in mice clamping times 
of usually 20-25 minutes are needed to induce renal injury, while in rats 45-60 
minutes of clamping time is needed to induce substantial IRI. Also, difference 
in relative strength of complement activation pathways could be of influence. 
In this respect, it has been shown that serum complement activity even among 
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rat strains are varying (60), explaining why in certain rat strains complement 
activation might be more involved. Indeed, the rat strain we used (Lewis), has a 
relatively low serum complement activity.
Despite the fact that complement activation was not involved in the induction of 
renal IRI in our rat model, we did find a pivotal role for MBL in the pathogenesis 
of renal IRI, since transient inhibition of MBL in the early phase following 
reperfusion was completely protective. It is tempting to speculate that these 
mechanisms might contribute to a previous observation that genetically 
determined high levels of MBL are an important risk factor for renal graft loss 
following clinical kidney transplantation (52;61). 
In human intestinal IRI, an association of MBL null alleles with preserved epithelial 
cell integrity was shown (62). Interestingly, also here no signs of complement 
activation were observed, suggesting that also in intestinal IRI, MBL might have 
a cytotoxic effect on epithelial cells. Moreover, MBL has been shown to bear 
anti-tumor activity to colorectal carcinoma cells, which has been termed MBL-
dependent cell-mediated cytotoxicity (63) .
Exposure of tubular epithelial cells to circulation-derived MBL following renal I/R 
was shown to mediate tubular injury. In normal physiologic conditions, these cells 
are not exposed to MBL (from the basolateral surface). However, during I/R there 
is an increased vessel destabilization, endothelial injury and leakage of plasma 
components in the interstitial compartment. In chapter 8 we demonstrated the 
presence of such vessel destabilization and loss of endothelial integrity shortly 
after I/R which was associated by a disturbance in the angiopoietin-1 and -2 
balance. This condition enables MBL to diffuse from circulation and reach the 
epithelial cells from the basolateral side. A therapeutic approach aimed to 
stabilize endothelial integrity might therefore be successful in several ways. 
Firstly, leakage of MBL from the vasculature is reduced, thereby preventing 
MBL to interact with tubular cells. Secondly, a stable endothelium prevents 
formation of edema and will consolidate the local blood flow. Thirdly, leukocyte 
interaction and infiltration might be reduced. Therefore, next to blocking MBL 
following renal I/R, a therapy targeted towards endothelial stabilization might 
be promising as well. 
9.3.2 MBL and TLR signaling
Stressed or dying cells release damage associated molecular pattern molecules 
(DAMPs), which can signal through pattern recognition receptors (PRR), a class 
of innate immune response-expressed proteins that respond to pathogen-
associated molecular patterns (PAMPs) and DAMPs. A subfamily of these 
membrane-associated PRR are the Toll-like receptors (TLRs), which sense 
PAMPs or DAMPs extracellularly or in endosomes and may link innate and 
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adaptive immune responses. TLRs are present on a variety of cell types including 
leukocytes, dendritic cells as well as epithelial and endothelial cells. Especially 
TLR-2 and 4 are highly expressed on PTEC. Interestingly, mice deficient for 
TLR-2, and -4 are protected against renal IRI (64;65) as shown by a reduction 
in kidney dysfunction, tubular injury and proinflammatory cytokines, and a 
concomitant decrease in infiltration by leukocytes. TLR4 signaling through the 
MyD88-dependent pathway is required for the full development of kidney IRI 
(65), as both TLR4 and MyD88 deficient mice were protected. It is known that 
there is a powerful crosstalk between complement and TLR activation in renal 
IRI (66). Recent studies have shown that there is tight and direct collaboration 
between MBL and other host defense pathways and receptors to both specify 
and amplify the immune response following TLR signaling. This is illustrated by 
the observation that MBL enhances TLR-2 and -6 signaling (67) and by a study 
showing a tight interaction of MBL with TLR-4 (68). Several endogenous ligands 
for TLRs like high-mobility group protein B1, hyaluronan and biglycan have been 
implicated in the pathophysiology of renal IRI (69-74), of which biglycan have 
been described to interact with MBL (75). It is therefore tempting to speculate 
about a possible role for MBL in TLR signaling following renal IRI, which might 
contribute to the protective effect observed in MBL-deficient mice or following 
therapeutic inhibition of MBL.
9.3.3 MBL and coagulation
Upon ligand binding by MBL, the MBL-associated serine proteases have been 
shown to not only cleave complement components, but also coagulation factors. 
For instance, MBL/MASP-1 has been shown to exert thrombin-like activity, to 
interact with plasma clot formation on different levels and to drive the formation 
of cross-linked fibrinogen (36;38;39) in a murine model of occlusive thrombosis. 
MASP-1 is therefore a significant contributor to coagulation and plays a key role 
in thrombus formation. Also MASP-2 is capable of promoting fibrinogen turnover 
and generation of a fibrin clot by cleavage of prothrombin, generating active 
thrombin (37). In addition, MBL is able to bind to fibrinogen and fibrin thereby 
augmenting clot formation by additional cleavage and activation of fibrinogen 
and prothrombin (37;76). Several studies have pointed out the relationship 
between IRI and the coagulation system. Treatment with Antithrombin III (77), 
tissue factor pathway inhibitor (78) or soluble thrombomodulin (79) following 
reperfusion in rats reduced renal dysfunction, tubular injury, microvascular 
leukocyte rolling and attachment and endothelial permeability, indicating that 
altered coagulation contribute to the pathogenesis of ischemic renal injury. De 
Vries et al (32) recently observed a release of prothrombin fragment 1 and 2, 
which are formed when prothrombin is converted to thrombin, shortly after living 
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donor transplantation. The rapid activation of coagulation by the transplanted 
kidney may lead to the generation of fibrin, which might damage the graft by clot 
formation in the microvasculature (32;80). The parallel expression of activation 
products of the coagulation, fibrinolysis, and complement systems has long been 
observed in both clinical and experimental settings. In man, enhanced thrombin 
generation after reperfusion of deceased donor kidneys might be a part of the 
explanation of the poorer outcome of transplantation observed in deceased 
compared to living donor kidneys (81). High pretransplantation levels of MBL, 
which is associated with patient and graft survival after kidney transplantation, 
might predispose to enhanced microvascular thrombosis through MBL/MASP-
mediated activation of coagulation. Therefore, thrombus formation and 
coagulopathy might be an additional way in which MBL is involved in renal IRI. 
9.3.4 Mechanism of MBL-mediated tubular injury 
PTEC that encounter nutrient and oxygen deprivation during ischemia use 
various adaptive responses to maintain homeostasis and survival, including the 
initiation of macroautophagy and the activation of the ER stress or unfolded 
protein response (UPR). These adaptive responses decrease energy expenditure, 
increase nutrient availability and promote cell survival. However, these biological 
processes also lead to the generation of proinflammatory cytokines and 
chemokines, indicating that stressed tissues generate alarm signals that produce 
an inflammatory microenvironment (82). In chapter 6, the thesis reports a 
possible mechanism by which MBL mediates direct tubular injury following renal 
I/R. Vascular leakage results in exposure of tubular cells to MBL, which was shown 
to be the primary culprit of tubular injury. We demonstrated that inhibition of 
MBL in vivo protected tubular cells from loss of vital GRP78 and subsequent 
tubular injury. GRP78 is a constitutively expressed molecular chaperone, 
however expression is enhanced under a variety of stressful conditions including 
hypoxia, glucose deprivation, alterations in intracellular calcium and oxidative 
stress (83), events that take place during renal I/R. Induction of GRP78 is critical 
for maintaining viability of cells that are subjected to such stresses and loss of 
GRP78 would therefore be detrimental (84;85). We demonstrated that renal I/R 
is accompanied by ER-stress and loss of GRP78 in the cortico-medullary region 
of kidney, the region that is mostly affected. Importantly, therapeutic inhibition 
of MBL protected tubular cells located in this region from loss of vital GRP78 and 
consequent tubular injury, indicating that MBL might be injurious to tubular cells 
by interfering with GRP78. Expression of proinflammatory IL-6, a consequence 
of GRP78 degradation (86) and ER-stress (82;87), was also significantly reduced 
by inhibition of MBL following reperfusion. 
Internalization of circulation-derived MBL in vivo was shown to be the process 
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by which tubular epithelial cells following renal I/R might be injured (41). By 
exposing tubular cells in vitro to MBL, we demonstrated that basolateral 
internalization of MBL by tubular cells induced a potent ER-stress response 
which was accompanied by an excessive ATP production, a subsequent loss 
of the mitochondrial membrane potential, production of mitochondrial 
superoxide followed by induction of cell death. Internalized MBL colocalized 
with mitochondria and GRP78. Although GRP78 is mostly known from its 
function as molecular chaperone in the ER, GRP78 has also been shown to be 
present, although in low amounts, on mitochondria, in the cytoplasm, on the 
cell membrane and as a secreted form (88-93). Membrane-bound GRP78 might 
be a possible candidate as a cellular receptor by which MBL is internalized. 
It has been shown that ligation of cell-surface GRP78 on cancer cells causes 
release of calcium from ER stores mediated via phospholipase C, thereby 
increasing cytosolic calcium (94). In line with this, it is known that especially 
tumor cells have increased levels of GRP78 on the cell surface. Importantly, is 
has been shown that MBL bears antitumor effects, which has been termed MBL-
dependent cell-mediated cytotoxicity (63). Since MBL is able to interact with 
GRP78, we speculate that, next to killing of tumor cells, the cytotoxic effect of 
MBL on tubular cells might be mediated by signaling through cell surface GRP78. 
Under physiologic conditions GRP78 is hardly present on normal cells, however 
induction of ER-stress has been shown to promote GRP78 localization on the 
surface of kidney cells (93). ER-stress induced by glucose deprivation during 
renal ischemia might be the initial trigger for GRP78 to traffic to the basolateral 
membrane of the tubular cells. Especially tubular cells in the cortico-medullary 
border are subjected to low oxygen and glucose levels during I/R, making these 
cells particular sensitive to ER-stress. Vascular leakage following reperfusion 
enables circulation-derived MBL to enter the interstium and there might bind to 
GRP78 on the basolateral surface of tubular cells. Signaling to GRP78 might then 
have detrimental effects. Next to signaling, internalization of MBL might also be 
mediated by GRP78, since evidence has emerged that GRP78 also serves as a 
receptor for viral entry into host cells (95). Since the ligand for MBL on tubular 
cells has not been found thus far, these speculations still need to be confirmed. 
These findings until now suggest that initially ER-stress is induced following MBL 
exposure, followed by disturbances in mitochondrial homeostasis. Release of 
calcium from ER stores might be the main cause of MBL-mediated ER-stress. An 
increase in cytosolic calcium in tubular cells then would lead to enhanced calcium 
influx into mitochondria, disrupting mitochondrial metabolism eventually 
leading to tubular cell death. 
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9.3.5 Therapeutic inhibition of MBL
Upon reperfusion of the ischemic kidney, MBL from circulation leaks into the 
interstitium where it is internalized by tubular cells and induces tubular injury. 
Unfortunately, to date no anti-MBL therapy or other treatments for renal IRI in 
the clinic exists. Recently however, several clinical possibilities of pharmacologic 
inhibition of complement, including C1 inhibitor (C1INH) and Eculizumab (anti-C5 
monoclonal antibody) have become available (31). 
C1INH, a physiologic serine protease inhibitor belonging to the serpin superfamily, 
acts as a major inhibitor of complement system activation and prevents 
uncontrolled complement activation. C1INH might be a possible therapeutic 
candidate to prevent renal IRI given that C1INH regulates vascular permeability 
(96) and might prevent leakage of MBL in the interstitial compartment following 
reperfusion. Secondly, C1INH targets the MASPs, which might be involved in the 
cytotoxic effect of MBL on tubular cells. Thirdly, complement that is activated at 
a later stage following reperfusion leading to exacerbation of tissue injury might 
be inhibited. Recombinant human C1INH, which recently has been registered 
for treatment of hereditary angioedema, is differentially glycosylated (97;98) 
with high oligo-mannose structures and therefore might include an additional 
inhibitory effect towards MBL recognizing mannose residues. We explored the 
therapeutic application of rhC1INH (chapter 7) in a rat model of renal IRI and 
studied whether rhC1INH is able to attenuated MBL-mediated tubular injury. 
We demonstrated that rhC1INH is functional active in rat serum and blocks 
both classical and lectin pathway activation in vitro. However, the therapeutic 
administration of rhC1INH in vivo did not attenuate renal dysfunction, tubular 
injury, inflammatory cell influx and complement activation following reperfusion 
in rats. Kinetic studies revealed that rhC1INH was cleared from circulation within 
2 hours, complement activity was only shortly reduced and circulating MBL 
levels were unaffected. In addition, we demonstrated that rhC1INH was not able 
to block the MBL-mediated cytotoxicity towards human tubular cells in vitro.
Recently, a clinical trial for the prevention and treatment of reperfusion injury 
in kidney transplantation has been started (NCT01756508). In this trial, C5 is 
targeted using the humanized monoclonal antibody (Eculizumab). This antibody 
binds to C5 and prevents cleavage of C5 and formation of C5b-9 and C5a. Our 
studies in rats and human however do not support a key role for C5 in renal IRI, 
given that inhibition of C5 using an identical antibody targeting rat C5 was not 
protective a no release of human sC5b-9 and C5a or local C5b-9 deposition could 
be detected early after clinical reperfusion. Importantly, our data demonstrate 
that therapeutic targeting of MBL following reperfusion might be very promising. 
Currently, a mouse monoclonal blocking antibody to human MBL (3F8) is available 
and in the near future will be humanized for therapeutic application in humans. 
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When clinically available, short interference with MBL using this antibody may 
have important therapeutical implications. In our rat model, we demonstrated 
that a single injection of anti-MBL antibody shortly before reperfusion provides 
an almost complete protection against renal IRI. In the clinical setting of kidney 
transplantation, a short treatment of the recipient with an anti-MBL antibody 
therefore could significantly alter the extent of kidney damage following renal 
IRI. 
9.4 CONCLUSIONS  
Although the main function of complement is to clear pathogens and 
maintaining homeostasis by clearing apoptotic cells and cellular debris, 
complement activation might also contribute to renal IRI by exacerbating local 
inflammation and tubular injury through release of C5a and formation of C5b-
9. Studies mainly performed in mice have demonstrated an important role 
for the alternative pathway. Nevertheless, in this thesis we show that human 
hypoxic PTEC predominantly activates the classical pathway of complement, 
demonstrating important species-specific differences in complement activation. 
In addition we showed that early following reperfusion in human there is only a 
very transient activation of complement in circulation, which is virtually absent 
at the tissue level. We also demonstrated that it is not reliable to assess sC5b-9 
in urine, given that spontaneous C5b-9 generation can occur, independent of 
a renal contribution. From these findings and kinetic data obtained from our 
rat IRI model, we conclude that complement activation following reperfusion 
is merely a secondary process activated by injured and apoptotic tubular cells 
in a relatively late phase following reperfusion (Fig 1). In contrast, early after 
reperfusion circulation-derived MBL, independent of complement activation, 
exerts cytotoxic effect to tubular cells mediating initial tubular injury. Although 
not shown in this thesis, MBL might also be involved in potentiating TLR signaling, 
which have been implicated in the pathophysiology of renal IRI. Furthermore, 
a crosstalk between MBL and coagulation might be involved, facilitating 
coagulation and clot formation in the renal microvasculature and contributing 
to the coagulopathy in renal IRI. 
In short, MBL is a highly versatile protein which, in addition to potent complement 
activation, also exerts direct cytotoxic effect, amplifies TLR signaling and promotes 
coagulation. In conclusion, this thesis documents the important role of MBL 
in the early pathogenesis of renal IRI and shows that complement activation 
is a relatively late process in the pathophysiology of renal IRI. Treatment with 
rhC1INH, or targeting C3 and C5 was not protective against renal IRI. In contrast, 
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interfering with MBL was highly effective in reducing renal IRI, indicating that MBL 
has a pivotal role in the pathophysiology of renal IRI. We demonstrate a crucial 
role for MBL in renal IRI and identify MBL as a novel therapeutic target in kidney 
transplantation. We therefore suggest that a short therapeutic intervention at 
the level of MBL might significantly alter the extent of kidney damage following 
renal I/R. The development and application of a humanized anti-MBL antibody 
might be a promising step forward in the treatment of renal IRI following kidney 
transplantation.
Figure 1. Role of complement and MBL in renal ischemia/reperfusion injury. Renal I/R 
is associated with a dysbalance of angiopoietins and vessel destabilization (chapter 8), 
resulting in vascular leakage, edema and extravasation of MBL and other complement 
molecules like C1q in the interstitial space (chapter 5). Basolateral exposure of tubular 
epithelial cells to MBL results in binding and internalization of MBL, which is accompanied 
by loss of ER-stress sensor GRP78, induction of endoplasmic reticulum-stress (chapter 
6) and subsequent tubular cell death within several hours of reperfusion (chapter 6). 
Injury to the tubular cells lead to activation of the complement system in the later 
phase of reperfusion and in human is mediated by natural IgM and C1q (chapter 2). In 
circulation or at the tissue level, no complement activation products could be detected 
early after reperfusion (chapter 3), while in the urine complement measurement is not 
reliable (chapter 4). Therapeutic targeting of MBL was highly protective against renal 
IRI, whereas blocking of complement activation at the level of C3 and C5 (chapter 5, 7) 
was not, indicating that MBL play a pivotal role in renal IRI, independent of complement 
activation. 
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Ischemie/reperfusie schade
Tussen de uitname en transplantatie van een donornier is er geen doorbloeding 
van het orgaan. Hierdoor ontstaat een tekort aan zuurstof, glucose en andere 
voedingstoffen en een opstapeling van afvalstoffen zoals koolstofdioxide in de 
nier. Deze toestand in het orgaan wordt ischemie genoemd. Door het tekort aan 
zuurstof tijdens ischemie kan de nier geen energie produceren en ontstaat er 
weefselschade die te vergelijken is met bijvoorbeeld een hersen- of hartinfarct. 
Alle levensprocessen zoals bewegen, maar ook bijvoorbeeld het stabiel en 
gezond houden van onze cellen, kosten energie. Deze energie wordt verkregen 
door de verbranding van suikers en vetten waarbij ook zuurstof benodigd is. 
Iedere cel in ons lichaam bevat een soort energiefabriekjes, mitochondriën 
genaamd, waarin met behulp van zuurstof, suikers en vetten verbrand worden. 
De energie die daaruit vrijkomt, wordt opgeslagen in de chemische vorm van 
adenosine trifosfaat (ATP). ATP is dus de chemische drager van energie in al onze 
cellen. We kunnen ATP vergelijken met de stroom die wordt opgewekt in een 
elektriciteitscentrale wanneer kolen en gas (net zoals suikers en vetten in onze 
cellen) verbrand worden. Zonder ATP in onze cellen kunnen wij niet leven. Tijdens 
de ischemie is er niet genoeg zuurstof en brandstof om ATP te produceren en 
ontstaat er weefselschade in de nier. We noemen deze schade ischemieschade. 
Het herstellen van de bloedtoevoer na een niertransplantatie wordt reperfusie 
genoemd. Bij de reperfusie van een ischemisch orgaan worden schadelijke 
afvalstoffen afgevoerd en zuurstof, glucose en andere belangrijke stoffen 
aangevoerd die nodig zijn om het weefsel te herstellen. Het lijkt tegenstrijdig, 
maar het is bekend dat de reperfusie van een ischemisch orgaan echter tot nog 
veel meer weefselschade leidt. De schade na de reperfusie noemen we daarom 
ischemie/reperfusie schade (I/R schade). 
Het is aangetoond dat I/R schade kort na de transplantatie een erg ongunstige 
invloed heeft op de functie van de nier op de lange termijn. Het is daarom dus 
erg belangrijk om deze I/R schade als gevolg van de onderbroken bloedtoevoer 
tijdens de niertransplantatie te voorkomen of zoveel mogelijk te beperken. 
Hierover gaat het onderzoek beschreven in dit proefschrift. 
De oorzaak van I/R schade is nog onvoldoende duidelijk en er is daarom op dit 
moment nog geen gerichte behandeling ontwikkeld om I/R schade te beperken. 
Bij het ontstaan van I/R schade speelt ons aangeboren afweersysteem een rol. 
Het complementsysteem waarover dit proefschrift vooral gaat, is een onderdeel 
hiervan. Dit complementsysteem doodt indringende bacteriën via een serie 
activerende factoren in het bloed. Voordat hierop dieper ingegaan zal worden, is 
enige uitleg van het immuunsysteem en de fysiologie van de nier nodig. 
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Fysiologie van de nier
Om ons bloed te filteren, bevatten onze nieren ongeveer 1 miljoen nierfiltertjes 
(glomeruli) waar het bloed doorheen stroomt. De glomerulus is een soort klein 
vergietje van 0,2 mm grootte dat kleine eiwitten, zouten, water en afvalstoffen 
uit het bloed doorlaat. Grote eiwitten en cellen passen echter niet door de 
gaatjes en verlaten de glomerulus weer via een afvoerend bloedvat. Het filtraat 
dat uit de glomerulus komt, wordt opgevangen in een nierbuisje (tubulus). Deze 
nierbuisjes (tubuli), waarvan er dus ook 1 miljoen zijn omdat ze verbonden zijn 
met de glomeruli, monden uit in het nierbekken waar de urine verzameld wordt 
voordat het naar de blaas toestroomt. 
In deze tubuli vindt een ontzettend belangrijk proces plaats, dat we tubulaire 
reabsorptie noemen. Dagelijks wordt door de nieren namelijk 180 liter filtraat 
(voorurine) geproduceerd, waarvan slechts 1-2 liter wordt uitgescheiden als 
urine. De voorurine, die belangrijke eiwitten, zouten en suikers bevat, wordt 
grotendeels weer opgenomen in het bloed via een laagje cellen dat zich aan de 
binnenkant van de tubuli bevindt. We noemen deze cellen tubulus epitheelcellen 
en het proces van opname heet dus tubulaire reabsorptie. Zonder dit proces 
zouden we binnen enkele minuten al onze eiwitten, water, zouten en suikers 
uit ons bloed verliezen. Het proces van tubulaire reabsorptie kost erg veel 
energie (ATP). Daarom bevatten de tubulus epitheelcellen veel mitochondriën 
en gebruiken ze veel zuurstof uit het bloed. Om de opgenomen stoffen terug te 
transporteren naar het bloed, zitten er veel kleine bloedvaatjes om de tubuli heen. 
Deze bloedvaatjes nemen de belangrijke stoffen via de tubulus epitheelcellen 
uit de urine weer op in bloed. Een nadeel hiervan is dat ook veel zuurstof dat 
eigenlijk bestemd is voor de tubulus epitheelcellen, weer opgenomen wordt in 
het bloed, terwijl de zuurstofbehoefte in de epitheelcellen juist groot is. Normaal 
gesproken is dit precies in balans. Echter bij een niertransplantatie, wanneer 
de bloed- en zuurstoftoevoer stopt, gaat het mis. De tubulus epitheelcellen die 
veel zuurstof nodig hebben om ATP te maken voor tubulaire reabsorptie, raken 
gestrest en gaan dood wanneer de bloedtoevoer te lang stopt. We noemen dit 
acute tubulus necrose (ATN). Bij ATN als gevolg van een ATP-tekort raken de 
tubulus cellen los van de tubuluswand waar ze op groeien en komen in de holte 
(lumen) van de nierbuisjes terecht. Hier gaan de cellen dood (necrose) en vallen 
uit elkaar in kleine deeltjes. Samen met gefilterde eiwitten vormen deze deeltjes 
grote klompen celmateriaal (casts), waardoor de nierbuisjes verstopt raken en 
de nierfunctie stopt. Vooral bij nieren die afkomstig zijn van overleden donoren 
en dus een lange ischemietijd hebben, is de tubulus necrose en I/R-schade 
groot. Het duurt daarom ook vaak enkele dagen voordat deze getransplanteerde 
nieren weer enigszins functioneren. In deze dagen is de patiënt aangewezen op 
nierdialyse. 
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Het complementsysteem
De belangrijkste functies van ons afweer- of immuunsysteem is om ons te 
beschermen tegen ziekteverwekkers (pathogenen) zoals bacteriën en virussen. 
De afweercellen in ons bloed die hierbij betrokken zijn, noemen we witte 
bloedcellen (leukocyten). Deze cellen worden geholpen door een groep eiwitten 
(proteïnen) in ons bloed die ook deel uit maken van ons afweersysteem. Eiwitten 
zijn biologische moleculen en zijn essentieel voor organismen. Ze bestaan uit 
lange ketens van aminozuren. Eiwitten hebben heel veel verschillende functies. 
In onze cellen zijn ze betrokken bij chemische omzettingen (enzymen), het in 
stand houden van de structuur van cellen (cytoskelet), transport van stoffen 
in, uit en binnenin de cel en voor communicatie tussen cellen (bijvoorbeeld 
hormonen).
In ons bloed bevindt zich een groep eiwitten die naast de witte bloedcellen 
betrokken is bij ons immuunsysteem. Deze eiwitten heten complementfactoren en 
samen vormen deze complementfactoren het zogenaamde complementsysteem. 
Het complementsysteem speelt samen met de witte bloedcellen en antistoffen 
(ook een groep eiwitten) een zeer belangrijke rol bij de afweer tegen 
ziekteverwekkers. Het complementsysteem is een systeem van factoren in het 
bloed dat verantwoordelijk is voor het lek maken (lyseren) van met antilichamen 
bedekte bacteriën en virussen. Deze complementfactoren maken samen gaatjes 
(poriën) in de wand van de bacterie waardoor deze lyseert en dood gaat. 
Onder normale omstandigheden verkeert het complementsysteem in een niet-
geactiveerde staat. Activatie en daarmee het ontstaan van biologische activiteit 
kunnen plaatsvinden na interactie van complementfactoren met bijvoorbeeld 
antistoffen die gebonden zijn aan een bacterie of rechtstreeks met allerlei 
bacteriën en virussen zonder tussenkomst van antilichamen.
Het complementsysteem werkt direct vanaf de geboorte en hoeft daarom niet 
geleerd te worden hoe om te gaan met ziekteverwekkers. Het maakt daarom 
deel uit van het zogenaamde aangeboren (innate) immuunsysteem. Wanneer 
een ziekteverwekker zoals een bacterie ons lichaam binnendringt, wordt het 
allereerst aangevallen door het complementsysteem. Het complementsysteem 
werkt als een soort kettingreactie. Er zijn allereerst enkele eiwitten in het 
complementsysteem die de ziekteverwekkers herkennen en hieraan binden. Eén 
van deze “herkennende” complementfactoren, waar dit promotieonderzoek 
ook overgaat, is Mannan-binding lectin (MBL). Deze complementfactor 
herkent bepaalde suikermoleculen (mannan en mannose) die voorkomen op 
ziekteverwekkers, maar ook op onze eigen cellen wanneer deze dood gaan. 
Wanneer MBL bindt aan een dergelijk suikermolecuul op bijvoorbeeld een 
bacterie, verandert de vorm van het MBL-eiwit en wordt het actief. Vervolgens 
ontstaat een kettingreactie waarbij verschillende complementfactoren elkaar 
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activeren en gebonden worden op het oppervlak van de ziekteverwekker. 
We noemen dit de lectine route activatie van het complementsysteem. 
Andere “herkennende” complementfactoren zijn C1q en properdine. Deze 
complementfactoren activeren weer een andere route of kettingreactie van het 
complementsysteem, namelijk de klassieke route door C1q en de alternatieve 
route door properdine. Uiteindelijk komen alle drie de routes uit bij het centrale 
molecuul van het complementsysteem, namelijk complement factor C3. 
Activatie van C3 leidt tot splitsing van het C3 molecuul in C3a en C3b. Het C3b 
wordt stevig (covalent) gebonden op het oppervlak van de bacterie. Activatie van 
het complementsysteem leidt dus altijd tot een laagje C3b dat de ziekteverwekker 
als het ware bedekt. Op deze manier vormt het complementsysteem een soort 
C3b vlaggetjes op de ziekteverwekker, waardoor deze als het ware gemarkeerd 
(geopsoniseerd) wordt om opgeruimd te worden. De witte bloedcellen hebben en 
soort antennes (receptoren) op hun oppervlak die de C3b vlaggetjes herkennen 
en de gemarkeerde bacterie vervolgens kunnen opeten (fagocyteren). 
Daarnaast kunnen andere complementfactoren (C5, C6, C7, C8, C9) ook op 
volgorde geactiveerd raken via C3b. Hierbij wordt eerst het C5 molecuul gesplitst 
in C5a en C5b. Vervolgens binden de factoren C6-C9 aan het gesplitste C5b en 
maken samen een gaatje (porie) in de bacterie, waarna deze lyseert. Het C5b-C9 
complex wordt daarom ook wel het Membrane-Attack-Complex (MAC) genoemd. 
Activatie van C5 tot C9 wordt de terminale route van het complementsysteem 
genoemd. 
Naast het opsoniseren met C3b (waardoor de ziekteverwekker gemarkeerd 
wordt voor opruiming) en het lyseren door het C5b-9 complex (waardoor de 
ziekteverwekker lek raakt), heeft het complementsysteem nog een derde 
functie. Bij de splitsing van C3 en C5 worden de splitsingsfactoren C3a en C5a 
gevormd. Deze factoren worden ook wel anaphylatoxines genoemd en trekken 
witte bloedcellen aan naar de plek van de ontsteking. Daarnaast activeren C3a 
en C5a ontstekingscellen en leiden ze tot contractie van gladde spiercellen, het 
lekken van de bloedvaten en het vrijmaken van histamine en ontstekingseiwitten. 
Het gevolg hiervan is dat een ontsteking (inflammatie) ontstaat en het weefsel 
rood en warm wordt. Onze eigen cellen zijn beschermd tegen activatie van het 
complement door zogenaamde complementregulatoren. Deze regulatoren 
voorkomen dat onze cellen bedekt raken met een laagje C3b of lek raken door 
het poriecomplex C5b-9 en zodoende een ontsteking veroorzaken.
Zoals al eerder gezegd, kunnen ook dode cellen in ons lichaam het 
complementsysteem activeren. Elke dag gaan er meer dan 100 miljard van 
onze cellen (o.a. door veroudering) dood. Tijdens het dood gaan verliezen deze 
lichaamseigen cellen ook hun complementregulatoren. Hierdoor activeren 
ook deze cellen het complementsysteem en raken bedekt met C3 om effectief 
188   •  Chapter 10
opgeruimd te worden. Zolang het slechts bij activatie van C3 blijft en er geen 
C5a en C5b-9 (MAC) gevormd wordt, verloopt dit opruimingsproces geruisloos 
zonder ontsteking. Personen die bijvoorbeeld C1q missen, ontwikkelen vaak 
auto-immuun ziekten die samenhangen met het verkeerd opruimen van de 
enorme hoeveelheid (eigen) dode cellen. Dit laat dus zien hoe belangrijk het 
complementsysteem ook bij het opruimen van dode cellen is.
Complement in nier ischemie/reperfusie schade
Het complementsysteem heeft dus een belangrijke en gunstige rol in ons 
immunsysteem. Echter bij bepaalde aandoeningen, zoals I/R in de nier gaat 
het mis. Door het ATP-tekort tijdens de ischemie en door de reperfusie 
verliezen de overlevende tubulus epitheelcellen in de nier hun beschermende 
complementregulatoren. Hierdoor raken deze cellen erg vatbaar voor 
complementactivatie. De cellen die tijdens de ischemie door het ATP-tekort al 
dood zijn gegaan, hebben ook hun complementregulatoren verloren. Hierdoor 
ontstaat in de dagen na de I/R een enorme activatie van het complementsysteem. 
Een studie in muizen heeft laten zien dat door het C5b-9 complex veel tubulus 
epitheelcellen lek raken en dood gaan. Daarnaast worden door de vorming 
van C3a en C5a ook veel ontstekingscellen aangetrokken, gaan de bloedvaatjes 
openstaan en ontstaat er vochtophoping in de nier (oedeem). Door dit oedeem 
worden de bloedvaatjes dichtgedrukt en kan er opnieuw ischemie optreden met 
als gevolg nog meer nierschade. Muizen waarin bepaalde complementfactoren, 
zoals C3 en MBL genetisch uitgeschakeld zijn, ontwikkelen veel minder schade 
na reperfusie van de ischemische nier. Ook muizen waarin het C5a therapeutisch 
weggevangen wordt, ontwikkelen minder I/R schade. Deze studies laten zien dat 
in muizen het complementsysteem in ieder geval een belangrijke rol speelt in 
I/R schade. 
Proefschrift samenvatting
Het doel van het onderzoek beschreven in dit proefschrift was het bestuderen 
van de rol van het complementsysteem in I/R schade in de nier. Zoals eerder 
gezegd, bevat het complementsysteem verschillende routes van activatie; de 
klassieke route via C1q, de lectine route via MBL en de alternatieve route via 
properdine. Om een therapie te ontwikkelen waarbij het complementsysteem 
geremd kan worden, is het van belang om te weten welke specifieke routes van 
het complementsysteem geactiveerd worden na I/R in de nier. Daarnaast is er 
veel onderzoek gedaan in muizen, maar is er nauwelijks iets bekend over de rol 
van complement in de mens na I/R van de nier. 
In hoofdstuk 2 hebben we daarom onderzocht welke route van het 
complementsysteem in werking wordt gezet door muis en menselijke niercellen 
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na I/R. Vooral de tubulus epitheelcellen in de nier raken beschadigd na I/R. 
We hebben daarom deze cellen geïsoleerd uit nieren van muizen en mensen, 
en deze cellen gekweekt in aan- of afwezigheid van zuurstof. Op deze manier 
simuleerden we het proces van ischemie tijdens een niertransplantatie. Na 
een aantal uur werden de ischemische niercellen weer van zuurstof voorzien 
en blootgesteld aan muis of menselijk bloed (reperfusie). Dit bloed bevat de 
complementfactoren die vervolgens geactiveerd konden worden. Wat we 
vervolgens waarnamen, was dat de gekweekte muis epitheelcellen na I/R de 
alternatieve route van het complementsysteem activeerden. We bevestigden 
daarmee publicaties van anderen betreffende dit onderzoek uitgevoerd in 
muizen. Verrassend was het echter dat de menselijke tubulus epitheelcellen 
deze alternatieve complementroute helemaal niet activeerden, maar wel 
herkend werden door IgM antilichamen en een andere complementfactor, 
namelijk C1q. Door de binding van IgM en C1q aan deze cellen werd vervolgens 
de  klassieke route van complement geactiveerd. Deze studie laat dus duidelijk 
zien dat er verschillen zijn tussen muis en menselijke tubulus epitheelcellen en 
het complementsysteem. Bij het ontwikkelen van een therapie gericht tegen 
een bepaalde route van het complementsysteem dient hier zeker rekening mee 
gehouden te worden. 
In hoofdstuk 3 werd onderzocht in welke mate complementactivatie voorkomt 
na een niertransplantatie in de mens. Hoewel er veel bekend is uit onderzoek 
in muizen, zijn er nauwelijks onderzoekgegevens beschikbaar van I/R schade na 
niertransplantatie in de mens. De reden hiervoor is dat I/R schade kort na een 
niertransplantatie optreedt en het tot op heden niet mogelijk was nierweefsel 
van patiënten en bloed uit de getransplanteerde nier kort na transplantatie 
te verkrijgen. We hebben daarom gebruikt gemaakt van een geheel nieuwe 
methode die recent ontwikkeld is op de afdeling Heelkunde in Leiden. Bij deze 
methode wordt via een kleine catheter bloed afgenomen dat direct afkomstig is 
uit de getransplanteerde nier. Hierdoor waren we in staat om daadwerkelijk te 
meten hoeveel complementactivatie er in de getransplanteerde nier plaatsvindt, 
terwijl eerder alleen systemische metingen (niet in de nier maar in het lichaam) 
mogelijk waren. Ook was het mogelijk om zowel voor, als 45 minuten na de 
niertransplantie een nierbiopt te nemen, zodat ook in het weefsel onderzocht 
kon worden in welke mate er activatie van complement plaatsvond op de 
epitheelcellen. Deze studie vond plaats in drie groepen patiënten. De eerste 
groep patiënten ontving een nier van een levende donor, de tweede groep van 
een hersendode donor en de derde groep van een overleden donor. Vooral 
de donornieren uit de derde groep zijn in relatief slechte staat vanwege de 
bloedcirculatie die al gedurende langere tijd stilstaat. 
In het weefsel en in het bloed werd vervolgens de complementactivatie bepaald 
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door het aankleuren en meten van C5b-9, het terminale eiwitcomplex van 
het complementsysteem. Verrassend genoeg was er in alle drie de groepen 
op het weefsel totaal geen complementactivatie aantoonbaar 45 minuten na 
de niertransplantatie. Alleen in de patiënten die een nier ontvingen van een 
overleden donor, was enkele seconden na de reperfusie C5b-9 aantoonbaar in 
het bloed, dit was echter zeer tijdelijk. Concluderend laat deze studie zien dat in 
de mens vroeg na transplantatie nauwelijks complementactivatie plaatsvindt in 
circulatie, en dat deze ook volledig afwezig is op het weefsel. Dit suggereert dat 
activatie van het complementsysteem in de mens een secundair proces is, en 
niet ten grondslag ligt aan de initiële ischemie/reperfusie schade die optreedt 
na niertransplantatie. 
Naast het aantonen van complementactivatie in het bloed en op het weefsel, is een 
derde mogelijkheid het meten van complementactivatieproducten (C5b-9) in de 
urine. Met de studie beschreven in hoofdstuk 4 werd getracht dit te doen. Doordat 
de glomeruli bij een niertransplantatie tijdelijk niet goed werken, kunnen kleine 
maar ook grotere eiwitten uit het bloed, waaronder ook complementfactoren in 
de (voor)urine terecht komen. Hier kunnen deze complementfactoren in contact 
komen met de (ischemische) tubulus epitheelcellen en geactiveerd worden. In 
eerste instantie vonden we inderdaad een duidelijk en significant verband met 
complementactivatieproducten (C5b-9) en de hoeveelheid eiwit in de urine 
afkomstig van getransplanteerde nieren. Echter na enkele controle experimenten 
met urine van gezonde individuen, waaraan bloed (met nog niet geactiveerde 
complementfactoren) werd toegevoegd, bleek dat complementactivatie in urine 
ook spontaan kan optreden zonder enige bijdrage vanuit de nier. Dit was tot nog 
toe niet bekend en uit vervolgonderzoek bleek dat deze complementactivatie 
ook kan ontstaan door dode epitheelcellen die normaal gesproken ook via de 
urine worden uitgescheiden. Het bleek dus niet mogelijk een betrouwbare 
meting van complementactivatie in urine van transplantatiepatiënten te doen, 
omdat dit beeld vertroebeld wordt door de spontane activatie die kan optreden.
Uit eerdere klinische studies in niertransplantatiepatiënten is gebleken dat 
patiënten met hoge MBL waarden in het bloed meer afstoting en een slechtere 
transplantaatoverleving hebben op langere termijn. MBL is het eiwit dat 
suikergroepen op cellen herkent en vervolgens de lectine route van complement 
activeert. In hoofdstuk 5 onderzochten we daarom de rol van MBL in I/R schade 
in de nier. Ook bestudeerden we de complementfactoren C3 en C5 die door MBL 
geactiveerd worden. We gebruikten hiervoor een I/R model in de rat, waarbij 
we voor 45 minuten de vaten naar de linker nier afklemden. Op deze manier 
wordt de I/R schade gesimuleerd die ook ontstaat wanneer een nier wordt 
uitgenomen bij een niertransplantatie een enige tijd bewaard wordt, voordat hij 
teruggeplaatst kan worden. Door de andere nier in de rat te verwijderen, waren 
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we in de staat de nierfunctie van de tijdelijk afgeklemde nier te meten. Na drie 
dagen werden de ratten opgeofferd en de nier verwijderd voor onderzoek. Als 
therapie werd vóór het afklemmen van de nier een antilichaam ingespoten dat 
aan MBL bindt en hierdoor de werking van dit eiwit blokkeert. In twee andere 
behandelgroepen werden voor het afklemmen, de complementfactoren C3 
en C5 in de rat therapeutisch geremd. Vervolgens werd om de 24 uur bloed 
afgenomen om de nierfunctie te bepalen. Hieruit bleek dat ratten die tijdelijk 
geen MBL in het bloed hadden, volledig beschermd waren tegen I/R schade als 
gevolg van het afklemmen. Dit betekent dus inderdaad dat MBL, dat normaal 
belangrijk is voor de afweer tegen ziekteverwekkers, een zeer nadelige rol heeft in 
niertransplantatie. Verrassend genoeg waren de ratten waarin C3 en C5 geremd 
werd, totaal niet beschermd. Omdat MBL bekend staat als een complementeiwit 
dat C3 uiteindelijk activeert, was deze vinding bijzonder. Dit betekent namelijk 
dat de nadelige werking van MBL in I/R schade in de nier onafhankelijk is 
van complementactivatie, iets dat totaal onbekend is. We konden laten zien 
dat kort na reperfusie, MBL uit de bloedvaatjes lekt en bindt aan de tubulus 
epitheelcellen in de nier. Vervolgens gaan deze epitheelcellen dood, waarna dan 
pas het complementsysteem geactiveerd wordt. Complementactivatie vindt dus 
uiteindelijk wel plaats, maar de initiële schade ontstaat door MBL. Wanneer 
we gekweekte menselijke tubulus epitheelcellen blootstelden aan (uit bloed 
gezuiverd) MBL, trad binnen 24 uur celdood op. Hierdoor konden we laten zien 
dat niet alleen in de rat, maar ook bij mensen blootstelling van de nier aan MBL 
schadelijk is. Via welke mechanisme MBL de epitheelcellen doodt, wordt nu 
vervolgens onderzocht.
In hoofdstuk 6 wordt dit onderzoek naar de cytotoxische (celdodende) werking 
van MBL op tubulusepitheel beschreven. We laten zien dat MBL bindt en 
opgenomen wordt in de tubulus epitheelcellen. Vervolgens ontstaat er stress 
in het deel van de cel, dat verantwoordelijk is voor de productie van eiwitten, 
het endoplasmatisch reticulum (ER). Als gevolg van deze ER-stress ontstaat er 
ook een probleem in de mitochondriën van de cellen en komen deze zonder 
ATP te zitten. In ratten konden we daarnaast laten zien dat het eiwit GRP78 in 
de tubulus epitheelcellen van de nier binnen enkele uren na reperfusie volledig 
verdwijnt, waarna deze cellen vervolgens dood gingen. GRP78 is een eiwit in 
het ER dat ervoor zorgt dat nieuw-geproduceerde eiwitten goed in elkaar 
gezet en gevouwen worden. Zonder GRP78 ontstaat er een ophoping van niet-
functionerende eiwitten in het ER en raken de cellen gestrest (ER-stress) en 
gaan uiteindelijk dood. Wanneer we nu voor de reperfusie, MBL therapeutisch 
blokkeerden in deze ratten, bleef het GRP78 ook aanwezig in de cellen en 
overleefden deze de ischemie/reperfusie. Dit laat dus duidelijk zien dat het 
wegvangen van MBL voorkomt dat het onmisbare GRP78 in de epitheelcellen 
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verdwijnt en er ischemie/reperfusie schade ontstaat. 
In hoofdstuk 7 onderzochten we of het medicijn, recombinant menselijk C1 
inhibitor (rhC1INH) dat momenteel gebruikt worden in de behandeling van 
hereditair angio-oedeem, ook effectief is tegen I/R schade in de nier. De hypothese 
is dat rhC1INH voorkomt dat de vaatjes gaan lekken na I/R waardoor MBL niet bij 
de epitheelcellen kan komen. Ten tweede remt het enkele complementfactoren 
en ten derde is er een direct remmend effect op MBL mogelijk, omdat rhC1INH 
enkele suikergroepen bevat waaraan MBL mogelijk kan binden. rhC1INH werd 
getest in het I/R model in de rat. Vijf minuten voor het afklemmen van de nier 
werd het ingespoten. Bloedmonsters werden vervolgens afgenomen om de 
nierfunctie te bepalen en na 24 uur werd de nier uitgenomen voor analyse. 
Helaas bleek het rhC1INH niet beschermt tegen I/R schade. Uit vervolgonderzoek 
bleek dat rhC1INH erg snel verwijderd wordt uit het bloed en daarnaast niet in 
staat is om het cytotoxische effect van MBL te remmen. 
Omdat na I/R, MBL uit de vaatjes lekt en zodoende bij de epitheelcellen kan 
komen, werd in hoofdstuk 8 onderzocht hoe de stabiliteit van deze vaatjes 
gereguleerd wordt. Angiopoetines zijn eiwitten die hierbij nauw betrokken 
zijn. Bepaalde cellen die de bloedvaten ondersteunen (pericyten) produceren 
Angiopoetine-1 (Ang-1), dat belangrijk is voor de stabiliteit van het bloedvat. 
Angiopoetine-2 (Ang-2), dat juist tegenovergesteld werkt en zorgt dat de vaatjes 
gaan lekken, kan worden geproduceerd door endotheelcellen aan de binnenkant 
van de bloedvaten. Zolang er meer Ang-1 dan Ang-2, blijven de bloedvaatjes 
stabiel. Wanneer echter door een niertransplantatie de endotheelcellen gestrest 
raken, wordt er meer Ang-2 geproduceerd en ontstaat er een verkeerde balans 
waardoor de bloedvaten gedestabiliseerd raken en gaan lekken. Hierdoor zou 
het onder andere mogelijk zijn dat MBL uit de vaatjes lekt, vervolgens bij de 
epitheelcellen kan komen en de tubulus epitheelschade veroorzaakt. Naast het 
wegvangen van MBL zou een therapie gericht op het stabiel houden van de 
bloedvaatjes daarom ook succesvol kunnen zijn. Ten eerste omdat dan voorkomen 
zal worden dat het MBL uit de bloedvaatjes lekt en bij de tubulus epitheelcellen 
kan komen. Ten tweede wordt de vorming van oedeem voorkomen en ten derde 
zal de ophoping van ontstekingscellen die uit het bloed komen, ook minder zijn. 
Conclusie
Het complementsysteem speelt een belangrijke en gunstige rol in het opruimen van 
ziekteverwekkers en dode cellen in ons lichaam. Echter, bij een niertransplantatie 
kan complementactivatie nadelig zijn en de I/R schade juist verergeren door het 
vrijkomen van C3a en C5a, en de vorming van het C5b-9 complex. Studies in 
muizen hebben een belangrijke rol aangetoond voor de alternatieve route van 
complementactivatie op (ischemische) tubulus epitheelcellen. In dit proefschrift 
Nederlandse samenvatting  •   193
   10
hebben we aangetoond dat bij ischemische menselijke tubulus epitheelcellen 
de klassieke route van complementactivatie betrokken is, wat laat zien dat er 
belangrijke verschillen zijn in het tubulusepitheel en complementsysteem tussen 
muis en mens. Daarnaast hebben we laten zien dat slechts enkele seconden 
na reperfusie er enige mate van complementactivatie in de circulatie optreedt, 
terwijl deze volledig afwezig is op de tubulus epitheelcellen. Ook hebben we 
aangetoond dat in de urine spontane complementactivatie kan optreden 
wanneer bloed in contact komt met urine. Dit proces is volledig onafhankelijk 
van de nier en maakt het lastig om betrouwbare complementmetingen te 
verrichten in de urine. 
In het I/R model in de rat hebben we vervolgens laten zien dat complementactivatie 
pas optreedt nadat er al I/R schade is ontstaan. Complementactivatie na I/R is dus 
meer een secundair proces en ligt niet ten grondslag aan de initiële I/R schade 
in de nier. Complementactivatie op beschadigde en dode tubulus epitheelcellen 
treedt uiteindelijk wel op, maar op een relatief laat moment na reperfusie. 
De belangrijkste vinding van dit promotieonderzoek is dat echter vroeg na 
reperfusie, MBL uit het bloed in de nier terechtkomt en wordt blootgesteld aan 
de tubulus epitheelcellen. MBL heeft vervolgens een cytotoxische (celdodende) 
werking op deze cellen. De cytotoxische werking van MBL is echter volledig 
onafhankelijk van complementactivatie. Het remmen van C3 en C5 beschermde 
daarom ook niet tegen I/R schade, terwijl het wegvangen van MBL bijna volledige 
bescherming bood. Ook konden we laten zien dat de blootstelling van MBL en 
het dood gaan van de tubulus epitheelcellen voorafging aan de activatie van 
het complementsysteem. MBL is daarom een zeer interessant therapeutisch 
doelwit en het tijdelijk remmen of wegvangen van MBL tijdens een klinische 
niertransplantatie zou daarom een veelbelovende behandeling kunnen zijn om 
I/R schade na niertransplantatie te voorkomen. 
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LIST OF ABBREVIATIONS
ABTS  2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
AKI  acute kidney injury 
ANG-1  angiopoietin-1
ANG-2  angiopoietin-2
AP  alternative pathway
ATF6  activating transcription factor 6
ATN  acute tubular necrosis 
ATP  adenosine triphosphate
BDD  brain dead donor
BUN  blood urea nitrogen
CDD  cardiac dead donor
COMP  cartilage oligomeric matrix protein
CP  classical pathway
CRD  carbohydrate recognition domain 
CRP  complement regulatory protein
CVF  cobra venom factor
DAB  3,3’-diaminobenzidine
DAMP  danger-associated molecular pattern
DC  dendritic cell
DGF  delayed graft function 
DIG  digitonin 
EC  endothelial cell
ER  endoplasmic reticulum
ERAD  ER-associated protein degradation 
FITC  fluorescein isothiocyanate
GlcNAc  N-acetyl-D-glucosamine
GPR78  78-kDa glucose-regulated protein 
HMGB1  High mobility group box 1
HPF  high power field
HRP  horseradish peroxidase 
HSA  human serum albumin 
HTK  histidine–tryptophan–ketoglutarate
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HUVEC  human umbilical vein endothelial cell
I/R  ischemia/reperfusion
IM-PTEC immortalized mouse proximal tubular epithelial cells
IRE-1  inositol-requiring enzyme-1 
IRI  ischemia/reperfusion injury  
KIM-1  kidney injury molecule-1 
LD  living donor
LP  lectin pathay
mAb   monoclonal antibody
MAC  membrane attack complex
MASP  MBL-associated serine protease
MBL  mannan-binding lectin 
MCP-1  macrophage chemoattractant protein-1
Mph  macrophage 
NGAL  neutrophil gelatinase-associated lipocalin
NHS  normal human serum
NMS  normal mouse serum
PDGFRβ platelet derived growth factor receptor β
PDI  protein disulfide isomerase
PERK  pancreatic ER kinase 
PI  propidium iodide 
PMN   neutrophil 
PO2  partial pressure of oxygen 
PRR  pattern recognition receptors
PTEC  proximal tubular epithelial cell
RECA-1  rat endothelial cell antigen-1
rhC1INH recombinant human C1 inhibitor
ROS  reactive oxygen species
RPS-15  ribosomal protein S-15
SD  standard deviation
SEM  standard error of the mean
SNP  single nucleotide polymorphism
TLR  toll-like receptor
UPR  unfolded protein response 
UW  University of Wisconsin
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Nierstichting-gefinancierd promotieonderzoek getiteld “The role of the lectin 
pathway of complement in renal ischemia/reperfusion injury and transplant 
rejection” op de afdeling Nierziekten van het LUMC onder supervisie van Prof. Dr. 
M.R. Daha en na diens emeritaat onder supervisie van Prof. Dr. C. van Kooten. De 
resultaten van het promotieonderzoek zijn beschreven in dit proefschrift. Eind 
2011 ontving hij een Kolff Postdoc Startup beurs van de Nierstichting getiteld 
“The role of ER-stress and autophagy in MBL-mediated tubular epithelial cell 
death following renal ischemia/reperfusion”. Vanaf 2012 verricht hij op dit 
onderwerp postdoctoraal onderzoek in de onderzoeksgroep van Prof. Dr. C. van 
Kooten. 
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